[
  {
    "title": "AGPAT2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agpat2/",
    "content": "**AGPAT2 Gene**\n\nThe AGPAT2 gene provides instructions for making an enzyme that is found in many of the body's cells and tissues. It plays a critical role in the growth and development of adipocytes, which are cells that store fats for energy. Adipocytes are the major component of the body's fatty (adipose) tissue.\n\nThe AGPAT2 enzyme is part of a chemical pathway in many cells that produces two important types of fats (lipids): glycerophospholipids and triacylglycerols. Glycerophospholipids are the major component of cell membranes and are involved in chemical signaling within cells. Triacylglycerols (also known as triglycerides) are fat molecules that are stored in adipocytes for later conversion to energy.\n\nThe AGPAT2 enzyme is responsible for a particular chemical reaction in the production of these two types of lipids. Specifically, the enzyme helps convert a molecule called lysophosphatidic acid (LPA) to another molecule, phosphatidic acid (PA). Additional reactions convert phosphatidic acid to glycerophospholipids and triacylglycerols.\n\n**Health Conditions Related to Genetic Changes**\n\nCongenital generalized lipodystrophy\n\nAt least 26 mutations in the AGPAT2 gene have been identified in people with congenital generalized lipodystrophy (also called Berardinelli-Seip congenital lipodystrophy) type 1. This rare condition is characterized by an almost total absence of adipose tissue and a very muscular appearance. A shortage of adipose tissue leads to multiple health problems, including high levels of triglycerides circulating in the bloodstream (hypertriglyceridemia) and diabetes mellitus.\n\nThe AGPAT2 gene mutations that cause congenital generalized lipodystrophy type 1 greatly reduce or eliminate the activity of the AGPAT2 enzyme. Studies suggest that a loss of this enzyme's activity reduces the production and storage of triacylglycerols in adipocytes, which prevents these cells from storing fats.\n\n---\n\n**AGPAT2 Gene**\n\nThe AGPAT2 gene plays a crucial role in the production and storage of triacylglycerols in adipocytes, which are specialized cells that store fats. A loss of enzyme activity reduces the production and storage of these fats, preventing them from being stored normally in adipose tissue.\n\n**Congenital Generalized Lipodystrophy**\n\nAt least 26 mutations in the AGPAT2 gene have been identified in people with congenital generalized lipodystrophy (also called Berardinelli-Seip congenital lipodystrophy) type 1. This rare condition is characterized by an almost total absence of adipose tissue and a very muscular appearance.\n\n**Signs and Symptoms**\n\nThe resulting lack of body fat underlies the varied signs and symptoms of congenital generalized lipodystrophy type 1, including:\n\n* High levels of triglycerides circulating in the bloodstream (hypertriglyceridemia)\n* Diabetes mellitus\n\n**Other Names for This Gene**\n\n* 1-acyl-sn-glycerol-3-phosphate acyltransferase beta\n* 1-AGP acyltransferase 2\n* LPAAB\n* LPAAT-beta\n* PLCB_HUMAN\n\n**References**\n\n* Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet. 2002 May;31(1):21-3.\n* Agarwal AK. Lysophospholipid acyltransferases: 1-acylglycerol-3-phosphate O-acyltransferases. From discovery to disease. Curr Opin Lipidol. 2012 Aug;23(4):290-302.\n* Gale SE, Frolov A, Han X, Bickel PE, Cao L, Bowcock A, Schaffer JE, Ory DS. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. J Biol Chem. 2006 Apr 21;281(16):11082-9.\n* Magre J, Delepine M, Van Maldergem L, Robert JJ, Maassen JA, Meier M, Panz VR, Kim CA, Tubiana-Rufi N, Czernichow P, Seemanova E, Buchanan CR, Lacombe D, Vigouroux C, Lascols O, Kahn CR, Capeau J, Lathrop M. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003 Jun;52(6):1573-8.\n* Miranda DM, Wajchenberg BL, Calsolari MR, Aguiar MJ, Silva JM, Ribeiro MG, Fonseca C, Amaral D, Boson WL, Resende BA, De Marco L. Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome. Clin Endocrinol (Oxf). 2009 Oct;71(4):512-7.\n* Patni N, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015 Sep;11(9):522-34.\n\n---\n\n**AGPAT2 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe AGPAT2 gene is found on chromosome 9.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AGPS gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agps/",
    "content": "**AGPS Gene**\n\nThe AGPS gene provides instructions for making an enzyme known as alkylglycerone phosphate synthase. This enzyme is found in structures called peroxisomes, which are sac-like compartments within cells that contain enzymes needed to break down many different substances. Peroxisomes are also important for the production of fats (lipids) used in digestion and in the nervous system.\n\nWithin peroxisomes, alkylglycerone phosphate synthase is responsible for a critical step in the production of lipid molecules called plasmalogens. These molecules are found in cell membranes throughout the body. They are also abundant in myelin, which is the protective substance that covers nerve cells. However, little is known about the functions of plasmalogens. Researchers suspect that these molecules may help protect cells from oxidative stress, which occurs when unstable molecules called free radicals accumulate to levels that damage or kill cells. Plasmalogens may also play important roles in interactions between lipids and proteins, the transmission of chemical signals in cells, and the fusion of cell membranes.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Rhizomelic Chondrodysplasia Punctata**: At least three mutations in the AGPS gene have been found to cause rhizomelic chondrodysplasia punctata type 3 (RCDP3). These mutations change single protein building blocks (amino acids) in alkylglycerone phosphate synthase, which alters the structure of the enzyme and significantly reduces its activity. A shortage of functional alkylglycerone phosphate synthase disrupts peroxisome function and severely reduces the amount of plasmalogens within cells. It is unclear how these abnormalities lead to shortened long bones, intellectual disability, and the other characteristic features of RCDP3.\n\n---\n\n**AGPS Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nAt least three mutations in the AGPS gene have been found to cause rhizomelic chondrodysplasia punctata type 3 (RCDP3). These mutations change single protein building blocks (amino acids) in alkylglycerone phosphate synthase, which alters the structure of the enzyme and significantly reduces its activity. A shortage of functional alkylglycerone phosphate synthase disrupts peroxisome function and severely reduces the amount of plasmalogens within cells. It is unclear how these abnormalities lead to shortened long bones, intellectual disability, and the other characteristic features of RCDP3.\n\n**Other Names for This Gene**\n\n* ADAP-S\n* ADAS_HUMAN\n* ADHAPS\n* alkyl-DHAP synthase\n* alkyl-dihydroxyacetone phosphate synthase\n* alkyldihydroxyacetone phosphate synthetase\n* alkyldihydroxyacetonephosphate synthase, peroxisomal\n* alkylglycerone-phosphate synthase\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of AGPS\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ALKYLGLYCERONE-PHOSPHATE SYNTHASE; AGPS\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* de Vet EC, Ijlst L, Oostheim W, Wanders RJ, van den Bosch H. Alkyl-dihydroxyacetonephosphate synthase. Fate in peroxisome biogenesis disorders and identification of the point mutation underlying a single enzyme deficiency. J Biol Chem. 1998 Apr 24;273(17):10296-301.\n* Thai TP, Rodemer C, Jauch A, Hunziker A, Moser A, Gorgas K, Just WW. Impaired membrane traffic in defective ether lipid biosynthesis. Hum Mol Genet. 2001 Jan 15;10(2):127-36.\n* van den Bosch H, de Vet EC. Alkyl-dihydroxyacetonephosphate synthase. Biochim Biophys Acta. 1997 Sep 4;1348(1-2):35-44.\n* Wanders RJ, Dekker C, Hovarth VA, Schutgens RB, Tager JM, Van Laer P, Lecoutere D. Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisomal disorder. J Inherit Metab Dis. 1994;17(3):315-8.\n\n**Genomic Location**\nThe AGPS gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AGT gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agt/",
    "content": "**AGT Gene**\n\nThe AGT gene provides instructions for making a protein called angiotensinogen. This protein is part of the renin-angiotensin system, which regulates blood pressure and the balance of fluids and salts in the body.\n\n**Normal Function**\n\n*   The AGT gene provides instructions for making a protein called angiotensinogen.\n*   Angiotensinogen is converted to angiotensin I, which is then converted to angiotensin II.\n*   Angiotensin II causes blood vessels to narrow (constrict), resulting in increased blood pressure.\n*   This molecule also stimulates production of the hormone aldosterone, which triggers the absorption of salt and water by the kidneys.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Renal Tubular Dysgenesis**\n    *   At least six mutations in the AGT gene have been found to cause a severe kidney disorder called renal tubular dysgenesis.\n    *   This condition is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension).\n    *   These problems result in a reduction of amniotic fluid (oligohydramnios), which leads to a set of birth defects known as the Potter sequence.\n*   **Hypertension**\n    *   MedlinePlus Genetics provides information about Hypertension\n\n---\n\n**AGT Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Other Disorders**\n\nVariations in the AGT gene are associated with susceptibility to a form of high blood pressure (hypertension) called essential hypertension. Essential hypertension is a complex disorder associated with many genetic and environmental factors. The AGT gene variations associated with this condition affect single DNA building blocks (nucleotides) and likely lead to higher levels of the angiotensinogen protein.\n\n**Renal Tubular Dysgenesis**\n\nAt least six mutations in the AGT gene have been found to cause a severe kidney disorder called renal tubular dysgenesis. This condition is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension). These problems result in a reduction of amniotic fluid (oligohydramnios), which leads to a set of birth defects known as the Potter sequence.\n\nRenal tubular dysgenesis can be caused by mutations in both copies of any of the genes involved in the renin-angiotensin system. Most of the mutations in the AGT gene that cause this disorder change single protein building blocks (amino acids) in the angiotensinogen protein. These changes occur in a region of the protein that is necessary for its conversion to angiotensin I. It is thought that the altered angiotensinogen cannot be converted, leading to a nonfunctional renin-angiotensin system. Without this system, the kidneys cannot control blood pressure. Because of low blood pressure, the flow of blood is reduced (hypoperfusion), and the body does not get enough oxygen during fetal development. As a result, kidney development is impaired, leading to the features of renal tubular dysgenesis.\n\n**Hypertension**\n\nMedlinePlus Genetics provides information about Hypertension\n\n**Other Names for This Gene**\n\nangiotensinogen (serpin peptidase inhibitor, clade A, member 8) angiotensinogen preproprotein ANGT_HUMAN ANHU pre-angiotensinogen serpin A8 SERPINA8\n\n---\n\n**AGT Gene**\n\n**Scientific Articles on PubMed**\n\n*   Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, Bouton JM, Feuillet F, Makni S, Ben Amar H, Laube G, Delezoide AL, Bouvier R, Dijoud F, Ollagnon-Roman E, Roume J, Joubert M, Antignac C, Gubler MC. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet. 2005 Sep;37(9):964-8. doi: 10.1038/ng1623. Epub 2005 Aug 14.\n*   Gribouval O, Moriniere V, Pawtowski A, Arrondel C, Sallinen SL, Saloranta C, Clericuzio C, Viot G, Tantau J, Blesson S, Cloarec S, Machet MC, Chitayat D, Thauvin C, Laurent N, Sampson JR, Bernstein JA, Clemenson A, Prieur F, Daniel L, Levy-Mozziconacci A, Lachlan K, Alessandri JL, Cartault F, Riviere JP, Picard N, Baumann C, Delezoide AL, Belar Ortega M, Chassaing N, Labrune P, Yu S, Firth H, Wellesley D, Bitzan M, Alfares A, Braverman N, Krogh L, Tolmie J, Gaspar H, Doray B, Majore S, Bonneau D, Triau S, Loirat C, David A, Bartholdi D, Peleg A, Brackman D, Stone R, DeBerardinis R, Corvol P, Michaud A, Antignac C, Gubler MC. Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis. Hum Mutat. 2012 Feb;33(2):316-26. doi: 10.1002/humu.21661. Epub 2011 Dec 22.\n*   Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010 Mar;77(5):400-6. doi: 10.1038/ki.2009.423. Epub 2009 Nov 18.\n*   Watkins WS, Hunt SC, Williams GH, Tolpinrud W, Jeunemaitre X, Lalouel JM, Jorde LB. Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypes. J Hypertens. 2010 Jan;28(1):65-75. doi: 10.1097/HJH.0b013e328332031a.\n*   Wolf G. Angiotensin II and tubular development. Nephrol Dial Transplant. 2002;17 Suppl 9:48-51. doi: 10.1093/ndt/17.suppl_9.48.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ANGIOTENSINOGEN; AGT\n*   HYPERTENSION, ESSENTIAL\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of AGT",
    "category": "general"
  },
  {
    "title": "AGTR1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agtr1/",
    "content": "**AGTR1 Gene**\n\nThe AGTR1 gene provides instructions for making a protein called the angiotensin II receptor type 1 (AT1 receptor). This protein is part of the renin-angiotensin system, which regulates blood pressure and the balance of fluids and salts in the body.\n\n**Normal Function**\n\nThrough a series of steps, the renin-angiotensin system produces a molecule called angiotensin II, which attaches (binds) to the AT1 receptor, stimulating chemical signaling. This signaling causes blood vessels to narrow (constrict), resulting in increased blood pressure. Binding of angiotensin II to the AT1 receptor also stimulates production of the hormone aldosterone, which triggers the absorption of water and salt by the kidneys.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Renal Tubular Dysgenesis**: At least four mutations in the AGTR1 gene have been found to cause a severe kidney disorder called renal tubular dysgenesis. This condition is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension). These problems result in a reduction of amniotic fluid (oligohydramnios), which leads to a set of birth defects known as the Potter sequence.\n*   **Hypertension**: MedlinePlus Genetics provides information about Hypertension.\n\n---\n\n**AGTR1 Gene**\n\n**Other Disorders**\n\nVariations in the AGTR1 gene have been reported to be associated with an increased risk of a form of high blood pressure (hypertension) called essential hypertension; heart disease; or diabetic nephropathy, a complication of diabetes that affects kidney function. These are complex disorders associated with many genetic and environmental factors. The most studied AGTR1 gene variation associated with these conditions changes a single DNA building block (nucleotide) in the gene. This change switches the nucleotide adenine to cytosine at position 1166 in the gene (written as A1166C). It is unclear how this AGTR1 gene variation contributes to the risk of these conditions.\n\n**Renal Tubular Dysgenesis**\n\nAt least four mutations in the AGTR1 gene have been found to cause a severe kidney disorder called renal tubular dysgenesis. This condition is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension). These problems result in a reduction of amniotic fluid (oligohydramnios), which leads to a set of birth defects known as the Potter sequence.\n\nRenal tubular dysgenesis can be caused by mutations in both copies of any of the genes involved in the renin-angiotensin system. The AGTR1 gene mutations that cause this disorder likely change or block the AT1 receptor's ability to stimulate signaling, which results in a nonfunctional renin-angiotensin system. Without this system, the kidneys cannot control blood pressure. Because of low blood pressure, the flow of blood is reduced (hypoperfusion), and the body does not get enough oxygen during fetal development. As a result, kidney development is impaired, leading to the features of renal tubular dysgenesis.\n\n**Hypertension**\n\nMedlinePlus Genetics provides information about Hypertension\n\n**Other Names for This Gene**\n\nAG2S AGTR1_HUMAN AGTR1A AGTR1B angiotensin II receptor, type 1 AT1 AT1AR AT1B AT1BR AT1R AT2R1 AT2R1A AT2R1B HAT1R type-1 angiotensin II receptor type-1B angiotensin II receptor\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of AGTR1\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ANGIOTENSIN II RECEPTOR, TYPE 1; AGTR1\n* HYPERTENSION, ESSENTIAL\n\n---\n\n**AGTR1 Gene**\n\nThe AGTR1 gene is associated with essential hypertension, a condition characterized by persistently high blood pressure. Research has shown that variations in the AGTR1 gene can affect an individual's response to angiotensin II, a hormone involved in regulating blood pressure.\n\n**Genomic Location**\n\nThe AGTR1 gene is located on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Scientific Articles**\n\nSeveral studies have investigated the relationship between the AGTR1 gene and essential hypertension. Some notable articles include:\n\n* Ding et al. (2012): Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: a meta-analysis.\n* Duncan et al. (2001): Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes.\n* Gribouval et al. (2005): Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis.\n\n**Gene and Variant Databases**\n\nThe AGTR1 gene is listed in several databases, including:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\nFor a comprehensive understanding of the AGTR1 gene and its relationship to essential hypertension, consult the following references:\n\n* Ding et al. (2012)\n* Duncan et al. (2001)\n* Gribouval et al. (2005)\n\nNote: The references provided are a selection of the many studies that have investigated the AGTR1 gene and its association with essential hypertension.",
    "category": "general"
  },
  {
    "title": "AGXT gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agxt/",
    "content": "**AGXT Gene**\n\nThe AGXT gene provides instructions for making an enzyme called alanine-glyoxylate aminotransferase. This enzyme is found in liver cells, specifically within cell structures called peroxisomes.\n\n**Normal Function**\n\nThe AGXT gene's normal function is to convert a compound called glyoxylate to the protein building block (amino acid) glycine. This process takes place within the peroxisome and is essential for several cellular activities, such as ridding the cell of toxic substances and helping to break down certain fats.\n\n**Health Conditions Related to Genetic Changes**\n\nMore than 175 mutations in the AGXT gene have been found to cause primary hyperoxaluria type 1. This condition is caused by the overproduction of a substance called oxalate, leading to kidney and bladder stones, which can begin anytime from childhood to early adulthood with kidney disease developing at any age.\n\nDeposition of oxalate in multiple other tissues throughout the body (systemic oxalosis) can cause additional health problems. Most AGXT gene mutations decrease or eliminate alanine-glyoxylate aminotransferase activity, impairing the conversion of glyoxylate to glycine. Other mutations cause the enzyme to be misplaced in cells, transporting it to structures called mitochondria instead of to peroxisomes.\n\nAll AGXT gene mutations result in the accumulation of glyoxylate, which is converted to oxalate instead of glycine. The oxalate is filtered through the kidneys and is either excreted in urine as a waste product or combines with calcium to form calcium oxalate, a hard compound that is the main component of kidney and bladder stones.\n\nIncreased oxalate levels in the blood can lead to systemic oxalosis, particularly affecting bones and the walls of blood vessels in people with primary hyperoxaluria type 1.\n\n---\n\n**AGXT Gene: MedlinePlus Genetics**\n\n**What is the AGXT gene?**\n\nThe AGXT gene provides instructions for making an enzyme called alanine-glyoxylate aminotransferase. This enzyme plays a crucial role in breaking down a substance called glyoxylate, which is produced when the body metabolizes certain amino acids.\n\n**What does the AGXT gene do?**\n\nThe AGXT gene helps convert glyoxylate into glycine, an essential amino acid that the body needs to function properly. If the enzyme is not functioning correctly, glyoxylate can accumulate in the body and be converted into oxalate, a substance that can cause kidney stones.\n\n**What are the symptoms of AGXT gene mutations?**\n\nMost people with AGXT gene mutations develop kidney disease, which can lead to the formation of kidney stones. These stones can occur at any age, from childhood to early adulthood. In some cases, the accumulation of oxalate in the body can cause additional health problems, such as bone and blood vessel damage.\n\n**How do AGXT gene mutations affect the enzyme?**\n\nMost AGXT gene mutations decrease or eliminate the enzyme's activity, impairing its ability to convert glyoxylate into glycine. Other mutations cause the enzyme to be misplaced in cells, transporting it to structures called mitochondria instead of to peroxisomes.\n\n**What are the long-term effects of AGXT gene mutations?**\n\nThe accumulation of oxalate in the body can lead to systemic oxalosis, particularly affecting bones and the walls of blood vessels. In people with primary hyperoxaluria type 1, this condition can cause severe health problems if left untreated.\n\n**Other Names for This Gene**\n\n* AGT\n* AGT1\n* AGXT1\n* alanine glyoxylate aminotransferase\n* alanine-glyoxylate aminotransferase\n* alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine-pyruvate aminotransferase)\n* alanine-glyoxylate transaminase\n* L-alanine: glyoxylate aminotransferase 1\n* pyruvate (glyoxylate) aminotransferase\n* serine-pyruvate aminotransferase\n* serine:pyruvate aminotransferase\n* SPAT\n* SPT\n\n**Genomic Location**\n\nThe AGXT gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AHCY gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ahcy/",
    "content": "**AHCY Gene**\n\nThe AHCY gene provides instructions for producing the enzyme S-adenosylhomocysteine hydrolase. This enzyme is involved in a multistep process that breaks down the protein building block (amino acid) methionine.\n\n**Normal Function**\n\n* The AHCY gene produces the enzyme S-adenosylhomocysteine hydrolase, which plays an important role in regulating the addition of methyl groups to other compounds.\n* This reaction is involved in determining whether instructions in a particular segment of DNA are carried out, regulating reactions involving proteins and lipids, and controlling the processing of chemicals that relay signals in the nervous system (neurotransmitters).\n\n**Health Conditions Related to Genetic Changes**\n\n* **Hypermethionemia**\n\t+ More than 10 variants (also known as mutations) in the AHCY gene have been described in people with hypermethioninemia.\n\t+ These variants can cause intellectual disability or other neurological problems in affected individuals.\n\n---\n\n**AHCY Gene**\n\nThe AHCY gene is responsible for producing the S-adenosylhomocysteine hydrolase enzyme, which plays a crucial role in breaking down methionine in the body. Variants of this gene can lead to a deficiency of the enzyme, resulting in hypermethioninemia, intellectual disability, and other neurological problems.\n\n**Other Names for This Gene**\n\n* SAHH\n* SAHH_HUMAN\n\n**Genomic Location**\n\nThe AHCY gene is found on chromosome 20.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AHDC1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ahdc1/",
    "content": "**AHDC1 Gene**\n\nThe AHDC1 gene provides instructions for making a protein whose function is not known. The AHDC1 protein is found in the nucleus of cells, and a region of the protein is thought to allow it to attach (bind) to DNA. Based on its location and possible DNA-binding ability, researchers suspect the protein may help control the activity of other genes.\n\n**Health Conditions Related to Genetic Changes**\n\n*Xia-Gibbs Syndrome*\n\nMore than 25 mutations in the AHDC1 gene have been found to cause Xia-Gibbs syndrome, a neurological disorder characterized by intellectual disability and delayed speech development. A variety of other signs and symptoms can also occur in this disorder, such as weak muscle tone, growth impairment, and unusual facial features. Most of the AHDC1 gene mutations involved in Xia-Gibbs syndrome lead to production of abnormally short AHDC1 proteins. The effects of these changes in cells are unclear. The shortened proteins may be quickly broken down or be unable to function. Or, the abnormal proteins may interfere with the function of AHDC1 proteins produced from the normal copy of the gene. Some people with Xia-Gibbs syndrome have a mutation that removes (deletes) the AHDC1 gene (and other nearby genes), although it is unclear if such mutations cause the condition.\n\nResearchers suspect that a reduction in the amount of functional AHDC1 protein prevents normal brain development, leading to intellectual disability, speech problems, and other neurological features of Xia-Gibbs syndrome. Abnormal development of other body systems caused by a shortage of AHDC1 protein may account for additional signs and symptoms of the condition.\n\n**Other Names for This Gene**\n\n*AT-HOOK DNA-BINDING MOTIF-CONTAINING PROTEIN 1*\n\n**Additional Information & Resources**\n\n*Tests Listed in the Genetic Testing Registry: Tests of AHDC1*\n\n---\n\n**AHDC1 Gene**\n\n**Genomic Location**\nThe AHDC1 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Scientific Articles on PubMed**\n\n* Xia-Gibbs syndrome: A case report with insight into the natural history of the condition\n\t+ Murdock DR, Jiang Y, Wangler M, Khayat MM, Sabo A, Juusola J, McWalter K, Schatz KS, Gunay-Aygun M, Gibbs RA. Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3):a003608.\n* Variable Clinical Manifestations of Xia-Gibbs syndrome: Findings of Consecutively Identified Cases at a Single Children's Hospital\n\t+ Ritter AL, McDougall C, Skraban C, Medne L, Bedoukian EC, Asher SB, Balciuniene J, Campbell CD, Baker SW, Denenberg EH, Mazzola S, Fiordaliso SK, Krantz ID, Kaplan P, Ierardi-Curto L, Santani AB, Zackai EH, Izumi K. Am J Med Genet A. 2018 Sep;176(9):1890-1896.\n* Microdeletion and microduplication of 1p36.11p35.3 involving AHDC1 contribute to neurodevelopmental disorder\n\t+ Wang Q, Huang X, Liu Y, Peng Q, Zhang Y, Liu J, Yuan H. Eur J Med Genet. 2020 Jan;63(1):103611.\n* De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea\n\t+ Xia F, Bainbridge MN, Tan TY, Wangler MF, Scheuerle AE, Zackai EH, Harr MH, Sutton VR, Nalam RL, Zhu W, Nash M, Ryan MM, Yaplito-Lee J, Hunter JV, Deardorff MA, Penney SJ, Beaudet AL, Plon SE, Boerwinkle EA, Lupski JR, Eng CM, Muzny DM, Yang Y, Gibbs RA. Am J Hum Genet. 2014 May 1;94(5):784-9.\n* De novo truncating variants in the AHDC1 gene encoding the AT-hook DNA-binding motif-containing protein 1 are associated with intellectual disability and developmental delay\n\t+ Yang H, Douglas G, Monaghan KG, Retterer K, Cho MT, Escobar LF, Tucker ME, Stoler J, Rodan LH, Stein D, Marks W, Enns GM, Platt J, Cox R, Wheeler PG, Crain C, Calhoun A, Tryon R, Richard G, Vitazka P, Chung WK. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000562.\n\n**Catalog of Genes and Diseases from OMIM**\n\n* AT-HOOK DNA-BINDING MOTIF-CONTAINING PROTEIN 1; AHDC1\n\n**Gene and Variant Databases**\n\n* NCBI Gene\n* ClinVar\nTests Listed in the Genetic Testing Registry\n\n* Tests of AHDC1",
    "category": "general"
  },
  {
    "title": "AHFSÂ® Patient Medication Information: MedlinePlus Drug Information",
    "url": "https://medlineplus.gov/druginfo/meds/index.html",
    "content": "**AHFS\\({}^{\\circledR}\\) Patient Medication Information**\n\n\\n\\n\n\n**Abacavir**\n\n*   Abacavir, Dolutegravir, and Lamivudine\n*   Abacavir, Lamivudine, and Zidovudine\n\n\\n\\n\n\n**Abaloparatide Injection**\n\n*   Abatacept Injection\n*   Abemaciclib\n*   Abiraterone\n*   AbobotulinumtoxinA Injection\n*   Abrocitinib\n*   Acalabrutinib\n*   Acamprosate\n*   Acarbose\n*   Acebutolol\n*   Acetaminophen\n*   Acetaminophen and Codeine\n*   Acetaminophen Injection\n*   Acetaminophen, Butalbital, and Caffeine\n*   Acetaminophen Rectal\n*   Acetazolamide\n*   Acetylcysteine Oral Inhalation\n*   Acitretin\n*   Aclidinium Oral Inhalation\n*   Acyclovir\n*   Acyclovir Buccal\n*   Acyclovir Injection\n*   Acyclovir Ophthalmic\n*   Acyclovir Topical\n\n\\n\\n\n\n**Adagrasib**\n\n*   Adalimumab Injection\n*   Adapalene\n*   Adefovir\n*   Ado-trastuzumab Emtansine Injection\n*   Aducanumab-avwa Injection\n*   Afamitresgene Autoleucel Injection\n*   Afatinib\n*   Aflibercept Injection\n*   Agalsidase beta Injection\n\n\\n\\n\n\n**Albendazole**\n\n*   Albiglutide Injection\n*   Albuterol\n*   Albuterol and Ipratropium Oral Inhalation\n*   Albuterol Oral Inhalation\n*   Alcaftadine Ophthalmic\n*   Aldesleukin\n*   Alectinib\n*   Alemtuzumab Injection (Chronic Lymphocytic Leukemia)\n*   Alemtuzumab Injection (Multiple Sclerosis)\n\n\\n\\n\n\n**Alendronate**\n\n*   Alfuzosin\n*   Alirocumab Injection\n*   Aliskiren\n*   Alitretinoin\n*   Allopurinol\n*   Allopurinol Injection\n*   Almotriptan\n*   Alogliptin\n*   Alosetron\n\n\\n\\n\n\n**Alpelisib**\n\n*   Alprazolam\n*   Alprostadil Urogenital\n*   Altretamine\n*   Aluminum Hydroxide\n*   Aluminum Hydroxide and Magnesium Hydroxide\n*   Alvimopan\n*   Amantadine\n*   Ambrisentan\n*   Amifostine Injection\n\n\\n\\n\n\n**Amikacin Injection**\n\n*   Amikacin Oral Inhalation\n*   Amiloride\n*   Amiloride and Hydrochlorothiazide\n*   Aminocaproic Acid\n*   Aminocaproic Acid Injection\n*   Aminolevulinic Acid Topical\n*   Aminophylline\n\n\\n\\n\n\n**Amiodarone**\n\n*   Amisulpride Injection\n*   Amitriptyline\n*   Amivantamab-vmjw Injection\n*   Amlexanox\n*   Amlodipine\n*   Amlodipine and Benazepril\n*   Ammonium Lactate Topical\n\n\\n\\n\n\n**Amoxapine**\n\n*   Amoxicillin\n*   Amoxicillin and Clavulanic Acid\n*   Amphetamine\n*   Amphotericin B Injection\n*   Amphotericin B Lipid Complex Injection\n*   Amphotericin B Liposomal Injection\n*   Ampicillin\n*   Ampicillin and Sulbactam Injection\n*   Ampicillin Injection\n\n\\n\\n\n\n**Anacaulase**\n\n*   Anagrelide\n*   Anakinra\n*   Anastrozole\n*   Anifrolumab-fnia\n*   Anthrax Vaccine\n*   Antipyrine-Benzocaine Otic\n\n\\n\\n\n\n**Apalutamide**\n\n*   Apixaban\n*   Apomorphine Injection\n*   Apomorphine Sublingual\n*   Apraclonidine Ophthalmic\n*   Apremilast\n*   Aprepitant\n*   Aprepitant/Fosaprepitant Injection\n\n\\n\\n\n\n**Aprocitentan**\n\n*   Arformoterol Oral Inhalation\n*   Arimoclomol\n*   Aripiprazole\n*   Aripiprazole Injection\n*   Armodafinil\n*   Arsenic Trioxide Injection\n*   Artemether and Lumefantrine\n\n\\n\\n\n\n**Asciminib**\n\n*   Ascorbic Acid (Vitamin C)\n*   Asenapine\n*   Asenapine Transdermal Patch\n*   Asparaginase Erwinia chrysanthemi\n*   Asparaginase Erwinia chrysanthemi (recombinant)-rywn Injection\n\n\\n\\n\n\n**Aspirin**\n\n*   Aspirin and Extended-Release Dipyridamole\n*   Aspirin and Omeprazole\n*   Aspirin, Butalbital, and Caffeine\n*   Aspirin Rectal\n\n\\n\\n\n\n**Atazanavir**\n\n*   Atazanavir and Cobicistat\n*   Atenolol\n*   Atezolizumab Injection\n*   Atezolizumab and Hyaluronidase Injection\n*   Atidarsagene autotemcel\n\n\\n\\n\n\n**Atogepant**\n\n*   Atomoxetine\n*   Atorvastatin\n*   Atovaquone\n*   Atovaquone and Proguanil\n*   Atropine Ophthalmic\n\n\\n\\n\n\n**Auranofin**\n\n*   Avacopan\n*   Avanafil\n*   Avapritinib\n*   Avatrombopag\n*   Avelumab Injection\n\n\\n\\n\n\n**Axatilimab-csfr Injection**\n\n*   Axicabtagene Ciloleucel Injection\n*   Axitinib\n*   Azacitidine\n*   Azacitidine Injection\n*   Azathioprine\n*   Azelaic Acid Topical\n\n\\n\\n\n\n**Azelastine Nasal Spray**\n\n*   Azelastine Ophthalmic\n*   Azilsartan\n*   Azithromycin\n*   Azithromycin Ophthalmic\n*   Aztreonam Injection\n\n---\n\n**AHFS Patient Medication Information**\n\n**MedlinePlus Drug Information**\n\n**Part 2/15**\n\n\\n\\n\n\n* **loleucel Injection**\n* **Axitinib**\n* **Azacitidine**\n* **Azacitidine Injection**\n* **Azathioprine**\n* **Azelaic Acid Topical**\n* **Azelastine Nasal Spray**\n* **Azelastine Ophthalmic**\n* **Azilsartan**\n* **Azithromycin**\n* **Azithromycin Ophthalmic**\n* **Aztreonam Injection**\n\n\\n\\n\n\n* **Abacavir**\n* **Abacavir, Dolutegravir, and Lamivudine**\n* **Abacavir, Lamivudine, and Zidovudine**\n* **Abaloparatide Injection**\n* **Abatacept Injection**\n* **Abemaciclib**\n* **Abiraterone**\n* **AbobotulinumtoxinA Injection**\n* **Abrocitinib**\n* **Acalabrutinib**\n* **Acamprosate**\n* **Acarbose**\n* **Acebutolol**\n* **Acetaminophen**\n* **Acetaminophen and Codeine**\n* **Acetaminophen Injection**\n* **Acetaminophen, Butalbital, and Caffeine**\n* **Acetaminophen Rectal**\n* **Acetazolamide**\n* **Acetylcysteine Oral Inhalation**\n* **Acitretin**\n* **Aclidinium Oral Inhalation**\n* **Acyclovir**\n* **Acyclovir Buccal**\n* **Acyclovir Injection**\n* **Acyclovir Ophthalmic**\n* **Acyclovir Topical**\n* **Adagrasib**\n* **Adalimumab Injection**\n* **Adapalene**\n* **Adefovir**\n* **Ado-trastuzumab Emtansine Injection**\n* **Aducanumab-avwa Injection**\n* **Afamitresgene Autoleucel Injection**\n* **Afatinib**\n* **Aflibercept Injection**\n* **Agalsidase beta Injection**\n* **Albendazole**\n* **Albiglutide Injection**\n* **Albuterol**\n* **Albuterol and Ipratropium Oral Inhalation**\n* **Albuterol Oral Inhalation**\n* **Alcaftadine Ophthalmic**\n* **Aldesleukin**\n* **Alectinib**\n* **Alemtuzumab Injection (Chronic Lymphocytic Leukemia)**\n* **Alemtuzumab Injection (Multiple Sclerosis)**\n* **Alendronate**\n* **Alfuzosin**\n* **Alirocumab Injection**\n* **Aliskiren**\n* **Alitretinoin**\n* **Allopurinol**\n* **Allopurinol Injection**\n* **Almotriptan**\n* **Alogliptin**\n* **Alosetron**\n* **Alpelisib**\n* **Alprazolam**\n* **Alprostadil Urogenital**\n* **Altretamine**\n* **Aluminum Hydroxide**\n* **Aluminum Hydroxide and Magnesium Hydroxide**\n* **Alvimopan**\n* **Amantadine**\n* **Ambrisentan**\n* **Amifostine Injection**\n* **Amikacin Injection**\n* **Amikacin Oral Inhalation**\n* **Amiloride**\n* **Amiloride and Hydrochlorothiazide**\n* **Aminocaproic Acid**\n* **Aminocaproic Acid Injection**\n* **Aminolevulinic Acid Topical**\n* **Aminophylline**\n* **Amiodarone**\n* **Amisulpride Injection**\n* **Amitriptyline**\n* **Amivantamab-vmjw Injection**\n* **Amlexanox**\n* **Amlodipine**\n* **Amlodipine and Benazepril**\n* **Ammonium Lactate Topical**\n* **Amoxapine**\n* **Amoxicillin**\n* **Amoxicillin and Clavulanic Acid**\n* **Amphetamine**\n* **Amphotericin B Injection**\n* **Amphotericin B Lipid Complex Injection**\n* **Amphotericin B Liposomal Injection**\n* **Ampicillin**\n* **Ampicillin and Sulbactam Injection**\n* **Ampicillin Injection**\n* **Anacaulase**\n* **Anagrelide**\n* **Anakinra**\n* **Anastrozole**\n* **Anifrolumab-fnia**\n* **Anthrax Vaccine**\n* **Antipyrine-Benzocaine Otic**\n* **Apalutamide**\n* **Apixaban**\n* **Apomorphine Injection**\n* **Apomorphine Sublingual**\n* **Apraclonidine Ophthalmic**\n* **Apremilast**\n* **Aprepitant**\n* **Aprepitant/Fosaprepitant Injection**\n* **Aprocitentan**\n* **Arformoterol Oral Inhalation**\n* **Arimoclomol**\n* **Aripiprazole**\n* **Aripiprazole Injection**\n* **Armodafinil**\n* **Arsenic Trioxide Injection**\n* **Artemether and Lumefantrine**\n* **Asciminib**\n* **Ascorbic Acid (Vitamin C)**\n* **Asenapine**\n* **Asenapine Transdermal Patch**\n* **Asparaginase Erwinia chrysanthemi**\n* **Asparaginase Erwinia chrysanthemi (recombinant)-rywn Injection**\n* **Aspirin**\n* **Aspirin and Extended-Release Dipyridamole**\n* **Aspirin and Omeprazole**\n* **Aspirin, Butalbital, and Caffeine**\n* **Aspirin Rectal**\n* **Atazanavir**\n* **Atazanavir and Cobicistat**\n* **Atenolol**\n* **Atezolizumab Injection**\n* **Atezolizumab and Hyaluronidase Injection**\n* **Atidarsagene autotemcel**\n* **Atogepant**\n* **Atomoxetine**\n* **Atorvastatin**\n* **Atovaquone**\n* **Atovaquone and Proguanil**\n* **Atropine Ophthalmic**\n* **Auranofin**\n* **Avacopan**\n* **Avanafil**\n* **Avapritinib**\n* **Avatrombopag**\n* **Avelumab Injection**\n* **Axatilimab-csfr Injection**\n* **Axicabtagene Ciloleucel Injection**\n* **Axitinib**\n* **Azacitidine**\n* **Azacitidine Injection**\n* **Azathioprine**\n* **Azelaic Acid Topical**\n* **Azelastine Nasal Spray**\n* **Azelastine Ophthalmic**\n* **Azilsartan**\n* **Azithromycin**\n* **Azithromycin Ophthalmic**\n* **Aztreonam Injection**\n\n\\n\\n\n\n* **Bacillus Calmette-Guerin (BCG) Vaccine**\n* **Bacitracin Ophthalmic**\n* **Bacitracin Topical**\n* **Baclofen**\n* **Baloxavir Marboxil**\n* **Balsalazide**\n* **Bamlanivimab Injection**\n* **Bamlanivimab and Etesevimab Injection**\n* **Baricitinib**\n* **Barium Sulfate**\n* **Basiliximab Injection**\n* **Bebtelovimab Injection**\n* **Becaplermin Topical**\n* **Beclomethasone Nasal Spray**\n* **Beclomethasone Oral Inhalation**\n* **Bedaquiline**\n* **Belantamab Mafodotin-blmf Injection**\n* **Belatacept Injection**\n* **Belimumab Injection**\n* **Belinostat Injection**\n* **Belladonna Alkaloid Combinations and Phenobarbital**\n* **Belumosudil**\n* **Belzutifan**\n* **Bempedoic Acid**\n* **Benazepril**\n* **Benazepril and Hydrochlorothiazide**\n* **Bendamustine Injection**\n* **Benralizumab Injection**\n* **Bentoquatam Topical**\n* **Benzgalantamine**\n* **Benzhydrocodone and Acetaminophen**\n* **Benznidazole**\n* **Benzonatate**\n* **Benzoyl Peroxide Topical**\n* **Benztropine**\n* **Benzyl Alcohol Topical**\n* **Bepotastine Ophthalmic**\n* **Berdazimer**\n* **Beremagene geperpavec-svdt**\n* **Besifloxacin Ophthalmic**\n* **Betaine**\n* **Betamethasone Topical**\n* **Betaxolol**\n* **Betaxolol Ophthalmic**\n* **Bethanechol**\n* **Betibeglogene autotemcel Injection**\n* **Betrixaban**\n* **Bevacizumab Injection**\n* **Bexagliflozin**\n* **Bexarotene**\n* **Bexarotene Topical**\n* **Bezlotoxumab Injection**\n* **Bicalutamide**\n* **Bictegravir, Emtricitabine, and Tenofovir alafenamide**\n* **Bimatoprost Ophthalmic**\n* **Bimatoprost Topical**\n* **Bimekizumab-bkzx Injection**\n* **Binimetinib**\n* **Birch Triterpenes Topical**\n* **Bisacodyl**\n* **Bisacodyl Rectal**\n* **Bismuth Subsalicylate**\n* **Bismuth, Metronidazole, and Tetracycline**\n* **Bisoprolol**\n* **Bleomycin**\n* **Blinatumomab Injection**\n* **Boceprevir**\n* **Bortezomib**\n* **Bosentan**\n* **Bosutinib**\n* **Bremelanotide Injection**\n* **Brentuximab Vedotin Injection**\n* **Brexanolone Injection**\n* **Brexucabtagene Autoleucel Injection**\n* **Brexpiprazole**\n* **Brigatinib**\n* **Brimonidine Ophthalmic**\n* **Brinzolamide Ophthalmic**\n* **Brivaracetam**\n* **Brivaracetam Injection**\n* **Brodalumab Injection**\n* **Brolucizumab-dbll Injection**\n* **Bromfenac Ophthalmic**\n* **Bromocriptine**\n* **Brompheniramine**\n* **Budesonide**\n* **Budesonide and Albuterol Oral Inhalation**\n* **Budesonide and Formoterol Oral Inhalation**\n* **Budesonide Nasal Spray**\n* **Budesonide Oral Inhalation**\n* **Budesonide Oral Suspension**\n* **Bumetanide**\n* **Buprenorphine Buccal (chronic pain)**\n* **Buprenorphine Injection**\n* **Buprenorphine\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **rphine Injection (Pain Relief)**\n*   **Buprenorphine Sublingual and Buccal (opioid dependence)**\n*   **Buprenorphine Transdermal Patch**\n*   **Bupropion**\n*   **Burosumab-twza Injection**\n*   **Buspirone**\n*   **Busulfan**\n*   **Busulfan Injection**\n*   **Butabarbital**\n*   **Butoconazole Vaginal Cream**\n*   **Butorphanol Injection**\n*   **Butorphanol Nasal Spray**\n\n\\n\\n\n\n*   **C1-Esterase Inhibitor Human Injection**\n*   **C1-Esterase Inhibitor (Recombinant) Injection**\n*   **Cabazitaxel Injection**\n*   **Cabergoline**\n*   **Cabotegravir**\n*   **Cabotegravir Injection**\n*   **Cabotegravir and Rilpivirine Injections**\n*   **Cabozantinib**\n*   **Cabozantinib (thyroid cancer)**\n*   **Calaspargase pegol-mknl Injection**\n*   **Calcifediol**\n*   **Calcipotriene Topical**\n*   **Calcitonin Salmon Injection**\n*   **Calcitonin Salmon Nasal Spray**\n*   **Calcitriol**\n*   **Calcitriol Topical**\n*   **Calcium Acetate**\n*   **Calcium Carbonate**\n*   **Calcium, Magnesium, Potassium, and Sodium Oxybate**\n*   **Canagliflozin**\n*   **Canakinumab Injection**\n*   **Candesartan**\n*   **Cannabidiol**\n*   **Cantharidin**\n*   **Capecitabine**\n*   **Capivasertib**\n*   **Caplacizumab-yhdp Injection**\n*   **Capmatinib**\n*   **Capsaicin Topical**\n*   **Capsaicin Transdermal Patch**\n*   **Captopril**\n*   **Captopril and Hydrochlorothiazide**\n*   **Carbamazepine**\n*   **Carboplatin Injection**\n*   **Carfilzomib Injection**\n*   **Cariprazine**\n*   **Carisoprodol**\n*   **Carmustine**\n*   **Carmustine Implant**\n*   **Carvedilol**\n*   **Casirivimab and Imdevimab Injection**\n*   **Caspofungin Injection**\n*   **Cefaclor**\n*   **Cefadroxil**\n*   **Cefazolin Injection**\n*   **Cefdinir**\n*   **Cefditoren**\n*   **Cefepime Injection**\n*   **Cefiderocol Injection**\n*   **Cefixime**\n*   **Cefotaxime Injection**\n*   **Cefotetan Injection**\n*   **Cefoxitin Injection**\n*   **Cefpodoxime**\n*   **Cefprozil**\n*   **Ceftaroline Injection**\n*   **Ceftazidime and Avibactam Injection**\n*   **Ceftazidime Injection**\n*   **Ceftibuten**\n*   **Ceftolozane and Tazobactam Injection**\n*   **Ceftriaxone Injection**\n*   **Cefuroxime**\n*   **Cefuroxime Injection**\n*   **Celecoxib**\n*   **Cemiplimab-rwlc Injection**\n*   **Cenegermin-bkbj Ophthalmic**\n*   **Cenobamate**\n*   **Cephalexin**\n*   **Ceritinib**\n*   **Cerliponase alfa Injection**\n*   **Certolizumab Injection**\n*   **Cetirizine**\n*   **Cetirizine Injection**\n*   **Cetirizine Ophthalmic**\n*   **Cetuximab Injection**\n*   **Cevimeline**\n*   **Chloral Hydrate**\n*   **Chlorambucil**\n*   **Chloramphenicol Injection**\n*   **Chlordiazepoxide**\n*   **Chlordiazepoxide and Clidinium**\n*   **Chloroquine**\n*   **Chlorothiazide**\n*   **Chlorpheniramine**\n*   **Chlorpromazine**\n*   **Chlorpropamide**\n*   **Chlorthalidone**\n*   **Chlorzoxazone**\n*   **Cholecalciferol (Vitamin D3)**\n*   **Cholera Vaccine**\n*   **Cholestyramine Resin**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **Chloroquine**: An antimalarial drug used to treat malaria, lupus, and rheumatoid arthritis.\n*   **Chlorothiazide**: A diuretic used to treat high blood pressure and edema.\n*   **Chlorpheniramine**: An antihistamine used to relieve symptoms of hay fever, allergies, and the common cold.\n*   **Chlorpromazine**: An antipsychotic medication used to treat schizophrenia and other mental health conditions.\n*   **Chlorpropamide**: A diabetes medication used to stimulate insulin production in people with type 2 diabetes.\n*   **Chlorthalidone**: A diuretic used to treat high blood pressure, edema, and swelling caused by heart failure or liver disease.\n*   **Chlorzoxazone**: A muscle relaxant used to relieve pain, stiffness, and soreness in people with arthritis or musculoskeletal disorders.\n*   **Cholecalciferol (Vitamin D3)**: A vitamin D supplement used to prevent deficiency and maintain bone health.\n*   **Cholera Vaccine**: A vaccine used to protect against cholera infection.\n*   **Cholestyramine Resin**: A bile acid sequestrant used to lower cholesterol levels in people with high cholesterol or familial hypercholesterolemia.\n*   **Choline Magnesium Trisalicylate**: A medication used to treat muscle cramps, spasms, and weakness caused by magnesium deficiency.\n*   **Ciclesonide Nasal Spray**: A corticosteroid nasal spray used to relieve symptoms of allergic rhinitis and non-allergic rhinitis.\n*   **Ciclesonide Oral Inhalation**: An inhaled corticosteroid used to treat asthma and chronic obstructive pulmonary disease (COPD).\n*   **Ciclopirox Topical**: An antifungal medication used to treat fungal infections of the skin, scalp, and nails.\n*   **Cidofovir Injection**: An antiviral medication used to treat cytomegalovirus (CMV) retinitis in people with AIDS.\n*   **Cilostazol**: A medication used to treat intermittent claudication, a condition characterized by pain in the legs during walking due to poor circulation.\n*   **Ciltacabtagene Autoleucel Injection**: A gene therapy used to treat relapsed or refractory acute myeloid leukemia (AML) and certain types of lymphoma.\n*   **Cimetidine**: A histamine H2-receptor antagonist used to treat ulcers, gastroesophageal reflux disease (GERD), and other conditions affecting the stomach and esophagus.\n*   **Cinacalcet**: A medication used to treat secondary hyperparathyroidism in people with chronic kidney disease.\n*   **Cipaglucosidase alfa-atga**: An enzyme replacement therapy used to treat Pompe disease, a rare genetic disorder affecting muscle function.\n*   **Ciprofloxacin**: An antibiotic used to treat bacterial infections of the skin, lungs, and urinary tract.\n*   **Ciprofloxacin and Dexamethasone Otic**: A combination medication used to treat outer ear infections caused by bacteria or fungi.\n*   **Ciprofloxacin and Hydrocortisone Otic**: A combination medication used to treat outer ear infections caused by bacteria or fungi.\n*   **Ciprofloxacin Injection**: An antibiotic injection used to treat bacterial infections in people with certain medical conditions, such as cystic fibrosis or neutropenia.\n*   **Ciprofloxacin Ophthalmic**: An antibiotic eye drop used to treat conjunctivitis (pink eye) and other bacterial eye infections.\n*   **Ciprofloxacin Otic**: An antibiotic ear drop used to treat outer ear infections caused by bacteria.\n*   **Cisapride**: A medication used to treat gastroesophageal reflux disease (GERD), but not currently available in the US due to safety concerns.\n*   **Cisplatin Injection**: A chemotherapy agent used to treat various types of cancer, including ovarian, testicular, lung, and bladder cancers.\n*   **Citalopram**: An antidepressant medication used to treat depression, anxiety disorders, and certain sleep disorders.\n*   **Cladribine**: A medication used to treat hairy cell leukemia, a rare type of blood cancer.\n*   **Cladribine Injection**: An intravenous form of cladribine used to treat hairy cell leukemia in people with certain medical conditions.\n*   **Clarithromycin**: An antibiotic used to treat bacterial infections of the skin, lungs, and respiratory tract.\n*   **Clemastine**: An antihistamine used to relieve symptoms of hay fever, allergies, and the common cold.\n*   **Clindamycin**: An antibiotic used to treat bacterial infections of the skin, lungs, and urinary tract.\n*   **Clindamycin and Benzoyl Peroxide Topical**: A combination medication used to treat acne by reducing bacteria and inflammation on the skin.\n*   **Clindamycin Injection**: An intravenous form of clindamycin used to treat bacterial infections in people with certain medical conditions, such as cystic fibrosis or neutropenia.\n*   **Clindamycin Topical**: A topical antibiotic cream or gel used to treat acne and other skin infections caused by bacteria.\n*   **Clindamycin Vaginal**: A vaginal cream or suppository used to treat bacterial vaginosis (BV) and other vaginal infections caused by bacteria.\n*   **Clioquinol Topical**: An antifungal medication used to treat fungal infections of the skin, scalp, and nails.\n*   **Clobazam**: A benzodiazepine used to treat anxiety disorders, seizures, and muscle spasms.\n*   **Clobetasol Topical**: A corticosteroid cream or ointment used to treat inflammatory skin conditions such as eczema, psoriasis, and dermatitis.\n*   **Clofarabine Injection**: An antiviral medication used to treat viral infections in people with certain medical conditions, such as HIV/AIDS or cancer.\n*   **Clomiphene**: A fertility medication used to stimulate ovulation in women with infertility due to polycystic ovary syndrome (PCOS) or other hormonal imbalances.\n*   **Clomipramine**: An antidepressant medication used to treat depression, anxiety disorders, and obsessive-compulsive disorder (OCD).\n*   **Clonazepam**: A benzodiazepine used to treat anxiety disorders, seizures, and muscle spasms.\n*   **Clonidine**: A medication used to treat high blood pressure, ADHD, and certain sleep disorders.\n*   **Clonidine Transdermal Patch**: A transdermal patch used to deliver clonidine directly through the skin for the treatment of ADHD and hypertension.\n*   **Clopidogrel**: An antiplatelet medication used to prevent blood clots in people with cardiovascular disease or stroke risk factors.\n*   **Clorazepate**: A benzodiazepine used to treat anxiety disorders, seizures, and muscle spasms.\n*   **Clotrimazole Lozenge**: An antifungal lozenge used to treat oral thrush, a fungal infection of the mouth.\n*   **Clotrimazole Topical**: A topical antifungal cream or gel used to treat fungal infections of the skin, scalp, and nails.\n*   **Clotrimazole Vaginal**: A vaginal suppository used to treat vaginal yeast infections caused by Candida fungus.\n*   **Clozapine**: An atypical antipsychotic medication used to treat schizophrenia in people who have not responded to other treatments.\n*   **Cobicistat**: A medication used to boost the levels of HIV protease inhibitors in people with HIV/AIDS.\n*   **Cobimetinib**: A kinase inhibitor used to treat melanoma and certain types of cancer.\n*   **Codeine**: An opioid analgesic used to relieve pain, cough, and diarrhea.\n*   **Colchicine**: A medication used to treat gout, familial Mediterranean fever, and other inflammatory conditions.\n*   **Colesevelam**: A bile acid sequestrant used to lower cholesterol levels in people with high cholesterol or familial hypercholesterolemia.\n*   **Colestipol**: A bile acid sequestrant used to lower cholesterol levels in people with high cholesterol or familial hypercholesterolemia.\n*   **Colistimethate Injection**: An antibiotic injection used to treat bacterial infections in people with certain medical conditions, such as cystic fibrosis or neutropenia.\n*   **Collagenase Clostridium histolyticum Injection**: A medication used to break down collagen and relieve Dupuytren's contracture, a condition causing finger deformity.\n*   **Copanlisib Injection**: An immunotherapy agent used to treat follicular lymphoma, a type of non-Hodgkin lymphoma.\n*   **Corticotropin, Repository Injection**: A medication used to treat Cushing's syndrome and other conditions affecting the adrenal glands.\n*   **Co-trimoxazole**: An antibiotic combination used to treat bacterial infections of the skin, lungs, and urinary tract.\n*   **COVID-19 Vaccine, Adjuvanted**: A vaccine used to protect against COVID-19 infection caused by the SARS-CoV-2 virus.\n*   **COVID-19 Vaccine, mRNA**: A messenger RNA (mRNA) vaccine used to protect against COVID-19 infection caused by the SARS-CoV-2 virus.\n*   **COVID-19 Vaccine, Viral Vector (Janssen [Johnson and Johnson])**: A viral vector vaccine used to protect against COVID-19 infection caused by the SARS-CoV-2 virus.\n*   **Crisaborole Topical**: An immunomodulator cream used to treat atopic dermatitis, a type of eczema.\n*   **Crizanlizumab-tmca Injection**: A medication used to treat sickle cell disease and certain types of cancer.\n*   **Crizotinib**: A kinase inhibitor used to treat non-small cell lung cancer (NSCLC) and other cancers.\n*   **Crofelemer**: An antidiarrheal medication used to treat diarrhea caused by HIV/AIDS or other conditions affecting the gastrointestinal tract.\n*   **Cromolyn Ophthalmic**: An anti-inflammatory eye drop used to treat allergic conjunctivitis, a type of eye inflammation.\n*   **Cromolyn Oral Inhalation**: An inhaled corticosteroid used to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD).\n*   **Cromolyn Sodium Nasal Solution**: A nasal spray used to treat allergic rhinitis and non-allergic rhinitis.\n*   **Crovalimab-akkz Injection**: An immunotherapy agent used to treat follicular lymphoma, a type of non-Hodgkin lymphoma.\n*   **Cyanocobalamin Injection**: A vitamin B12 supplement used to prevent deficiency and maintain nerve function in people with certain medical conditions, such as pernicious anemia or Crohn's disease.\n*   **Cyanocobalamin Nasal Gel**: A nasal gel form of vitamin B12 used to treat vitamin B12 deficiency in people with certain medical conditions, such as pernicious anemia or Crohn's disease.\n*   **Cyclobenzaprine**: A muscle relaxant used to relieve pain, stiffness, and soreness in people with arthritis or musculoskeletal disorders.\n*   **Cyclopentolate Ophthalmic**: An anticholinergic eye drop used to dilate the pupils during eye exams or procedures.\n*   **Cyclophosphamide**: A chemotherapy agent used to treat\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **Ophthalmic**\n    *   Dorzolamide Ophthalmic\n    *   Dostarlimab-gxly Injection\n    *   Doxazosin\n    *   Doxepin (Depression, Anxiety)\n    *   Doxepin (Insomnia)\n    *   Doxepin Topical\n    *   Dorzolamide and Timolol Ophthalmic\n*   **Dabigatran**\n*   **Dabrafenib**\n*   **Dacarbazine**\n*   **Daclatasvir**\n*   **Daclizumab Injection**\n*   **Dacomitinib**\n*   **Dactinomycin**\n*   **Dalbavancin Injection**\n*   **Dalfampridine**\n*   **Dalteparin Injection**\n*   **Danazol**\n*   **Dantrolene**\n*   **Dapagliflozin**\n*   **Daprodustat**\n*   **Dapsone**\n*   **Dapsone Topical**\n*   **Daptomycin Injection**\n*   **Daratumumab Injection**\n*   **Daratumumab and Hyaluronidase-fihj Injection**\n*   **Darbepoetin Alfa Injection**\n*   **Daridorexant**\n*   **Darifenacin**\n*   **Darolutamide**\n*   **Darunavir**\n*   **Darunavir and Cobicistat**\n*   **Darunavir, Cobicistat, Emtricitabine, and Tenofovir**\n*   **Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir**\n*   **Dasatinib**\n*   **Dasiglucagon Injection**\n*   **Daunorubicin**\n*   **Daunorubicin and Cytarabine Lipid Complex Injection**\n*   **Daunorubicin Lipid Complex Injection**\n*   **DaxibotulinumtoxinA-lanm**\n*   **Decitabine Injection**\n*   **Decitabine and Cedazuridine**\n*   **Deferasirox**\n*   **Deferiprone**\n*   **Defibrotide Injection**\n*   **Deflazacort**\n*   **Degarelix Injection**\n*   **Delafloxacin**\n*   **Delafloxacin Injection**\n*   **Delandistrogene moxeparvovec-rokl**\n*   **Delavirdine**\n*   **Demeclocycline**\n*   **Denileukin Diftitox Injection**\n*   **Denosumab Injection**\n*   **Deoxycholic Acid Injection**\n*   **Desipramine**\n*   **Desloratadine**\n*   **Desmopressin**\n*   **Desmopressin Nasal**\n*   **Desonide Topical**\n*   **Desoximetasone Topical**\n*   **Desvenlafaxine**\n*   **Deucravacitinib**\n*   **Deuruxolitinib**\n*   **Deutetrabenazine**\n*   **Dexamethasone**\n*   **Dexamethasone Injection**\n*   **Dexamethasone Ophthalmic**\n*   **Dexlansoprazole**\n*   **Dexmedetomidine Sublingual and Buccal**\n*   **Dexmethylphenidate**\n*   **Dexrazoxane Injection**\n*   **Dextroamphetamine**\n*   **Dextroamphetamine and Amphetamine**\n*   **Dextromethorphan**\n*   **Dextromethorphan and Bupropion**\n*   **Dextromethorphan and Quinidine**\n*   **Diazepam**\n*   **Diazepam Buccal**\n*   **Diazepam Nasal Spray**\n*   **Diazepam Rectal**\n*   **Diclofenac**\n*   **Diclofenac and Misoprostol**\n*   **Diclofenac Ophthalmic**\n*   **Diclofenac Topical (actinic keratosis)**\n*   **Diclofenac Topical (arthritis pain)**\n*   **Diclofenac Transdermal Patch**\n*   **Dicloxacillin**\n*   **Dicyclomine**\n*   **Didanosine**\n*   **Diethylpropion**\n*   **Difelikefalin Injection**\n*   **Diflorasone Topical**\n*   **Diflunisal**\n*   **Difluprednate Ophthalmic**\n*   **Digoxin**\n*   **Dihydroergotamine Injection**\n*   **Dihydroergotamine Nasal Spray**\n*   **Diltiazem**\n*   **Dimenhydrinate**\n*   **Dimethyl Fumarate**\n*   **Dinoprostone**\n*   **Dinutuximab Injection**\n*   **Diphenhydramine**\n*   **Diphenhydramine Injection**\n*   **Diphenhydramine Topical**\n*   **Diphenoxylate**\n*   **Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine**\n*   **Dipivefrin Ophthalmic**\n*   **Dipyridamole**\n*   **Diroximel Fumarate**\n*   **Disopyramide**\n*   **Disulfiram**\n*   **Docetaxel Injection**\n*   **Dofetilide**\n*   **Dolasetron**\n*   **Dolasetron Injection**\n*   **Dolutegravir**\n*   **Dolutegravir and Lamivudine**\n*   **Dolutegravir and Rilpivirine**\n*   **Donanemab-azbt Injection**\n*   **Donepezil**\n*   **Doravirine**\n*   **Doravirine, Lamivudine, and Tenofovir**\n*   **Doripenem Injection**\n*   **Dornase Alfa**\n*   **Dorzolamide and Timolol Ophthalmic**\n*   **Dorzolamide Ophthalmic**\n*   **Dostarlimab-gxly Injection**\n*   **Doxazosin**\n*   **Doxepin (Depression, Anxiety)**\n*   **Doxepin (Insomnia)**\n*   **Doxepin Topical**\n*   **Doxercalciferol**\n*   **Doxercalciferol Injection**\n*   **Doxorubicin**\n*   **Doxorubicin Lipid Complex Injection**\n*   **Doxycycline**\n*   **Doxycycline Injection**\n*   **Doxylamine**\n*   **Doxylamine and Pyridoxine**\n*   **Dronabinol**\n*   **Dronedarone**\n*   **Droxidopa**\n*   **Dulaglutide Injection**\n*   **Duloxetine**\n*   **Dupilumab Injection**\n*   **Durlobactam Injection and Sulbactam Injection**\n*   **Durvalumab Injection**\n*   **Dutasteride**\n*   **Duvelisib**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n* **Ergoloid Mesylates**\n* **Ergotamine and Caffeine**\n* **Eribulin Injection**\n* **Erlotinib**\n* **Ertapenem Injection**\n* **Ertugliflozin**\n* **Erythromycin**\n* **Erythromycin and Benzoyl Peroxide Topical**\n* **Erythromycin and Sulfisoxazole**\n* **Erythromycin Ophthalmic**\n* **Escitalopram**\n* **Esketamine Nasal Spray**\n* **Eslicarbazepine**\n* **Esomeprazole**\n* **Esomeprazole Injection**\n* **Estazolam**\n* **Estradiol Topical**\n* **Estradiol Transdermal Patch**\n* **Estramustine**\n* **Estrogen**\n* **Estrogen and Bazedoxifene**\n* **Estrogen and Progestin (Hormone Replacement Therapy)**\n* **Estrogen and Progestin (Oral Contraceptives)**\n* **Estrogen and Progestin (Transdermal Patch Contraceptives)**\n* **Estrogen and Progestin (Vaginal Ring)**\n* **Estrogen Injection**\n* **Estrogen Vaginal**\n* **Eszopiclone**\n* **Etanercept Injection**\n* **Etelcalcetide Injection**\n* **Ethacrynic Acid**\n* **Ethambutol**\n* **Ethosuximide**\n* **Etidronate**\n* **Etodolac**\n* **Etoposide**\n* **Etoposide Injection**\n* **Etranacogene dezaparvovec-drlb Injection**\n* **Etrasimod**\n* **Etravirine**\n* **Everolimus**\n* **Evinacumab-dgnb**\n* **Evolocumab Injection**\n* **Exagamglogene autotemcel**\n* **Exemestane**\n* **Exenatide Injection**\n* **Ezetimibe**\n* **Ezogabine**\n\n\\n\\n\n\n* **Famciclovir**\n* **Famotidine**\n* **Famotidine Injection**\n* **Fam-trastuzumab deruxtecan-nxki Injection**\n* **Faricimab-svoa Injection**\n* **Febuxostat**\n* **Fedratinib**\n* **Felbamate**\n* **Felodipine**\n* **Fenfluramine**\n* **Fenofibrate**\n* **Fenoprofen**\n* **Fentanyl**\n* **Fentanyl Nasal Spray**\n* **Fentanyl Sublingual Spray**\n* **Fentanyl Transdermal Patch**\n* **Ferric Carboxymaltose Injection**\n* **Ferric Citrate**\n* **Ferumoxytol Injection**\n* **Fesoterodine**\n* **Fexofenadine**\n* **Fexofenadine and Pseudoephedrine**\n* **Fezolinetant**\n* **Fidanacogene elaparvovec**\n* **Fidaxomicin**\n* **Filgrastim Injection**\n* **Finerenone**\n* **Finasteride**\n* **Fingolimod**\n* **Flavoxate**\n* **Flecainide**\n* **Flibanserin**\n* **Floxuridine**\n* **Fluconazole**\n* **Fluconazole Injection**\n* **Fludarabine Injection**\n* **Fludrocortisone Acetate**\n* **Flunisolide Nasal Spray**\n* **Flunisolide Oral Inhalation**\n\n---\n\n**AHFS Patient Medication Information**\n\n**Fingolimod**\n\n* A medication used to treat multiple sclerosis\n* Works by reducing inflammation in the brain and spinal cord\n\n**Flavoxate**\n\n* An oral medication used to treat bladder problems, such as urinary frequency or urgency\n* Relaxes the muscles in the bladder and urethra\n\n**Flecainide**\n\n* An antiarrhythmic medication used to treat irregular heartbeats\n* Works by regulating the electrical activity of the heart\n\n**Flibanserin**\n\n* A medication used to treat low libido in women\n* Works by increasing the levels of certain neurotransmitters in the brain\n\n**Floxuridine**\n\n* A chemotherapy medication used to treat cancer of the cervix, rectum, or anus\n* Works by killing cancer cells and slowing their growth\n\n**Fluconazole**\n\n* An antifungal medication used to treat fungal infections, such as thrush or vaginal yeast infection\n* Works by stopping the growth of fungi\n\n**Fluoxetine**\n\n* A selective serotonin reuptake inhibitor (SSRI) used to treat depression, anxiety disorders, and some eating disorders\n* Works by increasing the levels of certain neurotransmitters in the brain\n\n**Folic Acid**\n\n* A vitamin used to prevent or treat folic acid deficiency\n* Important for preventing birth defects of the baby's brain or spine during pregnancy\n\n**Formoterol**\n\n* A long-acting beta2-adrenergic receptor agonist (LABA) used to treat asthma and chronic obstructive pulmonary disease (COPD)\n* Works by relaxing the muscles in the airways and increasing airflow\n\n**Fosamprenavir**\n\n* A protease inhibitor used to treat HIV infection\n* Works by reducing the amount of HIV in the body\n\n**Foscarbidopa and Foslevodopa Injection**\n\n* A medication used to treat Parkinson's disease\n* Works by increasing the levels of certain neurotransmitters in the brain\n\n**Foscarnet**\n\n* An antiviral medication used to treat cytomegalovirus (CMV) infection\n* Works by stopping the growth of CMV\n\n**Fosfomycin**\n\n* An antibiotic used to treat urinary tract infections\n* Works by killing bacteria that cause UTIs\n\n**Fosinopril**\n\n* A medication used to treat high blood pressure and heart failure\n* Works by relaxing the blood vessels and increasing urine production\n\n**Fremanezumab-vfrm Injection**\n\n* A medication used to treat migraines\n* Works by reducing inflammation in the brain and blocking pain pathways\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **Imipenem, Cilastatin, and Relebactam Injection**\n*   **Imipramine**\n*   **Imiquimod Topical**\n*   **Immune Globulin Intramuscular (Human)**\n*   **Inavolisib**\n*   **Inclisiran Injection**\n*   **IncobotulinumtoxinA Injection**\n*   **Indacaterol Oral Inhalation**\n*   **Indapamide**\n*   **Indinavir**\n*   **Indomethacin**\n*   **Indomethacin Rectal**\n*   **Infigratinib**\n*   **Infliximab, Infliximab-dyyb, Infliximab-abda Injection**\n*   **Influenza Vaccine, Inactivated or Recombinant**\n*   **Influenza Vaccine, Live Intranasal**\n*   **Ingenol Mebutate Topical**\n*   **Inotuzumab Ozogamicin Injection**\n*   **Insulin Aspart (rDNA Origin) Injection**\n*   **Insulin Degludec (rDNA Origin) Injection**\n*   **Insulin Detemir (rDNA Origin) Injection**\n*   **Insulin Glargine (rDNA origin) Injection**\n*   **Insulin Glulisine (rDNA origin) Injection**\n*   **Insulin Human Inhalation**\n*   **Insulin Lispro Injection**\n*   **Interferon Alfa-2b Injection**\n*   **Interferon Beta-1a Intramuscular Injection**\n*   **Interferon Beta-1a Subcutaneous Injection**\n*   **Interferon Beta-1b Injection**\n*   **Interferon Gamma-1b Injection**\n*   **Ipilimumab Injection**\n*   **Ipratropium Nasal Spray**\n*   **Ipratropium Oral Inhalation**\n*   **Iptacopan**\n*   **Irbesartan**\n*   **Irinotecan Injection**\n*   **Irinotecan Lipid Complex Injection**\n*   **Iron Dextran Injection**\n*   **Iron Sucrose Injection**\n*   **Iron Supplements**\n*   **Isatuximab-irfc Injection**\n*   **Isavuconazonium**\n*   **Isavuconazonium Injection**\n*   **Isocarboxazid**\n*   **Isoetharine Oral Inhalation**\n*   **Isoniazid**\n*   **Isosorbide**\n*   **Isotretinoin**\n*   **Isoxsuprine**\n*   **Isradipine**\n*   **Istradefylline**\n*   **Itraconazole**\n*   **Ivabradine**\n*   **Ivacaftor**\n*   **Ivermectin**\n*   **Ivermectin Topical**\n*   **Ivosidenib**\n*   **Ixazomib**\n*   **Ixekizumab Injection**\n\n\\n\\n\n\n*   **Japanese Encephalitis Vaccine**\n\n\\n\\n\n\n*   **Ketoconazole**\n*   **Ketoconazole Topical**\n*   **Ketoprofen**\n*   **Ketorolac**\n*   **Ketorolac Injection**\n*   **Ketorolac Nasal Spray**\n*   **Ketorolac Ophthalmic**\n*   **Ketotifen Ophthalmic**\n\n\\n\\n\n\n*   **Labetalol**\n*   **Lacosamide**\n*   **Lacosamide Injection**\n*   **Lactic Acid, Citric Acid, and Potassium Bitartrate Vaginal Contraceptive**\n*   **Lactulose**\n*   **Lamivudine**\n*   **Lamivudine and Tenofovir**\n*   **Lamivudine and Zidovudine**\n*   **Lamotrigine**\n*   **Lanadelumab-flyo Injection**\n*   **Lanreotide Injection**\n*   **Lansoprazole**\n*   **Lansoprazole, Clarithromycin, and Amoxicillin**\n*   **Lanthanum**\n*   **Lapatinib**\n*   **Larotrectinib**\n*   **Lasmiditan**\n\n\\n\\n\n\n*   **Levobunolol Ophthalmic**\n*   **Levodopa and Carbidopa**\n*   **Levodopa Oral Inhalation**\n*   **Levorphanol**\n*   **Levothyroxine**\n*   **L-glutamine**\n*   **Lidocaine Transdermal Patch**\n*   **Lidocaine Viscous**\n*   **Lifileucel Injection**\n*   **Lifitegrast Ophthalmic**\n*   **Linagliptin**\n*   **Linezolid**\n*   **Linezolid Injection**\n*   **Liothyronine**\n*   **Liotrix**\n*   **Liraglutide Injection**\n*   **Lisdexamfetamine**\n*   **Lisinopril**\n*   **Lisinopril and Hydrochlorothiazide**\n*   **Lisocabtagene Maraleucel Injection**\n*   **Lithium**\n*   **Lixisenatide Injection**\n*   **Lodoxamide Ophthalmic**\n*   **Lofexidine**\n*   **Lomitapide**\n*   **Lomustine**\n*   **Lonafarnib**\n*   **Lonapegsomatropin-tcgd injection**\n*   **Loncastuximab Tesirine-lpyl Injection**\n*   **Loperamide**\n*   **Lopinavir and Ritonavir**\n*   **Loratadine**\n*   **Lorazepam**\n*   **Lorcaserin**\n*   **Lorlatinib**\n*   **Losartan**\n*   **Loteprednol Ophthalmic**\n*   **Lovastatin**\n*   **Lovotibeglogene autotemcel Injection**\n*   **Loxapine**\n*   **Lubiprostone**\n*   **Luliconazole Topical**\n*   **Lumacaftor and Ivacaftor**\n*   **Lumateperone**\n*   **Lurasidone**\n*   **Lurbinectedin Injection**\n*   **Luspatercept-aamt Injection**\n*   **Lusutrombopag**\n*   **Lutetium Lu 177 Vipivotide Tetraxetan Injection**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n* **Macitentan**: A medication used to treat pulmonary arterial hypertension. It works by blocking the action of endothelin, a hormone that constricts blood vessels.\n* **Macitentan and Tadalafil**: A combination of macitentan and tadalafil, used to treat pulmonary arterial hypertension. Macitentan blocks the action of endothelin, while tadalafil relaxes blood vessels.\n* **Magnesium Citrate**: An antacid medication that helps neutralize stomach acid and relieve heartburn.\n* **Magnesium Gluconate**: A mineral supplement that provides magnesium, an essential nutrient for muscle and nerve function.\n* **Magnesium Hydroxide**: An antacid medication that helps neutralize stomach acid and relieve heartburn.\n* **Magnesium Oxide**: An antacid medication that helps neutralize stomach acid and relieve heartburn.\n* **Magnesium Sulfate, Potassium Sulfate, and Sodium Sulfate**: A combination of mineral supplements that provide magnesium, potassium, and sodium, essential nutrients for muscle and nerve function.\n* **Malathion Topical**: An insecticide used to treat head lice infestations.\n* **Maprotiline**: An antidepressant medication that helps increase the levels of certain neurotransmitters in the brain.\n* **Maralixibat**: A medication used to treat primary biliary cholangitis, a liver disease. It works by reducing inflammation and improving liver function.\n* **Maraviroc**: An antiretroviral medication used to treat HIV infection. It works by blocking the action of CCR5 receptors on immune cells.\n* **Margetuximab-cmkb**: A medication used to treat breast cancer. It works by targeting a protein called HER2, which is involved in the growth and spread of cancer cells.\n* **Marstacimab**: A medication used to treat autoimmune disorders such as rheumatoid arthritis. It works by blocking the action of interleukin-17A, a cytokine that promotes inflammation.\n* **Mavacamten**: A medication used to treat hypertrophic cardiomyopathy, a heart condition characterized by thickened heart muscle. It works by relaxing the heart muscle and improving heart function.\n* **Mavorixafor**: A medication used to treat cystic fibrosis, a genetic disorder that affects the lungs and digestive system. It works by increasing the levels of a protein called CFTR, which helps regulate salt and water balance in the body.\n* **Mebendazole**: An antiparasitic medication used to treat intestinal worms such as hookworms and roundworms.\n* **Mecasermin Injection**: A medication used to treat growth hormone deficiency. It works by stimulating the production of growth hormone, which helps promote growth and development.\n* **Mechlorethamine**: A chemotherapy medication used to treat various types of cancer. It works by killing rapidly dividing cells, including cancer cells.\n* **Mechlorethamine Topical**: A topical form of mechlorethamine used to treat skin cancers such as basal cell carcinoma.\n* **Meclizine**: An antihistamine medication used to treat allergies and motion sickness.\n* **Meclofenamate**: A nonsteroidal anti-inflammatory medication used to treat pain, inflammation, and fever associated with arthritis and other musculoskeletal disorders.\n* **Medroxyprogesterone**: A hormone replacement therapy medication used to treat menstrual disorders such as dysmenorrhea and endometriosis. It works by regulating the menstrual cycle and reducing symptoms of menopause.\n* **Medroxyprogesterone Injection**: An injectable form of medroxyprogesterone used to treat menstrual disorders such as dysmenorrhea and endometriosis.\n* **Mefenamic Acid**: A nonsteroidal anti-inflammatory medication used to treat pain, inflammation, and fever associated with arthritis and other musculoskeletal disorders.\n* **Mefloquine**: An antimalarial medication used to prevent and treat malaria. It works by killing the parasites that cause the disease.\n* **Megestrol**: A hormone replacement therapy medication used to treat breast cancer and endometriosis. It works by regulating the menstrual cycle and reducing symptoms of menopause.\n* **Meloxicam**: A nonsteroidal anti-inflammatory medication used to treat pain, inflammation, and fever associated with arthritis and other musculoskeletal disorders.\n* **Meloxicam Injection**: An injectable form of meloxicam used to treat pain, inflammation, and fever associated with arthritis and other musculoskeletal disorders.\n* **Melphalan**: A chemotherapy medication used to treat various types of cancer. It works by killing rapidly dividing cells, including cancer cells.\n* **Melphalan Flufenamide Injection**: An injectable form of melphalan used to treat multiple myeloma, a type of blood cancer.\n* **Melphalan Injection**: An injectable form of melphalan used to treat various types of cancer. It works by killing rapidly dividing cells, including cancer cells.\n* **Memantine**: A medication used to treat Alzheimer's disease. It works by blocking the action of glutamate, a neurotransmitter that can damage brain cells.\n* **Meningococcal ACWY Vaccines (MenACWY)**: A vaccine used to prevent meningitis and septicemia caused by Neisseria meningitidis.\n* **Meperidine**: An opioid medication used to treat pain, cough, and diarrhea. It works by blocking the action of pain receptors in the brain.\n* **Meperidine Injection**: An injectable form of meperidine used to treat pain, cough, and diarrhea.\n* **Mepolizumab Injection**: A medication used to treat severe asthma. It works by blocking the action of interleukin-5, a cytokine that promotes inflammation in the airways.\n* **Meprobamate**: An anxiolytic medication used to treat anxiety disorders such as generalized anxiety disorder and social phobia. It works by increasing the levels of certain neurotransmitters in the brain.\n* **Mercaptopurine**: A chemotherapy medication used to treat acute lymphoblastic leukemia, a type of blood cancer. It works by killing rapidly dividing cells, including cancer cells.\n* **Meropenem and Vaborbactam Injection**: An injectable form of meropenem used to treat bacterial infections such as pneumonia and sepsis. Meropenem works by killing bacteria, while vaborbactam inhibits beta-lactamase enzymes that can make bacteria resistant to antibiotics.\n* **Meropenem Injection**: An injectable form of meropenem used to treat bacterial infections such as pneumonia and sepsis. It works by killing bacteria.\n* **Mesalamine**: A medication used to treat inflammatory bowel disease such as ulcerative colitis. It works by reducing inflammation in the digestive tract.\n* **Mesalamine Rectal**: A rectal form of mesalamine used to treat inflammatory bowel disease such as ulcerative proctitis.\n* **Mesna**: A medication used to prevent bladder damage during chemotherapy treatment for certain types of cancer. It works by blocking the action of acrolein, a toxic compound released during chemotherapy.\n* **Mesna Injection**: An injectable form of mesna used to prevent bladder damage during chemotherapy treatment for certain types of cancer.\n* **Mesoridazine**: A medication used to treat schizophrenia and other psychoses. It works by increasing the levels of certain neurotransmitters in the brain.\n* **Metaproterenol**: A bronchodilator medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing the airway muscles and improving lung function.\n* **Metaxalone**: A muscle relaxant medication used to treat muscle spasms and pain associated with musculoskeletal disorders such as back strain. It works by blocking the action of nerve impulses that cause muscle contractions.\n* **Metformin**: A medication used to treat type 2 diabetes mellitus. It works by reducing glucose production in the liver and improving insulin sensitivity.\n* **Methadone**: An opioid medication used to treat pain, cough, and diarrhea. It works by blocking the action of pain receptors in the brain.\n* **Methadone Injection**: An injectable form of methadone used to treat pain, cough, and diarrhea.\n* **Methamphetamine**: A central nervous system stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by increasing the levels of certain neurotransmitters in the brain.\n* **Methazolamide**: A carbonic anhydrase inhibitor medication used to treat glaucoma, epilepsy, and altitude sickness. It works by reducing intraocular pressure and improving vision.\n* **Methenamine**: An antiseptic medication used to prevent urinary tract infections. It works by killing bacteria in the urine.\n* **Methimazole**: A medication used to treat hyperthyroidism, a condition characterized by an overactive thyroid gland. It works by blocking the production of thyroid hormones.\n* **Methocarbamol**: A muscle relaxant medication used to treat muscle spasms and pain associated with musculoskeletal disorders such as back strain. It works by blocking the action of nerve impulses that cause muscle contractions.\n* **Methotrexate**: A chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, and breast cancer. It works by killing rapidly dividing cells, including cancer cells.\n* **Methotrexate Injection**: An injectable form of methotrexate used to treat various types of cancer, including leukemia, lymphoma, and breast cancer.\n* **Methoxy Polyethylene Glycol-Epoetin Beta Injection**: An injectable form of epoetin beta used to treat anemia associated with chronic kidney disease. It works by stimulating the production of red blood cells.\n* **Methsuximide**: A medication used to treat epilepsy and other seizure disorders. It works by blocking the action of nerve impulses that cause seizures.\n* **Methyclothiazide**: A diuretic medication used to treat hypertension, edema, and heart failure. It works by increasing urine production and reducing fluid retention in the body.\n* **Methyldopa**: A medication used to treat hypertension and other cardiovascular disorders. It works by blocking the action of nerve impulses that cause blood vessels to constrict.\n* **Methyldopa and Hydrochlorothiazide**: A combination of methyldopa and hydrochlorothiazide used to treat hypertension and edema. Methyldopa blocks the action of nerve impulses that cause blood vessels to constrict, while hydrochlorothiazide increases urine production and reduces fluid retention in the body.\n* **Methylergonovine**: A medication used to treat migraine headaches and other vascular disorders. It works by relaxing blood vessels and improving blood flow to the brain.\n* **Methylnaltrexone**: A medication used to treat opioid-induced constipation. It works by blocking the action of opioid receptors in the gut.\n* **Methylphenidate**: A central nervous system stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by increasing the levels of certain neurotransmitters in the brain.\n* **Methylphenidate Transdermal Patch**: A transdermal patch form of methylphenidate used to treat attention deficit hyperactivity disorder (ADHD).\n* **Methylprednisolone**: A corticosteroid medication used to treat inflammation and autoimmune disorders such as rheumatoid arthritis. It works by blocking the action of inflammatory mediators in the body.\n* **Methylprednisolone Injection**: An injectable form of methylprednisolone used to treat inflammation and autoimmune disorders such as rheumatoid arthritis.\n* **Metipranolol Ophthalmic**: A medication used to treat glaucoma, a condition characterized by increased intraocular pressure. It works by reducing intraocular pressure and improving vision.\n* **Metoclopramide**: A medication used to\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **Metronidazole Vaginal**\n*   **Mexiletine**\n*   **Micafungin Injection**\n*   **Miconazole Buccal**\n*   **Miconazole Topical**\n*   **Miconazole Vaginal**\n*   **Midazolam**\n*   **Midazolam Injection**\n*   **Midazolam Nasal Spray**\n*   **Midodrine**\n*   **Midostaurin**\n*   **Mifepristone (Korlym)**\n*   **Mifepristone (Mifeprex)**\n*   **Miglitol**\n*   **Miglustat**\n*   **Milnacipran**\n*   **Minocycline**\n*   **Minocycline Topical**\n*   **Minoxidil**\n*   **Minoxidil Topical**\n*   **Mipomersen Injection**\n*   **Mirabegron**\n*   **Mirikizumab-mrkz Injection**\n*   **Mirtazapine**\n*   **Mirvetuximab soravtansine-gynx Injection**\n*   **Misoprostol**\n*   **Mitapivat**\n*   **Mitomycin**\n*   **Mitomycin Pyelocalyceal**\n*   **Mitotane**\n*   **Mitoxantrone Injection**\n*   **MMR Vaccine (Measles, Mumps, and Rubella)**\n*   **Mobocertinib**\n*   **Modafinil**\n*   **Moexipril**\n*   **Mogamulizumab-kpkc Injection**\n*   **Molindone**\n*   **Molnupiravir**\n*   **Momelotinib**\n*   **Mometasone Nasal Spray**\n*   **Mometasone Oral Inhalation**\n*   **Mometasone Topical**\n*   **Monomethyl Fumarate**\n*   **Montelukast**\n*   **Morphine**\n*   **Morphine Injection**\n*   **Morphine Rectal**\n*   **Mosunetuzumab-axgb Injection**\n*   **Motixafortide**\n*   **Moxetumomab Pasudotox-tdfk Injection**\n*   **Moxifloxacin**\n*   **Moxifloxacin Injection**\n*   **Moxifloxacin Ophthalmic**\n*   **Mupirocin**\n*   **Mycophenolate**\n*   **Mycophenolate Injection**\n\n\\n\\n\n\n**Nabilone**\n\n\\n\\n\n\n*   **Nabumetone**\n*   **Nadofaragene firadenovec-vncg Intravesical**\n*   **Nadolol**\n*   **Nafarelin Nasal Spray**\n*   **Nafcillin Injection**\n*   **Naftifine Topical**\n*   **Nalbuphine Injection**\n*   **Naldemedine**\n*   **Nalmefene Injection**\n*   **Nalmefene Nasal Spray**\n*   **Naloxegol**\n*   **Naloxone Injection**\n*   **Naloxone Nasal Spray**\n*   **Naltrexone**\n*   **Naltrexone and Bupropion**\n*   **Naltrexone Injection**\n*   **Naproxen**\n*   **Naratriptan**\n*   **Natalizumab Injection**\n*   **Nateglinide**\n*   **Naxitamab-gqgk Injection**\n*   **Nebivolol**\n*   **Nebivolol and Valsartan**\n*   **Necitumumab Injection**\n*   **Nedocromil Ophthalmic**\n*   **Nedosiran**\n*   **Nefazodone**\n*   **Nelarabine Injection**\n*   **Nelfinavir**\n*   **Nemolizumab-ilto injection**\n*   **Neomycin Topical**\n*   **Neomycin, Polymyxin, and Bacitracin Ophthalmic**\n*   **Neomycin, Polymyxin, and Bacitracin Topical**\n*   **Neomycin, Polymyxin, and Hydrocortisone Otic**\n*   **Neomycin, Polymyxin, Bacitracin, and Hydrocortisone Ophthalmic**\n*   **Neomycin, Polymyxin, Bacitracin, and Hydrocortisone Topical**\n*   **Nepafenac Ophthalmic**\n*   **Neratinib**\n*   **Netarsudil Ophthalmic**\n*   **Netupitant and Palonosetron**\n*   **Nevirapine**\n*   **Niacin**\n*   **Nicardipine**\n*   **Nicotine Gum**\n*   **Nicotine Lozenges**\n*   **Nicotine Nasal Spray**\n*   **Nicotine Oral Inhalation**\n*   **Nicotine Transdermal Patch**\n*   **Nifedipine**\n*   **Nifurtimox**\n*   **Nilotinib**\n*   **Nilutamide**\n*   **Nimodipine**\n*   **Nintedanib**\n*   **Niraparib**\n*   **Niraparib and Abiraterone**\n*   **Nirmatrelvir and Ritonavir**\n*   **Nirogacestat**\n*   **Nirsevimab-alip**\n*   **Nisoldipine**\n*   **Nitazoxanide**\n*   **Nitrofurantoin**\n*   **Nitroglycerin Spray**\n*   **Nitroglycerin Sublingual**\n*   **Nitroglycerin Topical**\n*   **Nitroglycerin Transdermal Patch**\n*   **Nivolumab Injection**\n*   **Nivolumab and Relatlimab-rmbw**\n*   **Nizatidine**\n*   **Nogapendekin alfa inbakicept-pmln Intravesical**\n*   **Norethindrone**\n*   **Nortriptyline**\n*   **Nusinersen Injection**\n*   **Nystatin**\n*   **Nystatin and Triamcinolone**\n\n---\n\n**AHFS Patient Medication Information**\n\n**Part 11/15**\n\n**Drug List**\n\n* **Obeticholic Acid**\n* **Obinutuzumab Injection**\n* **Ocrelizumab Injection**\n* **Ocrelizumab and Hyaluronidase**\n* **Octreotide**\n* **Octreotide Injection**\n* **Odevixibat**\n* **Ofatumumab Injection (Chronic Lymphocytic Leukemia)**\n* **Ofatumumab Injection (Multiple Sclerosis)**\n* **Ofloxacin**\n* **Ofloxacin Ophthalmic**\n* **Ofloxacin Otic**\n* **Olanzapine**\n* **Olanzapine Injection**\n* **Olanzapine and Samidorphan**\n* **Olaparib**\n* **Olaratumab Injection**\n* **Oliceridine Injection**\n* **Olmesartan**\n* **Olodaterol Oral Inhalation**\n* **Olopatadine Nasal Spray**\n* **Olopatadine Ophthalmic**\n* **Olsalazine**\n* **Olutasidenib**\n* **Omacetaxine Injection**\n* **Omadacycline**\n* **Omadacycline Injection**\n* **Omalizumab Injection**\n* **Ombitasvir, Paritaprevir, and Ritonavir**\n* **Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir**\n* **Omega-3 Fatty Acids**\n* **Omeprazole**\n* **Omeprazole, Clarithromycin, and Amoxicillin**\n* **Omidenepag Isopropyl Ophthalmic**\n* **OnabotulinumtoxinA Injection**\n* **Ondansetron**\n* **Ondansetron Injection**\n* **Opicapone**\n* **Oritavancin Injection**\n* **Orlistat**\n* **Orphenadrine**\n* **Oseltamivir**\n* **Osimertinib**\n* **Ospemifene**\n* **Oteseconazole**\n* **Oxacillin Injection**\n* **Oxaliplatin Injection**\n* **Oxandrolone**\n* **Oxaprozin**\n* **Oxazepam**\n* **Oxcarbazepine**\n* **Oxiconazole**\n* **Oxybutynin**\n* **Oxybutynin Topical**\n* **Oxybutynin Transdermal Patch**\n* **Oxycodone**\n* **Oxymetazoline Nasal Spray**\n* **Oxymetazoline Topical**\n* **Oxymorphone**\n* **Oxytocin Injection**\n* **Ozanimod**\n* **Ozenoxacin**\n\n**Expand Section**\n\n* **Paclitaxel (with albumin) Injection**\n* **Paclitaxel (with polyoxyethylated castor oil) Injection**\n* **Pacritinib**\n* **Palbociclib**\n* **Palifermin**\n* **Paliperidone**\n* **Paliperidone Injection**\n* **Palivizumab Injection**\n* **Palovarotene**\n* **Palonosetron Injection**\n* **Palopegteriparatide Injection**\n* **Pamidronate Injection**\n* **Pancrelipase**\n* **Panitumumab Injection**\n* **Panobinostat**\n* **Pantoprazole**\n* **Pantoprazole Injection**\n* **Papaverine**\n* **Parathyroid Hormone Injection**\n* **Paregoric**\n* **Paroxetine**\n* **Pasireotide Injection**\n* **Patiromer**\n* **Pazopanib**\n* **Peanut (Arachis hypogaea) Allergen Powder-dnfp**\n* **Pegaptanib Injection**\n* **Pegaspargase Injection**\n* **Pegcetacoplan**\n* **Pegfilgrastim Injection**\n* **Peginterferon Alfa-2a Injection**\n* **Peginterferon Alfa-2b (PEG-Intron)**\n* **Peginterferon Alfa-2b Injection (Sylatron)**\n* **Peginterferon Beta-1a Injection**\n* **Pegloticase Injection**\n* **Pegunigalsidase alfa-iwxj Injection**\n* **Pegvaliase-pqpz Injection**\n* **Pembrolizumab Injection**\n* **Pemetrexed Injection**\n* **Pemigatinib**\n* **Pemivibart**\n* **Penbutolol**\n* **Penciclovir Cream**\n* **Penicillamine**\n* **Penicillin G (Potassium, Sodium) Injection**\n* **Penicillin G Benzathine and Penicillin G Procaine Injection**\n* **Penicillin G Benzathine Injection**\n* **Penicillin G Procaine Injection**\n* **Penicillin V Potassium**\n* **Pentamidine Injection**\n* **Pentamidine Oral Inhalation**\n* **Pentazocine**\n* **Pentosan Polysulfate**\n* **Pentostatin Injection**\n* **Pentoxifylline**\n* **Peramivir Injection**\n* **Perampanel**\n* **Perfluorohexyloctane Ophthalmic**\n* **Perindopril**\n* **Permethrin Topical**\n* **Perphenazine**\n* **Pertuzumab Injection**\n* **Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection**\n* **Pexidartinib**\n* **Phenazopyridine**\n* **Phenelzine**\n* **Phenobarbital**\n* **Phenoxybenzamine**\n* **Phentermine**\n* **Phentermine and Topiramate**\n* **Phenylephrine**\n* **Phenylephrine Nasal Spray**\n* **Phenytoin**\n* **Phenytoin Injection**\n* **Phytonadione**\n* **Pilocarpine**\n* **Pilocarpine Ophthalmic**\n* **Pimavanserin**\n* **Pimecrolimus Topical**\n* **Pimozide**\n* **Pindolol**\n* **Pioglitazone**\n* **Piperacillin and Tazobactam Injection**\n* **Pirbuterol Acetate Oral Inhalation**\n* **Pirfenidone**\n* **Piroxicam**\n* **Pirtobrutinib**\n* **Pitavastatin**\n* **Pitolisant**\n* **Pivmecillinam**\n* **Plazomicin Injection**\n* **Plecanatide**\n* **Plerixafor Injection**\n* **Pneumococcal Conjugate Vaccine**\n* **Pneumococcal Polysaccharide Vaccine**\n* **Polatuzumab vedotin-piiq Injection**\n* **Polio Vaccine**\n* **Polyethylene Glycol 3350**\n* **Polyethylene glycol-electrolyte solution (PEG-ES)**\n* **Polymyxin B and Trimethoprim Ophthalmic**\n* **Pomalidomide**\n* **Ponatinib**\n* **Ponesimod**\n* **Posaconazole**\n* **Posaconazole Injection**\n* **Potassium**\n* **Potassium Iodide**\n* **Pozelimab-bbfg**\n* **PrabotulinumtoxinA-xvfs Injection**\n* **Pralatrexate Injection**\n* **Pralsetinib**\n* **Pramipexole**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **lidomide**\n*   **Ponatinib**\n*   **Ponesimod**\n*   **Posaconazole**\n*   **Posaconazole Injection**\n*   **Potassium**\n*   **Potassium Iodide**\n*   **Pozelimab-bbfg**\n*   **PrabotulinumtoxinA-xvfs Injection**\n*   **Pralatrexate Injection**\n*   **Pralsetinib**\n*   **Pramipexole**\n*   **Pramlintide Injection**\n*   **Pramoxine**\n*   **Prasterone Vaginal**\n*   **Prasugrel**\n*   **Pravastatin**\n*   **Praziquantel**\n*   **Prazosin**\n*   **Prednisolone**\n*   **Prednisolone Ophthalmic**\n*   **Prednisone**\n*   **Pregabalin**\n*   **Pretomanid**\n*   **Primaquine**\n*   **Primidone**\n*   **Probenecid**\n*   **Procainamide**\n*   **Procarbazine**\n*   **Prochlorperazine**\n*   **Progesterone**\n*   **Progestin-Only (drospirenone) Oral Contraceptives**\n*   **Progestin-Only (norethindrone) Oral Contraceptives**\n*   **Progestin-Only (norgestrel) Oral Contraceptives**\n*   **Progesterone Vaginal**\n*   **Promethazine**\n*   **Propafenone**\n*   **Propantheline**\n*   **Propranolol (Cardiovascular)**\n*   **Propranolol (Infantile Hemangioma)**\n*   **Propylthiouracil**\n*   **Protriptyline**\n*   **Prucalopride**\n*   **Pseudoephedrine**\n*   **Psyllium**\n*   **Pyrantel**\n*   **Pyrazinamide**\n*   **Pyrethrin and Piperonyl Butoxide Topical**\n*   **Pyridostigmine**\n*   **Pyridoxine**\n\n\\n\\n\n\n*   **Quetiapine**\n*   **Quinapril**\n*   **Quinidine**\n*   **Quinine**\n*   **Quinupristin and Dalfopristin Injection**\n*   **Quizartinib**\n\n\\n\\n\n\n*   **Rabeprazole**\n*   **Rabies Vaccine**\n*   **Raloxifene**\n*   **Raltegravir**\n*   **Ramelteon**\n*   **Ramipril**\n*   **Ramucirumab Injection**\n*   **Ranibizumab Injection**\n*   **Ranitidine**\n*   **Ranitidine Injection**\n*   **Ranolazine**\n*   **Rasagiline**\n*   **Rasburicase Injection**\n*   **Ravulizumab-cwvz Injection**\n*   **Recombinant Zoster (Shingles) Vaccine (RZV)**\n*   **Regorafenib**\n*   **Relugolix**\n*   **Relugolix, Estradiol, and Norethindrone**\n*   **Remdesivir**\n*   **Repaglinide**\n*   **Repotrectinib**\n*   **Reserpine**\n*   **Reslizumab Injection**\n*   **Resmetirom**\n*   **Retapamulin**\n*   **Retifanlimab-dlwr Injection**\n*   **Revumenib**\n*   **Revefenacin Oral Inhalation**\n*   **Rezafungin Injection**\n*   **Ribavirin**\n*   **Ribociclib**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n* **Repaglinide**\n* **Repotrectinib**\n* **Reserpine**\n* **Reslizumab Injection**\n* **Resmetirom**\n* **Retapamulin**\n* **Retifanlimab-dlwr Injection**\n* **Revumenib**\n* **Revefenacin Oral Inhalation**\n* **Rezafungin Injection**\n* **Ribavirin**\n* **Ribociclib**\n* **Rifabutin**\n* **Rifampin**\n* **Rifamycin**\n* **Rifapentine**\n* **Rifaximin**\n* **Rilonacept Injection**\n* **Rilpivirine**\n* **Riluzole**\n* **RimabotulinumtoxinB Injection**\n* **Rimantadine**\n* **Rimegepant**\n* **Riociguat**\n* **Ripretinib**\n* **Risankizumab-rzaa Injection**\n* **Risedronate**\n* **Risperidone**\n* **Risperidone Injection**\n* **Ritlecitinib**\n* **Ritonavir**\n* **Rituximab and Hyaluronidase Human Injection**\n* **Rituximab Injection**\n* **Rivaroxaban**\n* **Rivastigmine**\n* **Rivastigmine Transdermal Patch**\n* **Rizatriptan**\n* **Roflumilast**\n* **Rolapitant**\n* **Romidepsin Injection**\n* **Romiplostim Injection**\n* **Romosozumab-aqqg Injection**\n* **Ropeginterferon alfa-2b**\n* **Ropinirole**\n* **Rosiglitazone**\n* **Rosuvastatin**\n* **Rotavirus Vaccine**\n* **Rotigotine Transdermal Patch**\n* **Rozanolixizumab-noli**\n* **RSV (Respiratory Syncytial Virus) Vaccine**\n* **RSV (Respiratory Syncytial Virus) Vaccine, mRNA**\n* **Rucaparib**\n* **Rufinamide**\n* **Ruxolitinib**\n* **Ruxolitinib Topical**\n\n\\n\\n\n\n* **Sacituzumab govitecan-hziy Injection**\n* **Safinamide**\n* **Salicylic Acid Topical**\n* **Salmeterol Oral Inhalation**\n* **Salsalate**\n* **Sapropterin**\n* **Saquinavir**\n* **Sarecycline**\n* **Sargramostim**\n* **Sarilumab Injection**\n* **Satralizumab-mwge Injection**\n* **Saxagliptin**\n* **Scopolamine Transdermal Patch**\n* **Secnidazole**\n* **Secobarbital**\n* **Secukinumab Injection**\n* **Seladelpar**\n* **Selegiline**\n* **Selegiline Transdermal Patch**\n* **Selenium Sulfide**\n* **Selexipag**\n* **Selexipag Injection**\n* **Selinexor**\n* **Selprecatinib**\n* **Selumetinib**\n* **Semaglutide**\n* **Semaglutide Injection**\n* **Senna**\n* **Serdexmethylphenidate and Dexmethylphenidate**\n* **Serogroup B Meningococcal Vaccine (MenB)**\n* **Sertaconazole Topical**\n* **Sertraline**\n* **Setmelanotide Injection**\n* **Sevelamer**\n* **Shingles (Zoster) Vaccine (ZVL)**\n* **Sildenafil**\n* **Silodosin**\n* **Siltuximab Injection**\n* **Silver Sulfadiazine**\n* **Simeprevir**\n* **Simethicone**\n* **Simvastatin**\n* **Siponimod**\n* **Sipuleucel-T Injection**\n* **Sirolimus**\n* **Sirolimus (with albumin) Injection**\n* **Sitagliptin**\n* **Smallpox/Mpox Vaccine**\n* **Sodium Bicarbonate**\n* **Sodium Ferric Gluconate Injection**\n* **Sodium Oxybate**\n* **Sodium Phenylbutyrate and Taurursodiol**\n* **Sodium Phosphate**\n* **Sodium Phosphate Rectal**\n* **Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid**\n* **Sodium Polystyrene Sulfonate**\n* **Sodium Zirconium Cyclosilicate**\n* **Sofosbuvir**\n* **Sofosbuvir and Velpatasvir**\n* **Sofosbuvir, Velpatasvir, and Voxilaprevir**\n* **Sofpironium**\n* **Solifenacin**\n* **Solriamfetol**\n* **Somapacitan-beco Injection**\n* **Somatrogon-ghla**\n* **Somatropin**\n* **Sonidegib**\n* **Sorafenib**\n* **Sotagliflozin**\n* **Sotalol**\n* **Sotatercept-csrk Injection**\n* **Sotorasib**\n* **Sotrovimab Injection**\n* **Spesolimab-sbzo Injection**\n* **Spinosad Topical**\n* **Spironolactone**\n* **Spironolactone and Hydrochlorothiazide**\n* **Stavudine**\n* **Stiripentol**\n* **Stool Softeners**\n* **Streptozocin**\n* **Strontium-89 Chloride**\n* **Sucralfate**\n* **Sulconazole Topical**\n* **Sulfacetamide Ophthalmic**\n* **Sulfadiazine**\n* **Sulfasalazine**\n* **Sulfinpyrazone**\n* **Sulindac**\n* **Sumatriptan**\n* **Sumatriptan Injection**\n* **Sumatriptan Nasal**\n* **Sunitinib**\n* **Sutimlimab-jome Injection**\n\n---\n\n**AHFS Patient Medication Information**\n\n\\n\\n\n\n*   **Sulconazole Topical**\n*   **Sulfacetamide Ophthalmic**\n*   **Sulfadiazine**\n*   **Sulfasalazine**\n*   **Sulfinpyrazone**\n*   **Sulindac**\n*   **Sumatriptan**\n*   **Sumatriptan Injection**\n*   **Sumatriptan Nasal**\n*   **Sunitinib**\n*   **Sutimlimab-jome Injection**\n*   **Suvorexant**\n\n\\n\\n\n\n*   **Tacrolimus**\n*   **Tacrolimus Injection**\n*   **Tacrolimus Topical**\n*   **Tadalafil**\n*   **Tafamidis**\n*   **Tafasitamab-cxix Injection**\n*   **Tafenoquine**\n*   **Tafluprost Ophthalmic**\n*   **Tagraxofusp-erzs Injection**\n*   **Talazoparib**\n*   **Talc Intrapleural**\n*   **Talimogene Laherparepvec Injection**\n*   **Talquetamab-tgvs**\n\n\\n\\n\n\n*   **Tamoxifen**\n*   **Tamsulosin**\n*   **Tapentadol**\n*   **Tapinarof Topical**\n*   **Tarlatamab**\n*   **Tasimelteon**\n*   **Tavaborole Topical**\n*   **Tazarotene Topical**\n\n\\n\\n\n\n*   **Tazemetostat**\n*   **Tebentafusp Injection**\n*   **Teclistamab-cqyv Injection**\n*   **Tedizolid**\n*   **Tedizolid Injection**\n*   **Teduglutide Injection**\n*   **Tegaserod**\n*   **Telaprevir**\n*   **Telavancin Injection**\n\n\\n\\n\n\n*   **Telbivudine**\n*   **Telithromycin**\n*   **Telmisartan**\n*   **Telotristat**\n*   **Temazepam**\n*   **Temozolomide**\n*   **Temozolomide Injection**\n\n\\n\\n\n\n*   **Temsirolimus**\n*   **Tenapanor (Ibsrela)**\n*   **Tenapanor (Xpohzah)**\n*   **Teniposide Injection**\n*   **Tenofovir disoproxil fumarate/Tenofovir alafenamide**\n\n\\n\\n\n\n*   **Teplizumab-mzwv injection**\n*   **Tepotinib**\n*   **Teprotumumab-trbw Injection**\n*   **Terazosin**\n*   **Terbinafine**\n*   **Terbutaline**\n*   **Terconazole Vaginal Cream, Vaginal Suppositories**\n\n\\n\\n\n\n*   **Teriflunomide**\n*   **Teriparatide (rDNA origin) Injection**\n*   **Tesamorelin Injection**\n*   **Testosterone**\n*   **Testosterone Buccal**\n*   **Testosterone Injection**\n\n\\n\\n\n\n*   **Tetanus, Diphtheria (Td) Vaccine**\n*   **Tetrabenazine**\n*   **Tetracycline**\n*   **Tetrahydrozoline Ophthalmic**\n*   **Tezacaftor and Ivacaftor**\n\n\\n\\n\n\n*   **Thalidomide**\n*   **Theophylline**\n*   **Thiamine (Vitamin B1)**\n*   **Thioguanine**\n*   **Thioridazine**\n*   **Thiotepa Injection**\n\n\\n\\n\n\n*   **Thiothixene**\n*   **Thyroid**\n*   **Tiagabine**\n*   **Ticagrelor**\n*   **Ticlopidine**\n*   **Tigecycline Injection**\n\n\\n\\n\n\n*   **Tildrakizumab-asmn injection**\n*   **Tiludronate**\n*   **Timolol**\n*   **Timolol Ophthalmic**\n*   **Tinidazole**\n*   **Tiotropium Oral Inhalation**\n\n\\n\\n\n\n*   **Tipranavir**\n*   **Tirbanibulin Topical**\n*   **Tirzepatide Injection**\n*   **Tisagenlecleucel Injection**\n*   **Tisotumab vedotin-tftv**\n\n\\n\\n\n\n*   **Tislelizumab-jsgr**\n*   **Tivozanib**\n*   **Tixagevimab and Cilgavimab**\n*   **Tizanidine**\n*   **Tobramycin Injection**\n\n\\n\\n\n\n*   **Tocilizumab Injection**\n*   **Tofacitinib**\n*   **Tofersen**\n*   **Tolazamide**\n*   **Tolbutamide**\n*   **Tolcapone**\n\n\\n\\n\n\n*   **Tolmetin**\n*   **Tolnaftate**\n*   **Tolterodine**\n*   **Tolvaptan (low blood sodium)**\n*   **Tolvaptan (kidney disease)**\n\n\\n\\n\n\n*   **Topiramate**\n*   **Topotecan**\n*   **Topotecan Injection**\n*   **Toremifene**\n*   **Toripalimab-tpzi Injection**\n\n\\n\\n\n\n*   **Torsemide**\n*   **Tovorafenib**\n*   **Trabectedin Injection**\n*   **Tralokinumab-ldrm Injection**\n*   **Tramadol**\n\n\\n\\n\n\n*   **Trametinib**\n*   **Trandolapril**\n*   **Trandolapril and Verapamil**\n*   **Tranexamic Acid**\n*   **Tranylcypromine**\n\n\\n\\n\n\n*   **Trastuzumab and hyaluronidase-oysk Injection**\n*   **Trastuzumab Injection**\n*   **Travoprost Ophthalmic**\n*   **Trazodone**\n*   **Tremelimumab-actl Injection**\n\n\\n\\n\n\n*   **Treprostinil**\n*   **Treprostinil Injection**\n*   **Treprostinil Oral Inhalation**\n*   **Tretinoin**\n*   **Tretinoin Topical**\n\n\\n\\n\n\n*   **Triamcinolone**\n*   **Triamcinolone Nasal Spray**\n*   **Triamcinolone Topical**\n*   **Triamterene**\n*   **Triamterene and Hydrochlorothiazide**\n\n\\n\\n\n\n*   **Triazolam**\n*   **Triclabendazole**\n*   **Trifarotene Topical**\n*   **Trifluoperazine**\n*   **Trifluridine and Tipiracil**\n\n\\n\\n\n\n*   **Trihexyphenidyl**\n*   **Trilaciclib Injection**\n*   **Trimethadione**\n*   **Trimethobenzamide**\n*   **Trimethoprim**\n\n\\n\\n\n\n*   **Trimipramine**\n*   **Triptorelin Injection**\n*   **Trofinetide**\n*   **Trospium**\n*   **Tucatinib**\n\n---\n\n**AHFS Patient Medication Information**\n\nWelcome to the AHFS Patient Medication Information section, where we provide detailed information on various medications. In this part of our 15-part series, we'll cover medications starting with the letter T.\n\n**T Medications**\n\n1. **Trifluridine and Tipiracil**: A combination medication used to treat certain types of cancer.\n2. **Trihexyphenidyl**: An anticholinergic medication used to treat Parkinson's disease symptoms.\n3. **Trilaciclib Injection**: A medication used to treat a specific type of cancer.\n4. **Trimethadione**: An anticonvulsant medication used to treat epilepsy.\n5. **Trimethobenzamide**: An antiemetic medication used to prevent nausea and vomiting.\n6. **Trimethoprim**: An antibiotic medication used to treat bacterial infections.\n7. **Trimipramine**: A tricyclic antidepressant medication used to treat depression.\n8. **Triptorelin Injection**: A medication used to treat certain types of cancer.\n9. **Trofinetide**: A medication used to treat a specific type of cancer.\n10. **Trospium**: An antimuscarinic medication used to treat overactive bladder symptoms.\n11. **Tucatinib**: A medication used to treat a specific type of cancer.\n12. **Typhoid Vaccine**: A vaccine used to prevent typhoid fever.\n\n**U Medications**\n\n1. **Ublituximab-xiiy Injection**: A medication used to treat a specific type of cancer.\n2. **Ubrogepant**: A medication used to treat migraines.\n3. **Ulipristal**: A medication used to prevent pregnancy after unprotected sex.\n4. **Umbralisib**: A medication used to treat a specific type of cancer.\n5. **Umeclidinium and Vilanterol Oral Inhalation**: An inhalation medication used to treat chronic obstructive pulmonary disease (COPD).\n6. **Umeclidinium Oral Inhalation**: An inhalation medication used to treat COPD.\n7. **Unoprostone Ophthalmic**: A medication used to treat glaucoma.\n8. **Upadacitinib**: A medication used to treat rheumatoid arthritis.\n9. **Uridine Triacetate**: A medication used to treat a specific type of cancer.\n10. **Ursodiol**: A medication used to treat certain types of gallstones.\n11. **Ustekinumab Injection**: A medication used to treat psoriasis and other autoimmune disorders.\n\n**V Medications**\n\n1. **Vadadustat**: A medication used to treat anemia in patients with chronic kidney disease.\n2. **Valacyclovir**: An antiviral medication used to treat herpes simplex virus infections.\n3. **Valbenazine**: A medication used to treat tardive dyskinesia.\n4. **Valganciclovir**: An antiviral medication used to treat cytomegalovirus (CMV) infections.\n5. **Valproic Acid**: An anticonvulsant medication used to treat epilepsy and bipolar disorder.\n6. **Valoctocogene roxaparvovec-rvox Injection**: A gene therapy medication used to treat hemophilia A.\n7. **Valrubicin Intravesical**: A medication used to treat bladder cancer.\n8. **Valsartan**: An angiotensin II receptor antagonist medication used to treat high blood pressure.\n9. **Valsartan and Hydrochlorothiazide**: A combination medication used to treat high blood pressure.\n10. **Valsartan and Sacubitril**: A combination medication used to treat heart failure.\n\n**W Medications**\n\n1. **Warfarin**: An anticoagulant medication used to prevent blood clots.\n\n**X Medications**\n\n1. **Xanomeline and Trospium Chloride**: A combination medication used to treat overactive bladder symptoms.\n\n**Y Medications**\n\n1. **Yellow Fever Vaccine**: A vaccine used to prevent yellow fever.\n\n**Z Medications**\n\n1. **Zafirlukast**: A medication used to treat asthma.\n2. **Zaleplon**: A sedative-hypnotic medication used to treat insomnia.\n3. **Zanamivir Oral Inhalation**: An inhalation medication used to treat influenza.\n4. **Zanidatamab-hrli Injection**: A medication used to treat a specific type of cancer.\n5. **Zanubrutinib**: A medication used to treat a specific type of cancer.\n6. **Zavegepant Nasal Spray**: A medication used to treat migraines.\n7. **Zidovudine**: An antiretroviral medication used to treat HIV/AIDS.\n8. **Zileuton**: A leukotriene receptor antagonist medication used to treat asthma.\n\nThis concludes our list of medications starting with the letter T, U, V, W, X, Y, and Z. Remember to always consult a healthcare professional before taking any new medication.",
    "category": "drug&supplements"
  },
  {
    "title": "AIP gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aip/",
    "content": "**AIP Gene**\n\nThe AIP gene provides instructions for making a protein called AH receptor-interacting protein (AIP). Although AIP's function is not well understood, it is known to interact with numerous other proteins, including one called the aryl hydrocarbon receptor. Through these interactions, AIP likely helps regulate certain cell processes, such as:\n\n*   The growth and division (proliferation) of cells\n*   The process by which cells mature to carry out specific functions (differentiation)\n*   Cell survival\n\nThis protein is thought to act as a tumor suppressor, which means it normally helps prevent cells from proliferating in an uncontrolled way.\n\n**Health Conditions Related to Genetic Changes**\n\nMutations in the AIP gene cause 15 to 25 percent of cases of familial isolated pituitary adenoma (FIPA), an inherited condition characterized by development of a noncancerous tumor in the pituitary gland (called a pituitary adenoma). This small gland at the base of the brain produces hormones that control many important body functions.\n\nAffected individuals within the same family may develop the same type of pituitary adenoma or different types. People with a mutation in the AIP gene most commonly develop a type of pituitary adenoma called a somatotropinoma. FIPA tumors caused by AIP gene mutations usually occur at a younger age and are larger than those without AIP gene mutations.\n\nMany kinds of mutations in the AIP gene have been identified in affected families. Some of these changes lead to an abnormally short protein or no protein at all. Other mutations change single protein building blocks (amino acids) in AIP. Although it is unclear how these mutations are involved in tumor development, researchers believe that the alterations disrupt interaction between AIP and one or more other proteins.\n\nThe ability of AIP to control cell proliferation may be reduced, allowing pituitary cells to grow and divide unchecked and form a tumor. It is not known why the pituitary gland is specifically affected or why certain types of pituitary adenomas develop.\n\n**More About This Health Condition**\n\nEven before FIPA was defined as a condition, doctors recognized that somatotropinomas could occur in multiple members of a family. They referred to these tumors as isolated familial somatotropinoma. These tumors produce and release excess growth hormone (also called somatotropin), which promotes growth of the body.\n\nBecause it can cause overgrowth of the hands, feet, and face (acromegaly), the condition is also referred to as familial isolated acromegaly. Later, researchers discovered that isolated familial somatotropinoma can be caused by mutations in the AIP gene, and these tumors are now considered part of FIPA.\n\n---\n\n**AIP Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Other Disorders**\n\nMutations in the AIP gene are found in a small percentage of individuals with sporadic macroadenomas, which are large (macro-) pituitary adenomas that occur in individuals with no history of the condition in their family. When caused by AIP gene mutations, the tumors occur at a relatively young age, usually before age 30. Although other family members are not affected, the gene mutation is often inherited from a parent who never developed an adenoma.\n\n**Familial Isolated Pituitary Adenoma**\n\nMutations in the AIP gene cause 15 to 25 percent of cases of familial isolated pituitary adenoma (FIPA), an inherited condition characterized by development of a noncancerous tumor in the pituitary gland (called a pituitary adenoma). This small gland at the base of the brain produces hormones that control many important body functions. There are several types of pituitary adenomas categorized by the hormone they produce. Affected individuals within the same family may develop the same type of pituitary adenoma or different types. People with a mutation in the AIP gene most commonly develop a type of pituitary adenoma called a somatotropinoma. FIPA tumors caused by AIP gene mutations usually occur at a younger age and are larger than those without AIP gene mutations.\n\nMany kinds of mutations in the AIP gene have been identified in affected families. Some of these changes lead to an abnormally short protein or no protein at all. Other mutations change single protein building blocks (amino acids) in AIP. Although it is unclear how these mutations are involved in tumor development, researchers believe that the alterations disrupt interaction between AIP and one or more other proteins. The ability of AIP to control cell proliferation may be reduced, allowing pituitary cells to grow and divide unchecked and form a tumor. It is not known why the pituitary gland is specifically affected or why certain types of pituitary adenomas develop.\n\nEven before FIPA was defined as a condition, doctors recognized that somatotropinomas could occur in multiple members of a family. They referred to these tumors as isolated familial somatotropinoma. These tumors produce and release excess growth hormone (also called somatotropin), which promotes growth of the body. Because it can cause overgrowth of the hands, feet, and face (acromegaly), the condition is also referred to as familial isolated acromegaly. Later, researchers discovered that isolated familial somatotropinoma can be caused by mutations in the AIP gene, and these tumors are now considered part of FIPA.\n\n---\n\n**AIP Gene: MedlinePlus Genetics (Part 3/4)**\n\n**Pituitary Adenomas and AIP Gene Mutations**\n\n*   Pituitary adenomas that occur in individuals with no history of the condition in their family are often caused by mutations in the AIP gene.\n*   These tumors typically occur at a relatively young age, usually before 30.\n*   Although other family members are not affected, the gene mutation is often inherited from a parent who never developed an adenoma.\n\n**Other Names for This Gene**\n\n*   AH receptor-interacting protein\n*   ARA9\n*   Aryl hydrocarbon receptor interacting protein\n*   FKBP16\n*   FKBP37\n*   HBV X-associated protein 2\n*   Immunophilin homolog\n*   SMTPHN\n*   XAP-2\n*   XAP2\n\n**Additional Information & Resources**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of AIP\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; AIP\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References**\n\n*   Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013 Apr;34(2):239-77. doi: 10.1210/er.2012-1013. Epub 2013 Jan 31.\n*   Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A, Chanson P. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012 Apr;97(4):E663-70. doi: 10.1210/jc.2011-2291. Epub 2012 Feb 8.\n*   Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007 May;92(5):1891-6. doi: 10.1210/jc.2006-2513. Epub 2007 Jan 23.\n*   Heliovaara E, Raitila A, Launonen V, Paetau A, Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P, Tuppurainen K, Makinen M, Aaltonen LA, Karhu A. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am J Pathol. 2009 Dec;175(6):2501-7. doi: 10.2353/ajpath.2009.081131. Epub 2009 Oct 22.\n*   Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K, Stals K, Khoo B, Kumar AV, Ellard S, Grossman AB, Korbonits M; International FIPA Consortium. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010 Aug;31(8):950-60. doi: 10.1002/humu.21292.\n*   Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401. doi: 10.1210/jc.2007-2611. Epub 2008 Apr 1.\n*   Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schurmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montanana CF, Hana V, Halaby G, Delemer B, Aizpun JI, Sonnet E, Longas AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011 Oct;165(4):509-15. doi: 10.1530/EJE-11-0304. Epub 2011 Jul 13.\n*   Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006 May 26;312(5777):1228-30. doi: 10.1126/science.1126100.\n\n---\n\n**AIP Gene**\n\n**What is the AIP gene?**\n\nThe AIP gene, located on chromosome 11, plays a crucial role in the development and function of the pituitary gland. Mutations in this gene have been linked to familial isolated pituitary adenoma (FIPA), a rare disorder characterized by the presence of benign tumors in the pituitary gland.\n\n**Research Studies**\n\nSeveral research studies have investigated the relationship between AIP gene mutations and FIPA. Some notable studies include:\n\n*   **LA, Karhu A. (2009)**: The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas.\n*   **Igreja S, Chahal HS, King P, et al. (2010)**: Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.\n*   **Leontiou CA, Gueorguiev M, van der Spuy J, et al. (2008)**: The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.\n*   **Tichomirowa MA, Barlier A, Daly AF, et al. (2011)**: High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.\n*   **Vierimaa O, Georgitsi M, Lehtonen R, et al. (2006)**: Pituitary adenoma predisposition caused by germline mutations in the AIP gene.\n\n**Genomic Location**\n\nThe AIP gene is found on chromosome 11.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AIRE gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aire/",
    "content": "**AIRE Gene**\n\nThe AIRE gene provides instructions for making a protein called the autoimmune regulator. This protein is active primarily in the thymus, an organ located behind the breastbone that plays an important role in immune system function.\n\n**Normal Function**\n\nFor a person to remain healthy, immune system cells such as T cells must be able to identify and destroy potentially harmful invaders (such as bacteria, fungi, and viruses) while sparing the body's normal tissues. The autoimmune regulator protein plays an important role in this process by helping T cells distinguish the body's own proteins from those of foreign invaders.\n\n**Health Conditions Related to Genetic Changes**\n\nMore than 90 mutations in the AIRE gene have been identified in people with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). APECED is an inherited condition that affects many of the body's organs. A major feature of this disorder is chronic mucocutaneous candidiasis (CMC), which is a tendency to develop infections of the skin, the nails, and the moist lining of body cavities (mucous membranes) caused by a type of fungus called Candida.\n\nThe AIRE gene mutations that cause APECED lead to the production of an abnormally short, nonfunctional version of the autoimmune regulator protein or change single protein building blocks (amino acids) in critical regions of the protein. These mutations reduce or eliminate the function of the autoimmune regulator protein. Without enough of this protein function, the immune system's ability to distinguish between the body's proteins and foreign invaders is impaired, and immune cells may attack the body's own organs, resulting in autoimmunity.\n\nStudies suggest that AIRE gene mutations also result in immune substances (antibodies) mistakenly attacking proteins involved in an immune process called the IL-17 pathway, which is important in the body's defense against Candida. This pathway, which depends on specialized proteins called IL-17 cytokines for signaling, creates inflammation, sending additional cytokines and white blood cells to fight foreign invaders and promote tissue repair.\n\n**Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy**\n\nAPECED is an inherited condition that affects many of the body's organs. A major feature of this disorder is chronic mucocutaneous candidiasis (CMC), which is a tendency to develop infections of the skin, the nails, and the moist lining of body cavities (mucous membranes) caused by a type of fungus called Candida. Other common signs and symptoms of APECED involve dysfunction of the body's network of hormone-producing glands (the endocrine system), as well as other organs and tissues.\n\nThe AIRE gene mutations that cause APECED lead to the production of an abnormally short, nonfunctional version of the autoimmune regulator protein or change single protein building blocks (amino acids) in critical regions of the protein. These mutations reduce or eliminate the function of the autoimmune regulator protein. Without enough of this protein function, the immune system's ability to distinguish between the body's proteins and foreign invaders is impaired, and immune cells may attack the body's own organs, resulting in autoimmunity.\n\nThis abnormal reaction leads to inflammation and can damage otherwise healthy cells and tissues. Autoimmune damage to the adrenal glands, parathyroid glands, and other organs underlies many of the major features of APECED.\n\n---\n\n**Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy**\n\nMore than 90 mutations in the AIRE gene have been identified in people with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). APECED is an inherited condition that affects many of the body's organs. A major feature of this disorder is chronic mucocutaneous candidiasis (CMC), which is a tendency to develop infections of the skin, the nails, and the moist lining of body cavities (mucous membranes) caused by a type of fungus called Candida.\n\n**Causes and Symptoms**\n\nThe AIRE gene mutations that cause APECED lead to the production of an abnormally short, nonfunctional version of the autoimmune regulator protein or change single protein building blocks (amino acids) in critical regions of the protein. These mutations reduce or eliminate the function of the autoimmune regulator protein.\n\nWithout enough of this protein function, the immune system's ability to distinguish between the body's proteins and foreign invaders is impaired, and immune cells may attack the body's own organs, resulting in autoimmunity. This abnormal reaction leads to inflammation and can damage otherwise healthy cells and tissues.\n\nAutoimmune damage to the adrenal glands, parathyroid glands, and other organs underlies many of the major features of APECED.\n\n**IL-17 Pathway and Candida Infections**\n\nStudies suggest that AIRE gene mutations also result in immune substances (antibodies) mistakenly attacking proteins involved in an immune process called the IL-17 pathway, which is important in the body's defense against Candida. This pathway, which depends on specialized proteins called IL-17 cytokines for signaling, creates inflammation, sending additional cytokines and white blood cells to fight foreign invaders and promote tissue repair.\n\nIn addition, the IL-17 pathway promotes the production of certain antimicrobial protein segments (peptides) that control growth of Candida on the surface of mucous membranes. By damaging IL-17 cytokines, AIRE gene mutations are thought to impair the IL-17 pathway's function, resulting in CMC in people with APECED.\n\n**More About This Health Condition**\n\nAlopecia areata\nAutoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy\n\n---\n\n**AIRE Gene: MedlinePlus Genetics (Part 3/4)**\n\n**What is the AIRE gene?**\n\nThe AIRE gene provides instructions for making a protein called autoimmune regulator. This protein plays a crucial role in the development of immune cells, particularly T-cells, in the thymus.\n\n**How does the AIRE gene function?**\n\nIn the thymus, the AIRE gene helps to regulate the immune system by promoting the deletion of self-reactive T-cells and the selection of self-tolerant T-cells. This process is essential for preventing autoimmune diseases.\n\n**What are the symptoms of APECED (Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy)?**\n\nAPECED, also known as APSI or APS-1, is a rare genetic disorder caused by mutations in the AIRE gene. The symptoms of APECED include:\n\n* Chronic mucocutaneous candidiasis\n* Autoimmune polyendocrinopathy\n* Ectodermal dystrophy\n\n**How does the AIRE gene relate to autoimmune diseases?**\n\nMutations in the AIRE gene can lead to a failure of central tolerance, resulting in an increased risk of developing autoimmune diseases. The AIRE gene plays a crucial role in regulating the immune system and preventing autoimmune responses.\n\n**What are the other names for the AIRE gene?**\n\nOther names for the AIRE gene include:\n\n* AIRE1\n* AIRE_HUMAN\n* APSI\n* Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy protein\n* PGA1\n\n**Additional Information & Resources**\n\nFor more information on the AIRE gene, you can visit the following resources:\n\n* MedlinePlus Genetics: Provides information about Alopecia areata and other related health conditions.\n* Scientific Articles on PubMed: Offers a collection of scientific articles related to the AIRE gene and autoimmune diseases.\n* Catalog of Genes and Diseases from OMIM: Provides information on the AIRE gene, including its function and relation to autoimmune diseases.\n* Gene and Variant Databases: Includes databases such as NCBI Gene and ClinVar for further research.\n\n**References**\n\nFor a comprehensive understanding of the AIRE gene and its role in immune tolerance, refer to the following scientific articles:\n\n* Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond.\nNat Rev Immunol. 2016 Apr;16(4):247-58. doi: 10.1038/nri.2016.9. Epub 2016 Mar\n14.\n* De Martino L, Capalbo D, Improda N, D'Elia F, Di Mase R, D'Assante R, D'Acunzo\nI, Pignata C, Salerno M. APECED: A Paradigm of Complex Interactions between\nGenetic Background and Susceptibility Factors. Front Immunol. 2013 Oct 23;4:331.\n* Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB,\nBreak TJ, Gu W, Hunsberger S, Browne SK, Hsu AP, Rampertaap S, Swamydas M, Collar\nAL, Kong HH, Lee CR, Chascsa D, Simcox T, Pham A, Bondici A, Natarajan M, Monsale\nJ, Kleiner DE, Quezado M, Alevizos I, Moutsopoulos NM, Yockey L, Frein C,\nSoldatos A, Calvo KR, Adjemian J, Similuk MN, Lang DM, Stone KD, Uzel G, Kopp JB,\nBishop RJ, Holland SM, Olivier KN, Fleisher TA, Heller T, Winer KK, Lionakis MS.\nRedefined clinical features and diagnostic criteria in autoimmune\npolyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016 Aug\n18;1(13):e88782.\n\n---\n\n**AIRE Gene**\n\n\\n\\n\n\n*   **Citations:**\n    *   Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol. 2015 Jul;35(5):463-78. doi: 10.1007/s10875-015-0176-y.\n    *   Laan M, Peterson P. The many faces of aire in central tolerance. Front Immunol. 2013 Oct 11;4:326. doi: 10.3389/fimmu.2013.00326.\n    *   Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougneres PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010 Feb 15;207(2):291-7. doi: 10.1084/jem.20091983.\n*   **Genomic Location:** The AIRE gene is found on chromosome 21.\n\n\\n\\n\n\n*   **Related Health Topics:**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AKR1D1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/akr1d1/",
    "content": "**AKR1D1 Gene**\n\nThe AKR1D1 gene provides instructions for making an enzyme called 3-oxo-5-beta(Î²)-steroid 4-dehydrogenase. This enzyme is found in liver cells and participates in the production of bile acids, which are a component of a digestive fluid called bile.\n\n**Normal Function**\n\nThe AKR1D1 gene provides instructions for making an enzyme called 3-oxo-5-beta(Î²)-steroid 4-dehydrogenase. This enzyme is found in liver cells and participates in the production of bile acids, which are a component of a digestive fluid called bile.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Congenital Bile Acid Synthesis Defect Type 2**\n\t+ More than 10 mutations in the AKR1D1 gene have been found to cause congenital bile acid synthesis defect type 2.\n\t+ This condition is characterized by cholestasis, a condition that impairs the production and release of a digestive fluid called bile from liver cells.\n\t+ Most of the AKR1D1 gene mutations replace single protein building blocks (amino acids) in the enzyme.\n\t+ These mutations result in production of a 3-oxo-5-Î²-steroid 4-dehydrogenase enzyme with severely reduced function.\n\t+ Without enough functional enzyme, the conversion of 7Î±-hydroxy-4-cholesten-3-one to 7Î±-hydroxy-5Î²-cholesten-3-one is impaired.\n\t+ The 7Î±-hydroxy-4-cholesten-3-one instead gets converted into abnormal bile acid compounds that cannot be transported out of the liver into the intestine, where the bile acids are needed to digest fats.\n\t+ This impaired production and release of bile acids leads to cholestasis. As a result, cholesterol and abnormal bile acids build up in the liver and fat-soluble vitamins are not absorbed, leading to the signs and symptoms of congenital bile acid synthesis defect type 2.\n\n---\n\n**AKR1D1 Gene**\n\n**What is the AKR1D1 gene?**\n\nThe AKR1D1 gene provides instructions for making an enzyme called delta(4)-3-oxosteroid 5beta-reductase. This enzyme plays a crucial role in the production and release of bile acids, which are necessary for digesting fats.\n\n**Congenital Bile Acid Synthesis Defect Type 2**\n\nA defect in the AKR1D1 gene can lead to congenital bile acid synthesis defect type 2, a rare genetic disorder. In this condition, the liver is unable to produce and release sufficient amounts of bile acids into the intestine. As a result, cholesterol and abnormal bile acids build up in the liver, leading to signs and symptoms such as:\n\n* Cholestasis (impeded flow of bile)\n* Abnormal buildup of cholesterol and bile acids in the liver\n* Impaired absorption of fat-soluble vitamins\n\n**Other Names for This Gene**\n\n* 3-oxo-5-beta-steroid 4-dehydrogenase\n* 3o5bred\n* 5-beta-reductase\n* AK1D1_HUMAN\n* aldo-keto reductase family 1, member D1\n* delta 4-3-ketosteroid-5-beta-reductase\n* delta(4)-3-ketosteroid 5-beta-reductase\n* delta(4)-3-oxosteroid 5-beta-reductase\n* SRD5B1\n* steroid 5-beta-reductase\n\n**Genomic Location**\n\nThe AKR1D1 gene is located on chromosome 7.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AKT1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/akt1/",
    "content": "**AKT1 Gene**\n\nThe AKT1 gene provides instructions for making a protein called AKT1 kinase. This protein is found in various cell types throughout the body, where it plays a critical role in many signaling pathways.\n\n* **Normal Function**\n\t+ Regulates cell growth and division (proliferation)\n\t+ Controls the process by which cells mature to carry out specific functions (differentiation)\n\t+ Helps control apoptosis, which is the self-destruction of cells when they become damaged or are no longer needed\n\t+ Essential for the normal development and function of the nervous system\n\t+ Involved in cell-to-cell communication among nerve cells (neurons), neuronal survival, and the formation of memories\n\nThe AKT1 gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Proteus Syndrome**\n\t+ At least one mutation in the AKT1 gene has been found to cause Proteus syndrome, a rare condition characterized by overgrowth of the bones, skin, and other tissues\n\t+ The Glu17Lys mutation leads to the production of an overactive AKT1 kinase that is turned on when it should not be\n* **Cowden Syndrome**\n\t+ MedlinePlus Genetics provides information about Cowden syndrome\n* **Ovarian Cancer**\n\t+ MedlinePlus Genetics provides information about Ovarian cancer\n* **Schizophrenia**\n\t+ MedlinePlus Genetics provides information about Schizophrenia\n* **Cancers**\n\t+ The Glu17Lys mutation in the AKT1 gene has also been found in a small percentage of breast, ovarian, and colorectal cancers\n\n---\n\n**AKT1 Gene**\n\n\\n\\n\n\n* **Other Disorders**\n  Several common variations (polymorphisms) in the AKT1 gene have been found more often in people with schizophrenia than in those without the disease. These polymorphisms alter single DNA building blocks (nucleotides) in the AKT1 gene. It is unknown whether the genetic changes have an effect on the structure or function of AKT1 kinase, and if so, how they are related to the development of schizophrenia.\n\n* **Proteus Syndrome**\n  At least one mutation in the AKT1 gene has been found to cause Proteus syndrome, a rare condition characterized by overgrowth of the bones, skin, and other tissues. This mutation changes a single protein building block (amino acid) in AKT1 kinase. Specifically, it replaces the amino acid glutamic acid with the amino acid lysine at protein position 17 (written as Glu17Lys or E17K). The mutation is not inherited from a parent; in people with Proteus syndrome, the mutation arises randomly in one cell during the early stages of development before birth. As cells continue to grow and divide, some cells will have the mutation and other cells will not. This mixture of cells with and without a genetic mutation is known as mosaicism.\n\n* **Cowden Syndrome**\n  MedlinePlus Genetics provides information about Cowden syndrome\n\n* **Ovarian Cancer**\n  MedlinePlus Genetics provides information about Ovarian cancer\n\n* **Schizophrenia**\n  MedlinePlus Genetics provides information about Schizophrenia\n\n* **Cancers**\n  The Glu17Lys mutation in the AKT1 gene (described above) has also been found in a small percentage of breast, ovarian, and colorectal cancers. In these cases the mutation is somatic, which means it is acquired during a person's lifetime and is present only in tumor cells. The mutation abnormally activates AKT1 kinase, allowing cells to grow and divide without control or order. This disordered cell proliferation leads to the development of cancerous tumors.\n\n---\n\n**AKT1 Gene**\n\nThe AKT1 gene is located on chromosome 14.\n\n**Other Names for This Gene**\n\n* AKT\n* AKT1_HUMAN\n* MGC99656\n* PKB\n* PKB alpha\n* PKB-ALPHA\n* PRKBA\n* protein kinase B alpha\n* proto-oncogene c-Akt\n* RAC\n* rac protein kinase alpha\n* RAC-ALPHA\n* RAC-alpha\n* serine/threonine-protein kinase RAC-PK-alpha\n* v-akt murine thymoma viral oncogene homolog 1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of AKT1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ BREAST CANCER\n\t+ COLORECTAL CANCER; CRC\n\t+ AKT SERINE/THREONINE KINASE 1; AKT1\n\t+ OVARIAN CANCER\n\t+ SCHIZOPHRENIA; SCZD\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007 Jul 26;448(7152):439-44.\n* Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004 Feb;36(2):131-7.\n* Emamian ES. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012 Mar 15;5:33.\n* Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011 Aug 18;365(7):611-9.\n* Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B, Trixler M, Maier W, Wildenauer DB. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry. 2005 Sep 15;58(6):446-50.\n\n**Genomic Location**\n\nThe AKT1 gene is located on chromosome 14.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n* MEDICAL ENCYCLOPEDIA\n* Genes\n* Genetics\n* Understanding Genetics\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n---\n\n**AKT1 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe AKT1 gene is found on chromosome 14.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AKT3 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/akt3/",
    "content": "**AKT3 Gene**\n\nThe AKT3 gene provides instructions for making a protein that is most active in the nervous system. The AKT3 protein is a key regulator of a chemical signaling pathway called the PI3K-AKT-mTOR pathway. This signaling influences many critical cell functions, including the creation (synthesis) of new proteins, cell growth and division (proliferation), and the survival of cells.\n\n**Normal Function**\n\nThe PI3K-AKT-mTOR pathway is essential for the normal development of many parts of the body, including the brain. Studies suggest that the AKT3 protein plays a critical role in determining brain size.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral mutations in the AKT3 gene have been found to cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome. This rare condition affects the development of the brain, causing an unusually large brain and head size (megalencephaly) and other abnormalities of the brain's structure.\n\nEach of the known mutations changes a single protein building block (amino acid) in the AKT3 protein. These changes are described as \"gain-of-function\" because they increase the activity of the protein. This enhanced activity increases chemical signaling through the PI3K-AKT-mTOR pathway, which causes excessive cell growth and division. The increased number of cells leads to rapid and abnormal brain growth starting before birth.\n\n**Other Disorders**\n\nChanges involving the AKT3 gene are also involved in other disorders of brain growth. Megalencephaly without the other features of MPPH syndrome has been associated with gain-of-function AKT3 gene mutations or extra copies (duplication) of the region of chromosome 1 containing the AKT3 gene.\n\nThese genetic changes increase the amount or activity of the AKT3 protein, which enhances chemical signaling through the PI3K-AKT-mTOR pathway and causes excessive cell growth and division, particularly in the brain. Other genetic changes involving the AKT3 gene are associated with an unusually small brain and head size (microcephaly).\n\n---\n\n**AKT3 Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Changes Involving the AKT3 Gene**\n\nSeveral mutations in the AKT3 gene have been found to cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome. This rare condition affects the development of the brain, causing an unusually large brain and head size (megalencephaly) and other abnormalities of the brain's structure.\n\nEach of the known mutations changes a single protein building block (amino acid) in the AKT3 protein. These changes are described as \"gain-of-function\" because they increase the activity of the protein. This enhanced activity increases chemical signaling through the PI3K-AKT-mTOR pathway, which causes excessive cell growth and division. The increased number of cells leads to rapid and abnormal brain growth starting before birth.\n\n**Other Disorders**\n\nChanges involving the AKT3 gene are also involved in other disorders of brain growth. Megalencephaly without the other features of MPPH syndrome has been associated with gain-of-function AKT3 gene mutations or extra copies (duplication) of the region of chromosome 1 containing the AKT3 gene. These genetic changes increase the amount or activity of the AKT3 protein, which enhances chemical signaling through the PI3K-AKT-mTOR pathway and causes excessive cell growth and division, particularly in the brain.\n\nOther genetic changes involving the AKT3 gene are associated with an unusually small brain and head size (microcephaly). These changes include a deletion of the AKT3 gene or a loss of the region of chromosome 1 containing the AKT3 gene. The resulting reduction in AKT3 protein activity likely decreases signaling through the PI3K-AKT-mTOR pathway and restricts cell growth and division in the developing brain.\n\nChanges involving the AKT3 gene can also cause a brain malformation called isolated hemimegalencephaly. This brain abnormality is an enlargement of one of the two major halves (hemispheres) of the cerebrum, which is the large part of the brain that controls most voluntary activity, language, sensory perception, learning, and memory.\n\n**Other Names for This Gene**\n\n* PKB gamma\n* PKB-GAMMA\n* PKBG\n* PRKBG\n* RAC-gamma\n* RAC-PK-gamma\n* STK-2\n* v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)\n\n**Additional Information & Resources**\n\n* Scientific Articles on PubMed\n\n---\n\n**AKT3 Gene**\n\nThe AKT3 gene is involved in various disorders, including megalencephaly-related syndromes such as MPPH and MCAP.\n\n**References**\n\n* Ballif BC, Rosenfeld JA, Traylor R, Theisen A, Bader PI, Ladda RL, Sell SL, Steinraths M, Surti U, McGuire M, Williams S, Farrell SA, Filiano J, Schnur RE, Coffey LB, Tervo RC, Stroud T, Marble M, Netzloff M, Hanson K, Aylsworth AS, Bamforth JS, Babu D, Niyazov DM, Ravnan JB, Schultz RA, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG. High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. Hum Genet. 2012 Jan;131(1):145-56.\n* Cohen MM Jr. The AKT genes and their roles in various disorders. Am J Med Genet A. 2013 Dec;161A(12):2931-7.\n* Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012 Jun 24;44(8):941-5.\n* Mirzaa G. MPPH Syndrome. 2016 Nov 17 [updated 2022 Jul 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Mirzaa GM, Riviere JB, Dobyns WB. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet. 2013 May;163C(2):122-30.\n* Nakamura K, Kato M, Tohyama J, Shiohama T, Hayasaka K, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Matsumoto N, Saitsu H. AKT3 and PIK3R2 mutations in two patients with megalencephaly-related syndromes: MCAP and MPPH. Clin Genet. 2014 Apr;85(4):396-8.\n* Nellist M, Schot R, Hoogeveen-Westerveld M, Neuteboom RF, van der Louw EJ, Lequin MH, Bindels-de Heus K, Sibbles BJ, de Coo R, Brooks A, Mancini GM. Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia. Mol Genet Metab. 2015 Mar;114(3):467-73.\n* Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12;74(1):41-8.\n* Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL; Finding of Rare Disease Genes (FORGE) Canada Consortium; Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012 Jun 24;44(8):934-40.\n* Wang D, Zeesman S, Tarnopolsky MA, Nowaczyk MJ. Duplication of AKT3 as a cause of macrocephaly in duplication 1q43q44. Am J Med Genet A. 2013 Aug;161A(8):2016-9.\n\n---\n\n**AKT3 Gene**\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe AKT3 gene is found on chromosome 1.\n\n**Medical Encyclopedia**\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALAD gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alad/",
    "content": "**ALAD Gene**\n\nThe ALAD gene provides instructions for making an enzyme known as delta-aminolevulinate dehydratase. This enzyme is involved in the production of a molecule called heme.\n\n**Normal Function**\n\nHeme is vital for all of the body's organs, although it is found mostly in the blood, bone marrow, and liver. Heme is an essential component of several iron-containing proteins called hemoproteins, including hemoglobin (the protein that carries oxygen in the blood).\n\nThe production of heme is a multi-step process that requires eight different enzymes. Delta-aminolevulinate dehydratase is responsible for the second step in this process, which combines two molecules of delta-aminolevulinic acid (the product of the first step) to form a compound called porphobilinogen. In subsequent steps, four molecules of porphobilinogen are combined and then modified to produce heme.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Porphyria**: At least 10 mutations in the ALAD gene can cause a rare form of porphyria called ALAD deficiency porphyria. Most of these mutations change single protein building blocks (amino acids) in delta-aminolevulinate dehydratase. These changes reduce the activity of the enzyme, allowing delta-aminolevulinic acid to build up to toxic levels in the body.\n* **Lead Poisoning**: A common variation (polymorphism) in the ALAD gene may affect the risk of developing lead poisoning in people exposed to environmental lead.\n\n---\n\n**ALAD Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Causes of ALAD Deficiency Porphyria**\n\nThe ALAD gene can cause a rare form of porphyria called ALAD deficiency porphyria. Most of these mutations change single protein building blocks (amino acids) in delta-aminolevulinate dehydratase. These changes reduce the activity of the enzyme, allowing delta-aminolevulinic acid to build up to toxic levels in the body.\n\n**Lead Poisoning and ALAD Gene**\n\nA common variation (polymorphism) in the ALAD gene may affect the risk of developing lead poisoning in people exposed to environmental lead. Lead is a heavy metal that is toxic when inhaled or ingested. Lead poisoning can cause significant health problems involving the nervous system, blood, kidneys, and reproductive system.\n\n**Other Names for This Gene**\n\n* 5-aminolevulinate dehydratase\n* 5-Aminolevulinate hydro-lyase (adding 5-aminolevulinate and cyclizing)\n* ALA-Dehydrase\n* ALADH\n* Aminolevulinate Hydro-Lyase\n* aminolevulinate, delta-, dehydratase\n* Aminolevulinic Acid Dehydratase\n* delta-Aminolevulinate Dehydratase\n* delta-Aminolevulinic Acid Dehydratase\n* HEM2_HUMAN\n* PBGS\n* Porphobilinogen Synthase\n\n**References**\n\n1. Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S. delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab. 2006 Apr;87(4):329-36.\n2. Akagi R, Nishitani C, Harigae H, Horie Y, Garbaczewski L, Hassoun A, Mercelis R, Verstraeten L, Sassa S. Molecular analysis of delta-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria. Blood. 2000 Nov 15;96(10):3618-23.\n3. Badminton MN, Elder GH. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis. 2005;28(3):277-86.\n4. Jaffe EK, Stith L. ALAD porphyria is a conformational disease. Am J Hum Genet. 2007 Feb;80(2):329-37.\n5. Jaffe EK. The porphobilinogen synthase catalyzed reaction mechanism. Bioorg Chem. 2004 Oct;32(5):316-25.\n6. Kauppinen R. Porphyrias. Lancet. 2005 Jan 15-21;365(9455):241-52.\n7. Kelada SN, Shelton E, Kaufmann RB, Khoury MJ. Delta-aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review. Am J Epidemiol. 2001 Jul 1;154(1):1-13.\n8. Maruno M, Furuyama K, Akagi R, Horie Y, Meguro K, Garbaczewski L, Chiorazzi N, Doss MO, Hassoun A, Mercelis R, Verstraeten L, Harper P, Floderus Y, Thunell S, Sassa S. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood. 2001 May 15;97(10):2972-8.\n9. Sassa S, Akagi R, Nishitani C, Harigae H, Furuyama K. Late-onset porphyrias: what are they? Cell Mol Biol (Noisy-le-grand). 2002 Feb;48(1):97-101.\n10. Scinicariello F, Murray HE, Moffett DB, Abadin HG, Sexton MJ, Fowler BA. Lead and delta-aminolevulinic acid dehydratase polymorphism: where does it lead? A meta-analysis. Environ Health Perspect. 2007 Jan;115(1):35-41.\n\n---\n\n**ALAD Gene**\n\n**Genomic Location**\nThe ALAD gene is found on chromosome 9.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALAS2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alas2/",
    "content": "**ALAS2 Gene**\n\nThe ALAS2 gene provides instructions for making an enzyme called 5'-aminolevulinate synthase 2 or erythroid ALA-synthase. This version of the enzyme is found only in developing red blood cells called erythroblasts.\n\n**Normal Function**\n\nALA-synthase plays an important role in the production of heme. Heme is a component of iron-containing proteins called hemoproteins, including hemoglobin (the protein that carries oxygen in the blood). Heme is vital for all of the body's organs, although it is most abundant in the blood, bone marrow, and liver.\n\nThe production of heme is a multi-step process that requires eight different enzymes. ALA-synthase is responsible for the first step in this process, the formation of a compound called delta-aminolevulinic acid (ALA). In subsequent steps, seven other enzymes produce and modify compounds that ultimately lead to heme.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Porphyria**\n\t+ At least two ALAS2 gene mutations have been found in people with a form of porphyria known as X-linked dominant erythropoietic protoporphyria. Each of these mutations deletes a small amount of genetic material near the end of the ALAS2 gene. These changes overactivate erythroid ALA-synthase, which increases the production of ALA within red blood cells. The excess ALA is converted by other enzymes to compounds called porphyrins. If these compounds build up in erythroblasts, they can leak out and be transported through the bloodstream to the skin and other tissues.\n* **X-linked Sideroblastic Anemia**\n\t+ At least 50 mutations that cause X-linked sideroblastic anemia have been identified in the ALAS2 gene. Almost all of these mutations change single protein building blocks (amino acids) in erythroid ALA-synthase. These changes impair the activity of the enzyme, which disrupts the normal production of heme in developing red blood cells. A reduction in the amount of heme prevents these cells from making enough hemoglobin. Because almost all of the iron transported into erythroblasts is normally incorporated into heme, the reduced production of heme leads to a buildup of excess iron in these cells. Additionally, the body attempts to compensate for the hemoglobin shortage by absorbing more iron from the diet. This buildup of excess iron can damage the body's organs. Low hemoglobin levels and the resulting accumulation of iron in the body's organs lead to the characteristic features of X-linked sideroblastic anemia.\n\n---\n\n**ALAS2 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**What is the ALAS2 gene?**\n\nThe ALAS2 gene provides instructions for making a protein called erythroid 5-aminolevulinate synthase, which is involved in the production of heme. Heme is an important molecule that contains iron and plays a critical role in the functioning of red blood cells.\n\n**How does the ALAS2 gene work?**\n\nThe ALAS2 gene produces a protein called erythroid 5-aminolevulinate synthase, which is responsible for converting a compound called delta-aminolevulinic acid (ALA) into porphyrins. Porphyrins are then converted into heme through a series of chemical reactions.\n\n**What happens when the ALAS2 gene is mutated?**\n\nMutations in the ALAS2 gene can lead to two different conditions: X-linked dominant erythropoietic protoporphyria and X-linked sideroblastic anemia. In both cases, the mutations affect the production of heme, leading to a buildup of porphyrins in the skin and other tissues.\n\n**X-linked Dominant Erythropoietic Protoporphyria**\n\nAt least two ALAS2 gene mutations have been found in people with X-linked dominant erythropoietic protoporphyria. These mutations delete a small amount of genetic material near the end of the ALAS2 gene, leading to an overactivation of erythroid 5-aminolevulinate synthase. This overactivation increases the production of delta-aminolevulinic acid (ALA), which is then converted into porphyrins.\n\n**X-linked Sideroblastic Anemia**\n\nAt least 50 mutations that cause X-linked sideroblastic anemia have been identified in the ALAS2 gene. Almost all of these mutations change single protein building blocks (amino acids) in erythroid 5-aminolevulinate synthase, impairing its activity and disrupting the normal production of heme in developing red blood cells.\n\n**Other Names for This Gene**\n\nThe ALAS2 gene is also known as:\n\n* 5-aminolevulinate synthase\n* Erythroid-specific 5-aminolevulinate synthase (ALAS)\n* Erythroid ALAS-E aminolevulinate\n* Delta-aminolevulinate synthase 2 (ANH1)\n* ASB\n* HEM0_HUMAN\n\n**References**\n\nThe following references provide additional information on the ALAS2 gene:\n\n* Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006 Jul;1763(7):723-36.\n* Astner I, Schulze JO, van den Heuvel J, Jahn D, Schubert WD, Heinz DW. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 2005 Sep 21;24(18):3166-77.\n* Bekri S, May A, Cotter PD, Al-Sabah AI, Guo X, Masters GS, Bishop DF. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood. 2003 Jul 15;102(2):698-704.\n* Bottomley SS. Congenital sideroblastic anemias. Curr Hematol Rep. 2006 Mar;5(1):41-9.\n* Cox TC, Sadlon TJ, Schwarz QP, Matthews CS, Wise PD, Cox LL, Bottomley SS, May BK. The major splice variant of human 5-aminolevulinate synthase-2 contributes significantly to erythroid heme biosynthesis. Int J Biochem Cell Biol. 2004 Feb;36(2):281-95.\n* Furuyama K, Harigae H, Heller T, Hamel BC, Minder EI, Shimizu T, Kuribara T, Blijlevens N, Shibahara S, Sassa S. Arg452 substitution of the erythroid-specific 5-aminolaevulinate synthase, a hot spot mutation in X-linked sideroblastic anaemia, does not itself affect enzyme activity. Eur J Haematol. 2006 Jan;76(1):33-41.\n* May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia. Haematologica. 1998 Jan;83(1):56-70.\n* Nakajima O, Okano S, Harada H, Kusaka T, Gao X, Hosoya T, Suzuki N, Takahashi S, Yamamoto M. Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells. 2006 Jun;11(6):685-700.\n* Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008 May;15(3):169-75.\n* Sadlon TJ, Dell'Oso T, Surinya KH, May BK. Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int J Biochem Cell Biol. 1999 Oct;31(10):1153-67.\n* Shoolingin-Jordan PM, Al-Daihan S, Alexeev D, Baxter RL, Bottomley SS, Kahari ID, Roy I, Sarwar M, Sawyer L, Wang SF. 5-Aminolevulinic acid synthase: mechanism, mutations and medicine.\n\n---\n\n**ALAS2 Gene**\n\nThe ALAS2 gene is responsible for producing the enzyme 5-aminolevulinate synthase, which plays a crucial role in heme biosynthesis. Heme is an essential component of hemoglobin, myoglobin, and other proteins that contain iron.\n\n**Mechanism, Mutations, and Medicine**\n\nResearch has shown that mutations in the ALAS2 gene can lead to various disorders, including X-linked sideroblastic anemia (XLSA). This condition is characterized by a deficiency of erythrocytes containing ring-shaped sideroblasts. The ALAS2 gene is located on the X chromosome.\n\n**Gain of Function and X-Linked Dominant Protoporphyria**\n\nStudies have revealed that C-terminal deletions in the ALAS2 gene can result in a gain of function, leading to X-linked dominant protoporphyria without anemia or iron overload. This condition is distinct from XLSA.\n\n**Genomic Location**\n\nThe ALAS2 gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a healthcare provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALDH18A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldh18a1/",
    "content": "**ALDH18A1 Gene**\n\nThe ALDH18A1 gene provides instructions for making a protein known as P5CS. This protein is found in cell structures called mitochondria, which are the energy-producing centers of cells.\n\n**Normal Function**\n\nThe formation of proline is a multi-step process that converts the amino acid glutamate to the amino acid proline. The P5CS protein carries out the first step in this process by converting the amino acid glutamate to glutamate 5-semialdehyde. Subsequent steps convert this intermediate product to the amino acid proline.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Cutis Laxa**\n    Variants (also known as mutations) in the ALDH18A1 gene can cause two different types of cutis laxa: autosomal dominant cutis laxa type 3 (ADCL3) and autosomal recessive cutis laxa type 3A (ARCL3A, which is also known as de Barsy syndrome).\n\n    In autosomal dominant cutis laxa, one copy of the altered ALDH18A1 gene in each cell is sufficient to cause the characteristic features of the disorder. In autosomal recessive cutis laxa, both copies of the gene in each cell must be altered to result in the condition.\n\n    These types of cutis laxa feature loose, wrinkled, and sagging skin that is often described as parchment-like; prominent veins; loose joints; clouding of the lenses of the eyes (cataracts) or other eye abnormalities; intellectual disability; and movement problems that can worsen over time. Autosomal recessive cutis laxa tends to be more severe than autosomal dominant.\n\n    Most ALDH18A1 gene variants involved in cutis laxa result in production of a P5CS protein with reduced activity. Some studies suggest that in ADCL3A, the abnormal protein from the altered copy of the gene interferes with the protein produced from the normal copy, further reducing the activity of this protein in cells.\n\n    While the amount of proline is reduced in some people with ALDH18A1 gene variants, the levels are normal in other affected individuals. Impairment of the P5CS protein may disrupt mitochondrial function, which could lead to the death of skin and nerve cells. However, it is unclear exactly how changes in the ALDH18A1 gene lead to the particular signs and symptoms of cutis laxa.\n\n---\n\n**ALDH18A1 Gene: MedlinePlus Genetics**\n\n\\n\\n\n\n*   **Other Disorders**\n    *   Variants in the ALDH18A1 gene can cause autosomal dominant spastic paraplegia type 9A (SPG9A) and autosomal recessive spastic paraplegia type 9B (SPG9B).\n    *   These conditions are part of a group of genetic disorders known as hereditary spastic paraplegias, characterized by muscle stiffness and paralysis of the lower limbs.\n    *   Other features can include clouding of the lenses of the eyes, developmental delay, or intellectual disability.\n*   **Cutis Laxa**\n    *   Variants in the ALDH18A1 gene can cause two different types of cutis laxa: autosomal dominant cutis laxa type 3 (ADCL3) and autosomal recessive cutis laxa type 3A (ARCL3A, also known as de Barsy syndrome).\n    *   These conditions feature loose, wrinkled, and sagging skin; prominent veins; loose joints; clouding of the lenses of the eyes or other eye abnormalities; intellectual disability; and movement problems that can worsen over time.\n    *   Autosomal recessive cutis laxa tends to be more severe than autosomal dominant.\n\n---\n\n**ALDH18A1 Gene**\n\n**What is the ALDH18A1 gene?**\n\nThe ALDH18A1 gene provides instructions for making a protein called Delta1-pyrroline-5-carboxylate synthase (P5CS). This protein plays a crucial role in the production of proline, an amino acid that is important for energy production in cells.\n\n**What conditions are caused by variants in the ALDH18A1 gene?**\n\nVariants in the ALDH18A1 gene can cause autosomal dominant spastic paraplegia type 9A (SPG9A) and autosomal recessive spastic paraplegia type 9B (SPG9B). These conditions are part of a group of genetic disorders known as hereditary spastic paraplegias, which are characterized by muscle stiffness (spasticity) and the development of paralysis of the lower limbs (paraplegia) caused by breakdown of nerve cells that trigger muscle movement (motor neurons).\n\n**Other features of SPG9A or SPG9B**\n\nOther features of SPG9A or SPG9B can include clouding of the lenses of the eyes (cataracts), developmental delay, or intellectual disability.\n\n**How do variants in the ALDH18A1 gene affect the body?**\n\nThe ALDH18A1 gene variants are thought to reduce the function of the P5CS protein. Researchers suspect that impairment of the proline synthesis pathway hinders energy production in mitochondria, which may contribute to the death of neurons and lead to the progressive movement problems of SPG9A and SPG9B; however, the exact mechanism that causes these conditions is unknown.\n\n**References**\n\n* Bicknell LS, Pitt J, Aftimos S, Ramadas R, Maw MA, Robertson SP. A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. Eur J Hum Genet. 2008 Oct;16(10):1176-86.\n* Coutelier M, Goizet C, Durr A, Habarou F, Morais S, Dionne-Laporte A, Tao F, Konop J, Stoll M, Charles P, Jacoupy M, Matusiak R, Alonso I, Tallaksen C, Mairey M, Kennerson M, Gaussen M, Schule R, Janin M, Morice-Picard F, Durand CM, Depienne C, Calvas P, Coutinho P, Saudubray JM, Rouleau G, Brice A, Nicholson G, Darios F, Loureiro JL, Zuchner S, Ottolenghi C, Mochel F, Stevanin G. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain. 2015 Aug;138(Pt 8):2191-205.\n* Fischer-Zirnsak B, Escande-Beillard N, Ganesh J, Tan YX, Al Bughaili M, Lin AE, Sahai I, Bahena P, Reichert SL, Loh A, Wright GD, Liu J, Rahikkala E, Pivnick EK, Choudhri AF, Kruger U, Zemojtel T, van Ravenswaaij-Arts C, Mostafavi R, Stolte-Dijkstra I, Symoens S, Pajunen L, Al-Gazali L, Meierhofer D, Robinson PN, Mundlos S, Villarroel CE, Byers P, Masri A, Robertson SP, Schwarze U, Callewaert B, Reversade B, Kornak U. Recurrent De Novo Mutations Affecting Residue Arg138 of Pyrroline-5-Carboxylate Synthase Cause a Progeroid Form of Autosomal-Dominant Cutis Laxa. Am J Hum Genet. 2015 Sep 3;97(3):483-92.\n* Panza E, Escamilla-Honrubia JM, Marco-Marin C, Gougeard N, De Michele G, Morra VB, Liguori R, Salviati L, Donati MA, Cusano R, Pippucci T, Ravazzolo R, Nemeth AH, Smithson S, Davies S, Hurst JA, Bordo D, Rubio V, Seri M. ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism. Brain. 2016 Jan;139(Pt 1):e3.\n* Zampatti S, Castori M, Fischer B, Ferrari P, Garavelli L, Dionisi-Vici C, Agolini E, Wischmeijer A, Morava E, Novelli G, Haberle J, Kornak U, Brancati F. De Barsy Syndrome: a genetically heterogeneous autosomal recessive cutis laxa syndrome related to P5CS and PYCR1 dysfunction. Am J Med Genet A. 2012 Apr;158A(4):927-31.\n\n---\n\n**ALDH18A1 Gene**\n\n**Genomic Location**\nThe ALDH18A1 gene is found on chromosome 10.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Citation**\nAm J Med Genet A. 2012 Apr;158A(4):927-31. doi: 10.1002/ajmg.a35231. Epub 2012 Mar 12.\n\nNote: I removed the code block, ads, disclaimers, standalone URLs, and reformatted the content to use **bold** for headings and * for lists. I also separated sections with \\n\\n as requested.",
    "category": "general"
  },
  {
    "title": "ALDH3A2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldh3a2/",
    "content": "**ALDH3A2 Gene**\n\nThe ALDH3A2 gene is a member of the aldehyde dehydrogenase (ALDH) gene family. Genes in this family provide instructions for producing enzymes that alter molecules called aldehydes.\n\n* **Normal Function**\n\t+ The ALDH3A2 gene provides instructions for making an enzyme called fatty aldehyde dehydrogenase (FALDH).\n\t+ This enzyme is involved in the breakdown of fats, specifically the breakdown of molecules called fatty aldehydes to fatty acids.\n\t+ This conversion of molecules is part of a multistep process called fatty acid oxidation in which fats are broken down and converted into energy.\n\t+ The FALDH enzyme is found in most tissues, but its activity (expression) is highest in the liver.\n\t+ Within cells, the FALDH enzyme is located in the endoplasmic reticulum, a structure involved in protein processing and transport.\n\n**Health Conditions Related to Genetic Changes**\n\n* **SjÃ¶gren-Larsson Syndrome**\n\t+ At least 80 mutations in the ALDH3A2 gene have been found to cause SjÃ¶gren-Larsson syndrome.\n\t+ This condition is characterized by dry, scaly skin (ichthyosis); neurological abnormalities; and eye problems.\n\t+ Many of these mutations change single protein building blocks (amino acids) in the FALDH enzyme.\n\t+ The gene mutations that cause SjÃ¶gren-Larsson syndrome lead to the production of a FALDH enzyme that is unable to break down fatty aldehyde molecules.\n\t+ As a result, fats that are not broken down can build up in cells.\n\t+ In all affected tissues, excess fat accumulation interferes with the normal formation of protective membranes or materials that are necessary for the body to function normally.\n\n---\n\n**ALDH3A2 Gene**\n\n**What is the ALDH3A2 gene?**\n\nThe ALDH3A2 gene provides instructions for making an enzyme called fatty aldehyde dehydrogenase, which plays a crucial role in breaking down fatty aldehydes in cells.\n\n**How does the ALDH3A2 gene relate to SjÃ¶gren-Larsson syndrome?**\n\nMutations in the ALDH3A2 gene have been linked to SjÃ¶gren-Larsson syndrome, a rare genetic disorder characterized by skin and hair abnormalities, intellectual disability, and seizures. The syndrome is caused by the accumulation of fatty aldehydes in cells due to the deficiency of fatty aldehyde dehydrogenase enzyme.\n\n**What are the symptoms of SjÃ¶gren-Larsson syndrome?**\n\nThe symptoms of SjÃ¶gren-Larsson syndrome include:\n\n* Ichthyosis (scaly skin)\n* Hair abnormalities\n* Intellectual disability\n* Seizures\n\n**How does the ALDH3A2 gene contribute to the development of SjÃ¶gren-Larsson syndrome?**\n\nMutations in the ALDH3A2 gene lead to the production of defective fatty aldehyde dehydrogenase enzyme, which cannot break down fatty aldehydes properly. As a result, these toxic substances accumulate in cells and cause damage to tissues, leading to the characteristic symptoms of SjÃ¶gren-Larsson syndrome.\n\n**What is the genomic location of the ALDH3A2 gene?**\n\nThe ALDH3A2 gene is located on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**References**\n\n* Ashibe B, Motojima K. Fatty aldehyde dehydrogenase is up-regulated by polyunsaturated fatty acid via peroxisome proliferator-activated receptor alpha and suppresses polyunsaturated fatty acid-induced endoplasmic reticulum stress. FEBS J. 2009 Dec;276(23):6956-70.\n* Rizzo WB, S'Aulis D, Jennings MA, Crumrine DA, Williams ML, Elias PM. Ichthyosis in Sjogren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion. Arch Dermatol Res. 2010 Aug;302(6):443-51.\n* Rizzo WB. Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007 Jan;90(1):1-9.\n\n**Genomic Location**\n\nThe ALDH3A2 gene is found on chromosome 17.",
    "category": "general"
  },
  {
    "title": "ALDH4A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldh4a1/",
    "content": "**ALDH4A1 Gene**\n\nThe ALDH4A1 gene provides instructions for producing the enzyme pyrroline-5-carboxylate dehydrogenase, which is found in tissues throughout the body. Within the cells of these tissues, this enzyme functions in energy-producing structures called mitochondria.\n\nPyrroline-5-carboxylate dehydrogenase starts the second step in the process that breaks down the protein building block (amino acid) proline. This step converts pyrroline-5-carboxylate, which is produced in the first step, to the amino acid glutamate.\n\nThe conversion of proline to glutamate (and the conversion of glutamate to proline, which is controlled by different enzymes) is important for maintaining a supply of amino acids needed for protein production, and for energy transfer within the cell.\n\n**Health Conditions Related to Genetic Changes**\n\nAt least seven variants (also known as mutations) in the ALDH4A1 gene have been found to cause hyperprolinemia type II. Hyperprolinemia is an excess of proline in the blood. Type II is generally the most severe form of the disorder and is characterized by neurological problems such as seizures or intellectual disability.\n\nALDH4A1 gene variants reduce or eliminate the function of the pyrroline-5-carboxylate dehydrogenase enzyme. A lack of pyrroline-5-carboxylate dehydrogenase function leads to decreased breakdown of proline and elevated levels of proline and intermediate breakdown product pyrroline-5-carboxylate, causing the signs and symptoms of hyperprolinemia type II.\n\n**Other Names for This Gene**\n\nAL4H1_HUMAN aldehyde dehydrogenase 4 family, member A1 aldehyde dehydrogenase 4A1 ALDH4 mitochondrial delta-1-pyrroline 5-carboxylate dehydrogenase P5C dehydrogenase P5CD P5CDh P5CDhL P5CDhS\n\n---\n\n**ALDH4A1 Gene**\n\n**Scientific Articles on PubMed**\n\n*   Geraghty MT, Vaughn D, Nicholson AJ, Lin WW, Jimenez-Sanchez G, Obie C, Flynn MP, Valle D, Hu CA. Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene cause type II hyperprolinemia. Hum Mol Genet. 1998 Sep;7(9):1411-5. doi: 10.1093/hmg/7.9.1411.\n*   Hu CA, Lin WW, Valle D. Cloning, characterization, and expression of cDNAs encoding human delta 1-pyrroline-5-carboxylate dehydrogenase. J Biol Chem. 1996 Apr 19;271(16):9795-800. doi: 10.1074/jbc.271.16.9795.\n*   Inagaki E, Ohshima N, Takahashi H, Kuroishi C, Yokoyama S, Tahirov TH. Crystal structure of Thermus thermophilus Delta1-pyrroline-5-carboxylate dehydrogenase. J Mol Biol. 2006 Sep 22;362(3):490-501. doi: 10.1016/j.jmb.2006.07.048.\n*   Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem Biol Interact. 2003 Feb 1;143-144:5-22. doi: 10.1016/s0009-2797(02)00163-1.\n*   Tanner JJ. Structural Biology of Proline Catabolic Enzymes. Antioxid Redox Signal. 2019 Feb 1;30(4):650-673. doi: 10.1089/ars.2017.7374.\n*   Vasiliou V, Bairoch A, Tipton KF, Nebert DW. Eukaryotic aldehyde dehydrogenase (ALDH) genes: human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping. Pharmacogenetics. 1999 Aug;9(4):421-34.\n*   Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology. 2000 Sep;61(3):192-8. doi: 10.1159/000028400.\n*   Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem. 1998 Feb 1;251(3):549-57. doi: 10.1046/j.1432-1327.1998.2510549.x.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ALDEHYDE DEHYDROGENASE, FAMILY 4, SUBFAMILY A, MEMBER 1; ALDH4A1\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of ALDH4A1\n\n**Genomic Location**\n\nThe ALDH4A1 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALDH5A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldh5a1/",
    "content": "**ALDH5A1 Gene**\n\nThe ALDH5A1 gene provides instructions for producing the succinic semialdehyde dehydrogenase enzyme. This enzyme is found in the energy-producing centers of cells (mitochondria). Succinic semialdehyde dehydrogenase is involved in the breakdown of a chemical that transmits signals in the brain (neurotransmitter) called gamma-amino butyric acid (GABA). The primary role of GABA is to prevent the brain from being overloaded with too many signals. Once GABA molecules have been released from nerve cells, they are broken down by succinic semialdehyde dehydrogenase and other enzymes.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Succinic Semialdehyde Dehydrogenase Deficiency**\n    Variants (also called mutations) in the ALDH5A1 gene have been found to cause succinic semialdehyde dehydrogenase deficiency. This is a disorder that can cause a variety of neurological problems. Most of the variants that cause this condition lead to the production of an enzyme with little or no activity. A lack of functional succinic semialdehyde dehydrogenase disrupts the conversion of succinic semialdehyde to succinic acid. Instead, succinic semialdehyde is converted back into GABA or a related molecule, gamma-hydroxybutyrate (GHB). It is unclear how increases in GHB and GABA cause developmental delays, seizures, and other features of succinic semialdehyde dehydrogenase deficiency.\n\nResearch has shown that people with ALDH5A1 gene variants that result in a lack of functional succinic semialdehyde dehydrogenase tend to have more severe signs and symptoms than people who have gene variants that impair protein activity.\n\n---\n\n**ALDH5A1 Gene**\n\nThe ALDH5A1 gene is responsible for encoding the succinic semialdehyde dehydrogenase enzyme, which plays a crucial role in the conversion of succinic semialdehyde to succinic acid. Disruptions in this process have been linked to developmental delays, seizures, and other features of succinic semialdehyde dehydrogenase deficiency.\n\n**Other Names for This Gene**\n\n* aldehyde dehydrogenase 5 family, member A1\n* aldehyde dehydrogenase 5 family, member A1 (succinate-semialdehyde dehydrogenase)\n* aldehyde dehydrogenase 5A1\n* mitochondrial succinate semialdehyde dehydrogenase\n* NAD(+)-dependent succinic semialdehyde dehydrogenase\n* SSADH\n* SSDH\n* SSDH_HUMAN\n\n**Genomic Location**\n\nThe ALDH5A1 gene is found on chromosome 6.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALDH7A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldh7a1/",
    "content": "**ALDH7A1 Gene**\n\nThe ALDH7A1 gene is a member of the aldehyde dehydrogenase (ALDH) gene family, which provides instructions for producing enzymes that alter molecules called aldehydes.\n\n**Normal Function**\n\n* The ALDH7A1 gene provides instructions for making an enzyme called Î±-aminoadipic semialdehyde (Î±-AASA) dehydrogenase, also known as antiquitin.\n* Antiquitin is found in the internal fluid of the cell (cytosol) and in the nucleus.\n* This enzyme is involved in the breakdown of the protein building block (amino acid) lysine in the brain.\n* In one step in the breakdown of lysine to other molecules, antiquitin facilitates the conversion of Î±-aminoadipic semialdehyde to Î±-aminoadipate.\n* The breakdown of lysine in the brain is necessary for energy production and to produce other needed molecules.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Pyridoxine-dependent epilepsy**: A variety of mutations in the ALDH7A1 gene have been found to cause pyridoxine-dependent epilepsy. Most of these mutations are specific to single families.\n* One mutation occurs in multiple people with this condition; it replaces the amino acid glutamine with the amino acid glycine at position 399 in the antiquitin protein (written as Glu399Gln or E399Q).\n* All mutations that cause pyridoxine-dependent epilepsy produce a nonfunctional antiquitin protein.\n* A shortage (deficiency) of antiquitin leads to the buildup of Î±-aminoadipic semialdehyde, resulting in a disruption in the activity of pyridoxine, a form of vitamin B6 derived from food.\n* Pyridoxine plays a role many processes in the body, such as the breakdown of amino acids and chemicals in the brain called neurotransmitters. It is unclear how a lack of pyridoxine causes the seizures characteristic of this condition.\n\n---\n\n**ALDH7A1 Gene**\n\nThe ALDH7A1 gene is responsible for producing the antiquitin protein, which plays a crucial role in the breakdown of amino acids and neurotransmitters in the brain. A mutation in this gene can lead to pyridoxine-dependent epilepsy, a rare genetic disorder characterized by seizures that are triggered by a lack of vitamin B6.\n\n**How the Mutation Affects the Body**\n\nThe mutation causes the production of a nonfunctional antiquitin protein, resulting in a shortage (deficiency) of the protein. This leads to the buildup of Î±-aminoadipic semialdehyde, which disrupts the activity of pyridoxine, a form of vitamin B6 derived from food. Pyridoxine plays a role in many processes in the body, including the breakdown of amino acids and neurotransmitters.\n\n**Other Names for This Gene**\n\n* AL7A1_HUMAN\n* aldehyde dehydrogenase 7 family, member A1\n* aldehyde dehydrogenase 7A1\n* antiquitin\n* antiquitin 1\n* ATQ1\n* EPD\n* PDE\n\n**Genomic Location**\n\nThe ALDH7A1 gene is found on chromosome 5.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALDOB gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aldob/",
    "content": "**ALDOB Gene**\n\nThe ALDOB gene provides instructions for making the aldolase B enzyme. This enzyme is one of a group of three aldolase enzymes that are responsible for breaking down certain molecules in cells throughout the body.\n\n* Four identical aldolase B enzymes need to be attached (bound) to each other in a four-enzyme unit called a tetramer to work.\n* Aldolase B is found primarily in the liver, but it is also present at lower levels in kidney and intestinal cells.\n* Aldolase B is involved in the breakdown (metabolism) of the simple sugar fructose, which is found mostly in fruits and is used in the body for energy.\n* Aldolase B is responsible for the second step in the metabolism of fructose, which breaks down the molecule fructose-1-phosphate into glyceraldehyde and dihydroxyacetone phosphate.\n* To a lesser degree, aldolase B is also involved in the breakdown of the simple sugar glucose.\n\n**Health Conditions Related to Genetic Changes**\n\nHereditary Fructose Intolerance\n\nMore than 50 mutations in the ALDOB gene have been found to cause hereditary fructose intolerance, a condition characterized by nausea and intestinal discomfort following ingestion of foods containing fructose. Most of these mutations replace single protein building blocks (amino acids) in the aldolase B enzyme and result in the production of an enzyme with reduced function.\n\n* A mutation found in approximately half of people with hereditary fructose intolerance replaces the amino acid alanine with the amino acid proline at position 149 in the enzyme (written as Ala149Pro or A149P).\n* This mutation alters the 3-dimensional shape of the enzyme, making it difficult for the aldolase B enzymes to bind together and form tetramers.\n* If it is not in a tetramer, aldolase B cannot metabolize fructose.\n* A lack of functional aldolase B results in an accumulation of fructose-1-phosphate in liver cells, which is toxic and leads to the death of liver cells over time.\n* Additionally, the breakdown products of fructose-1-phosphase are needed in the body to produce energy and to maintain blood glucose levels.\n\n---\n\n**Hereditary Fructose Intolerance**\n\nHereditary fructose intolerance is a condition characterized by nausea and intestinal discomfort following ingestion of foods containing fructose. This condition is caused by mutations in the ALDOB gene, which codes for the aldolase B enzyme.\n\n**The Role of Aldolase B Enzyme**\n\nAldolase B enzyme plays a crucial role in breaking down fructose-1-phosphate into glyceraldehyde and dihydroxyacetone phosphate. The breakdown products of fructose-1-phosphase are needed in the body to produce energy and maintain blood glucose levels.\n\n**Consequences of Aldolase B Deficiency**\n\nA lack of functional aldolase B results in an accumulation of fructose-1-phosphate in liver cells, which is toxic and leads to the death of liver cells over time. This combination of decreased cellular energy, low blood glucose, and liver cell death leads to the features of hereditary fructose intolerance.\n\n**Other Names for the ALDOB Gene**\n\n*   ALDB\n*   ALDO2\n*   aldolase 2\n*   aldolase B, fructose-bisphosphatase\n*   aldolase B, fructose-bisphosphate\n*   liver-type aldolase\n\n**References**\n\n*   Dalby AR, Tolan DR, Littlechild JA. The structure of human liver fructose-1,6-bisphosphate aldolase. Acta Crystallogr D Biol Crystallogr. 2001 Nov;57(Pt 11):1526-33.\n*   Esposito G, Vitagliano L, Santamaria R, Viola A, Zagari A, Salvatore F. Structural and functional analysis of aldolase B mutants related to hereditary fructose intolerance. FEBS Lett. 2002 Nov 6;531(2):152-6.\n*   Malay AD, Allen KN, Tolan DR. Structure of the thermolabile mutant aldolase B, A149P: molecular basis of hereditary fructose intolerance. J Mol Biol. 2005 Mar 18;347(1):135-44.\n*   Santer R, Rischewski J, von Weihe M, Niederhaus M, Schneppenheim S, Baerlocher K, Kohlschutter A, Muntau A, Posselt HG, Steinmann B, Schneppenheim R. The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe. Hum Mutat. 2005 Jun;25(6):594.\n\n**Genomic Location**\n\nThe ALDOB gene is found on chromosome 9.\n\n---\n\n**ALDOB Gene**\n\n\\n\\n* **What is the ALDOB gene?**\n* **How do changes in the ALDOB gene affect the body?**\n* **Can changes in the ALDOB gene be inherited?**\n* **Is there any treatment or management for conditions caused by changes in the ALDOB gene?**\n\nNote: I removed the code block, ads, disclaimers, and standalone URLs as per your instructions. I also kept the medical information, HTML tags, and structure of the original content. I used **bold** for headings and * for lists to make it more readable. Finally, I separated the sections with \\n\\n as requested.",
    "category": "general"
  },
  {
    "title": "ALG1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alg1/",
    "content": "**ALG1 Gene**\n\nThe ALG1 gene provides instructions for making an enzyme that is involved in a process called glycosylation.\n\n**Normal Function**\n\nDuring this process, complex chains of sugar molecules (oligosaccharides) are attached to proteins and fats (lipids). Glycosylation modifies proteins so they can fully perform their functions and modifies lipids so they can help cells interact with each other. Oligosaccharides are made up of many sugar molecules that are attached to one another in a stepwise process, forming a complex chain.\n\nThe enzyme produced from the ALG1 gene transfers a simple sugar called mannose to growing oligosaccharides at a particular step in the formation of the chain. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or lipid.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **ALG1-congenital disorder of glycosylation**: At least 15 mutations in the ALG1 gene have been found to cause ALG1-congenital disorder of glycosylation (ALG1-CDG). This condition typically leads to intellectual disability, delayed development, weak muscle tone (hypotonia), and other signs and symptoms that affect many body systems. Mutations in the ALG1 gene result in the production of an abnormal enzyme with little activity. The poorly functioning enzyme cannot add mannose to sugar chains efficiently, and the resulting oligosaccharides are often incomplete. Although the short oligosaccharides can be transferred to proteins and lipids, the process is not as efficient as with the full-length oligosaccharide. The wide variety of signs and symptoms in ALG1-CDG are likely due to impaired glycosylation of proteins and lipids that are needed for normal function of many organs and tissues.\n\n**Other Names for This Gene**\n\n*   None\n\n**Additional Information & Resources**\n\n*   None\n\n---\n\n**ALG1 Gene**\n\nThe ALG1 gene is responsible for the production of an abnormal enzyme with little activity. This enzyme plays a crucial role in the glycosylation process, where sugar molecules are attached to proteins and lipids. The poorly functioning enzyme cannot add mannose to sugar chains efficiently, resulting in incomplete oligosaccharides.\n\n**Other Names for This Gene**\n\n* asparagine-linked glycosylation 1 homolog (yeast, beta-1,4-mannosyltransferase)\n* asparagine-linked glycosylation 1, beta-1,4-mannosyltransferase homolog\n* asparagine-linked glycosylation protein 1 homolog\n* beta-1,4 mannosyltransferase\n* beta-1,4-mannosyltransferase chitobiosyldiphosphodolichol beta-mannosyltransferase\n* GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase\n* GDP-mannose-dolichol diphosphochitobiose mannosyltransferase\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ALG1\n\nScientific Articles on PubMed:\n\n* Dupre T, Vuillaumier-Barrot S, Chantret I, Sadou Yaye H, Le Bizec C, Afenjar A, Altuzarra C, Barnerias C, Burglen L, de Lonlay P, Feillet F, Napuri S, Seta N, Moore SE. Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital disorders of glycosylation type Ik): five new patients and seven novel mutations. J Med Genet. 2010 Nov;47(11):729-35.\n* Jaeken J, Lefeber D, Matthijs G. Clinical utility gene card for: ALG1 defective congenital disorder of glycosylation. Eur J Hum Genet. 2015 Oct;23(10):1431.\n* Morava E, Vodopiutz J, Lefeber DJ, Janecke AR, Schmidt WM, Lechner S, Item CB, Sykut-Cegielska J, Adamowicz M, Wierzba J, Zhang ZH, Mihalek I, Stockler S, Bodamer OA, Lehle L, Wevers RA. Defining the phenotype in congenital disorder of glycosylation due to ALG1 mutations. Pediatrics. 2012 Oct;130(4):e1034-9.\n\nCatalog of Genes and Diseases from OMIM:\n\n* ALG1 CHITOBIOSYLDIPHOSPHODOLICHOL BETA-MANNOSYLTRANSFERASE; ALG1\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**Genomic Location**\n\nThe ALG1 gene is found on chromosome 16.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALG1-congenital disorder of glycosylation: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/alg1-congenital-disorder-of-glycosylation/",
    "content": "**ALG1-congenital disorder of glycosylation**\n\nALG1-congenital disorder of glycosylation (ALG1-CDG, also known as congenital disorder of glycosylation type Ik) is an inherited disorder with varying signs and symptoms that typically develop during infancy and can affect several body systems.\n\n* **Symptoms:**\n\t+ Intellectual disability\n\t+ Delayed development\n\t+ Weak muscle tone (hypotonia)\n\t+ Seizures\n\t+ Movement problems such as involuntary rhythmic shaking (tremor) or difficulties with movement and balance (ataxia)\n\t+ Problems with blood clotting, leading to abnormal clotting or bleeding episodes\n\t+ Abnormally low levels of proteins called antibodies (or immunoglobulins), particularly immunoglobulin G (IgG)\n\t+ Physical abnormalities such as:\n\t\t- Small head size (microcephaly)\n\t\t- Unusual facial features\n\t\t- Joint deformities called contractures\n\t\t- Long, slender fingers and toes (arachnodactyly)\n\t\t- Unusually fleshy pads at the tips of the fingers and toes\n\t+ Eye problems such as:\n\t\t- Eyes that do not point in the same direction (strabismus)\n\t\t- Involuntary eye movements (nystagmus)\n\t\t- Vision loss (rarely)\n\t+ Less common abnormalities include respiratory problems, reduced sensation in their arms and legs (peripheral neuropathy), swelling (edema), and gastrointestinal difficulties.\n\nThe signs and symptoms of ALG1-CDG are often severe, with affected individuals surviving only into infancy or childhood. However, some people with this condition are more mildly affected and survive into adulthood.\n\n---\n\n**ALG1-congenital disorder of glycosylation**\n\n**What is ALG1-CDG?**\n\nALG1-CDG (also known as congenital disorder of glycosylation type Ik) is an inherited disorder with varying signs and symptoms that typically develop during infancy and can affect several body systems.\n\n**Signs and Symptoms**\n\nIndividuals with ALG1-CDG often have intellectual disability, delayed development, and weak muscle tone (hypotonia). Many affected individuals develop seizures that can be difficult to treat. Individuals with ALG1-CDG may also have movement problems such as involuntary rhythmic shaking (tremor) or difficulties with movement and balance (ataxia).\n\nPeople with ALG1-CDG often have problems with blood clotting, which can lead to abnormal clotting or bleeding episodes. Additionally, affected individuals may produce abnormally low levels of proteins called antibodies (or immunoglobulins), particularly immunoglobulin G (IgG). Antibodies help protect the body against infection by foreign particles and germs. A reduction in antibodies can make it difficult for affected individuals to fight infections.\n\nSome people with ALG1-CDG have physical abnormalities such as a small head size (microcephaly); unusual facial features; joint deformities called contractures; long, slender fingers and toes (arachnodactyly); or unusually fleshy pads at the tips of the fingers and toes. Eye problems that may occur in people with this condition include eyes that do not point in the same direction (strabismus) or involuntary eye movements (nystagmus). Rarely, affected individuals develop vision loss.\n\nLess common abnormalities that occur in people with ALG1-CDG include respiratory problems, reduced sensation in their arms and legs (peripheral neuropathy), swelling (edema), and gastrointestinal difficulties.\n\n**Frequency**\n\nALG1-CDG appears to be a rare disorder; fewer than 30 affected individuals have been described in the scientific literature.\n\n**Causes**\n\nMutations in the ALG1 gene cause ALG1-CDG. This gene provides instructions for making an enzyme that is involved in a process called glycosylation. During this process, complex chains of sugar molecules (oligosaccharides) are added to proteins and fats (lipids). Glycosylation modifies proteins and lipids so they can fully perform their functions.\n\nThe enzyme produced from the ALG1 gene transfers a simple sugar called mannose to growing oligosaccharides at a particular step in the formation of the sugar chain. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or lipid.\n\nALG1 gene mutations lead to the production of an abnormal enzyme with reduced activity. The poorly functioning enzyme cannot add mannose to sugar chains efficiently, and the resulting oligosaccharides are often incomplete. Although the short oligosaccharides can be transferred to proteins and fats, the process is not as efficient as with the full-length oligosaccharide.\n\n**Inheritance**\n\nThis condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n---\n\n**ALG1-congenital disorder of glycosylation**\n\nThis condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents of an individual with this condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n**Other Names for This Condition**\n\n* ALG1-CDG\n* Carbohydrate deficient glycoprotein syndrome type Ik\n* CDG1K\n* CDGIk\n* Congenital disorder of glycosylation type 1K\n* Mannosyltransferase 1 deficiency\n\n**Genetic Testing Information**\n\n* Genetic Testing Registry: ALG1-congenital disorder of glycosylation\n\n**Genetic and Rare Diseases Information Center**\n\n* ALG1-CDG\n* Congenital disorder of glycosylation\n\n**Patient Support and Advocacy Resources**\n\n* National Organization for Rare Disorders (NORD)\n\n**Catalog of Genes and Diseases from OMIM**\n\n* CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K\n\n**Scientific Articles on PubMed**\n\n* PubMed\n\n**References**\n\n* Dupre T, Vuillaumier-Barrot S, Chantret I, Sadou Yaye H, Le Bizec C, Afenjar A, Altuzarra C, Barnerias C, Burglen L, de Lonlay P, Feillet F, Napuri S, Seta N, Moore SE. Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital disorders of glycosylation type Ik): five new patients and seven novel mutations. J Med Genet. 2010 Nov;47(11):729-35.\n* Jaeken J, Lefeber D, Matthijs G. Clinical utility gene card for: ALG1 defective congenital disorder of glycosylation. Eur J Hum Genet. 2015 Oct;23(10):1431.\n* Morava E, Vodopiutz J, Lefeber DJ, Janecke AR, Schmidt WM, Lechner S, Item CB, Sykut-Cegielska J, Adamowicz M, Wierzba J, Zhang ZH, Mihalek I, Stockler S, Bodamer OA, Lehle L, Wevers RA. Defining the phenotype in congenital disorder of glycosylation due to ALG1 mutations. Pediatrics. 2012 Oct;130(4):e1034-9.\n* Rohlfing AK, Rust S, Reunert J, Tirre M, Du Chesne I, Wemhoff S, Meinhardt F, Hartmann H, Das AM, Marquardt T. ALG1-CDG: a new case with early fatal outcome. Gene. 2014 Jan 25;534(2):345-51.\n\n**Understanding Genetics**\n\n* What is the prognosis of a genetic condition?\n* How can gene variants affect health and development?\n* What does it mean if a disorder seems to run in my family?\n* What are the different ways a genetic condition can be inherited?\n* How are genetic conditions treated or managed?",
    "category": "general"
  },
  {
    "title": "ALG12 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alg12/",
    "content": "**ALG12 Gene**\n\nThe ALG12 gene provides instructions for making an enzyme that is involved in a process called glycosylation. During this process, complex chains of sugar molecules (oligosaccharides) are attached to proteins and fats (lipids). Glycosylation modifies proteins so they can fully perform their functions.\n\n**Normal Function**\n\nThe ALG12 gene transfers a simple sugar called mannose to growing oligosaccharides at a particular step in the formation of the chain. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or lipid.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **ALG12-congenital disorder of glycosylation**: At least 13 mutations in the ALG12 gene have been found to cause ALG12-congenital disorder of glycosylation (ALG12-CDG). This condition typically leads to delayed growth and development, weak muscle tone (hypotonia), and other signs and symptoms. Mutations in the ALG12 gene result in the production of an abnormal enzyme with little activity. Without a properly functioning enzyme, mannose cannot be added to the chain efficiently, and the resulting oligosaccharides are often incomplete. Although the short oligosaccharides can be transferred to proteins and lipids, the process is not as efficient as with the full-length oligosaccharide. As a result, glycosylation is reduced. The wide variety of signs and symptoms in ALG12-CDG are likely due to impaired glycosylation of proteins and lipids that are needed for normal function in many organs and tissues, including the brain.\n\n**References**\n\n*   At least 13 mutations in the ALG12 gene have been found to cause ALG12-congenital disorder of glycosylation (ALG12-CDG).\n\n---\n\n**ALG12 Gene**\n\n**What is ALG12?**\n\nALG12, also known as alpha-1,6-mannosyltransferase, is a gene that plays a crucial role in the glycosylation process of proteins and lipids. The protein produced by this gene is involved in the transfer of mannose sugars to proteins and lipids, which is essential for their proper functioning.\n\n**Function of ALG12**\n\nThe ALG12 protein is responsible for transferring mannose sugars to proteins and lipids through a process called glycosylation. This process involves the addition of a specific sugar molecule, mannose, to the protein or lipid, which is necessary for its proper functioning.\n\n**Signs and Symptoms of ALG12 Deficiency**\n\nIndividuals with a deficiency in the ALG12 gene may experience a wide range of signs and symptoms due to impaired glycosylation of proteins and lipids. These can include developmental delays, intellectual disability, seizures, and other neurological problems.\n\n**Other Names for This Gene**\n\n* Asparagine-linked glycosylation 12 homolog (S. cerevisiae, alpha-1,6-mannosyltransferase)\n* Asparagine-linked glycosylation 12 homolog (yeast, alpha-1,6-mannosyltransferase)\n* Asparagine-linked glycosylation 12, alpha-1,6-mannosyltransferase homolog\n* Asparagine-linked glycosylation protein 12 homolog\n* CDG1G\n* Dol-P-Man dependent alpha-1,6-mannosyltransferase\n* Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase\n* Dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichol alpha-1,6-mannosyltransferase\n* Dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl-alpha-1,6-mannosyltransferase\n* Dolichyl-P-mannose:Man-7-GlcNAc-2-PP-dolichyl-alpha-6-mannosyltransferase\n* ECM39\n* hALG12\n* Mannosyltransferase ALG12 homolog\n* Membrane protein SB87\n* PP14673\n\n**Genomic Location**\n\nThe ALG12 gene is located on chromosome 22.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALG12-congenital disorder of glycosylation: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/alg12-congenital-disorder-of-glycosylation/",
    "content": "**ALG12-congenital disorder of glycosylation**\n\nALG12-congenital disorder of glycosylation (ALG12-CDG, also known as congenital disorder of glycosylation type Ig) is an inherited disorder with varying signs and symptoms that can affect several body systems. Individuals with ALG12-CDG typically develop signs and symptoms of the condition during infancy.\n\n**Symptoms**\n\n* Problems feeding\n* Difficulty growing and gaining weight at the expected rate (failure to thrive)\n* Intellectual disability\n* Delayed development\n* Weak muscle tone (hypotonia)\n* Seizures\n\nSome people with ALG12-CDG have physical abnormalities such as:\n\n* Small head size (microcephaly)\n* Unusual facial features, including:\n\t+ Folds of skin that cover the inner corners of the eyes (epicanthal folds)\n\t+ A prominent nasal bridge\n\t+ Abnormally shaped ears\n* Abnormal genitalia in males, including:\n\t+ Small penis (micropenis)\n\t+ Undescended testes\n\nPeople with ALG12-CDG often produce abnormally low levels of proteins called antibodies (or immunoglobulins), particularly immunoglobulin G (IgG). This can make it difficult for affected individuals to fight infections.\n\nLess common abnormalities seen in people with ALG12-CDG include:\n\n* Weakened heart muscle (cardiomyopathy)\n* Poor bone development, which can lead to skeletal abnormalities.\n\n---\n\n**ALG12-congenital disorder of glycosylation**\n\n**What is ALG12-CDG?**\n\nALG12-congenital disorder of glycosylation (ALG12-CDG) is a rare inherited disorder with varying signs and symptoms that can affect several body systems. Individuals with ALG12-CDG typically develop signs and symptoms of the condition during infancy.\n\n**Signs and Symptoms**\n\n* Problems feeding\n* Difficulty growing and gaining weight at the expected rate (failure to thrive)\n* Intellectual disability\n* Delayed development\n* Weak muscle tone (hypotonia)\n* Seizures\n* Physical abnormalities such as:\n\t+ Small head size (microcephaly)\n\t+ Unusual facial features, including folds of skin that cover the inner corners of the eyes (epicanthal folds), a prominent nasal bridge, and abnormally shaped ears\n\t+ Abnormal genitalia in males, such as a small penis (micropenis) and undescended testes\n\n**Immune System**\n\n* Affected individuals often produce abnormally low levels of proteins called antibodies (or immunoglobulins), particularly immunoglobulin G (IgG).\n* Antibodies help protect the body against infection by attaching to specific foreign particles and germs, marking them for destruction.\n* A reduction in antibodies can make it difficult for affected individuals to fight infections.\n\n**Less Common Abnormalities**\n\n* Weakened heart muscle (cardiomyopathy)\n* Poor bone development, which can lead to skeletal abnormalities\n\n**Causes**\n\nMutations in the ALG12 gene cause ALG12-CDG. This gene provides instructions for making an enzyme that is involved in a process called glycosylation.\n\n**Inheritance**\n\nThis condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n---\n\n**ALG12-congenital disorder of glycosylation**\n\nThis condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n**Other Names for This Condition**\n\n* ALG12-CDG\n* CDG Ig\n* Congenital disorder of glycosylation type 1G\n* Congenital disorder of glycosylation type Ig\n\n**Additional Information & Resources**\n\n* Genetic Testing Registry: ALG12-congenital disorder of glycosylation\n* Genetic and Rare Diseases Information Center:\n\t+ ALG12-CDG\n\t+ Congenital disorder of glycosylation\n* Patient Support and Advocacy Resources:\n\t+ National Organization for Rare Disorders (NORD)\n* Catalog of Genes and Diseases from OMIM:\n\t+ CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G\n* Scientific Articles on PubMed:\n\t+ PubMed\n\n**Genetic Testing Information**\n\n* Genetic Testing Registry: ALG12-congenital disorder of glycosylation\n\n**Genetic and Rare Diseases Information Center**\n\n* ALG12-CDG\n* Congenital disorder of glycosylation\n\n**Patient Support and Advocacy Resources**\n\n* National Organization for Rare Disorders (NORD)\n\n**Catalog of Genes and Diseases from OMIM**\n\n* CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G\n\n**Scientific Articles on PubMed**\n\n* PubMed\n\n**References**\n\n* Chantret I, Dupre T, Delenda C, Bucher S, Dancourt J, Barnier A, Charollais A, Heron D, Bader-Meunier B, Danos O, Seta N, Durand G, Oriol R, Codogno P, Moore SE. Congenital disorders of glycosylation type Ig is defined by a deficiency in dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl mannosyltransferase. J Biol Chem. 2002 Jul 12;277(28):25815-22.\n* Grubenmann CE, Frank CG, Kjaergaard S, Berger EG, Aebi M, Hennet T. ALG12 mannosyltransferase defect in congenital disorder of glycosylation type lg. Hum Mol Genet. 2002 Sep 15;11(19):2331-9.\n* Kranz C, Basinger AA, Gucsavas-Calikoglu M, Sun L, Powell CM, Henderson FW, Aylsworth AS, Freeze HH. Expanding spectrum of congenital disorder of glycosylation Ig (CDG-Ig): sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomyopathy, genital malformations, and early lethality. Am J Med Genet A. 2007 Jun 15;143A(12):1371-8.\n* Murali C, Lu JT, Jain M, Liu DS, Lachman R, Gibbs RA, Lee BH, Cohn D, Campeau PM. Diagnosis of ALG12-CDG by exome sequencing in a case of severe skeletal dysplasia. Mol Genet Metab Rep. 2014;1:213-219.\n* Thiel C, Schwarz M, Hasilik M, Grieben U, Hanefeld F, Lehle L, von Figura K, Korner C. Deficiency of dolichyl-P-Man:Man7GlcNAc2-PP-dolichyl mannosyltransferase causes congenital disorder of glycosylation type Ig. Biochem J. 2002 Oct 1;367(Pt 1):195-201.\n\n**Understanding Genetics**\n\n* What is the prognosis of a genetic condition?\n* How can gene variants affect health and development?\n* What does it mean if a disorder seems to run in my family?\n* What are the different ways a genetic condition can be inherited?\n* How are genetic conditions treated or managed?",
    "category": "general"
  },
  {
    "title": "ALG6 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alg6/",
    "content": "**ALG6 Gene**\n\nThe ALG6 gene provides instructions for making an enzyme that is involved in a process called glycosylation. Glycosylation is a process by which sugar molecules (oligosaccharides) are attached to proteins and fats.\n\n*   **Normal Function:** The enzyme produced from the ALG6 gene transfers a simple sugar called glucose to the growing oligosaccharide. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or fat.\n*   **Health Conditions Related to Genetic Changes:**\n\n    *   **ALG6-congenital disorder of glycosylation:** At least 20 mutations in the ALG6 gene have been found to cause ALG6-congenital disorder of glycosylation (ALG6-CDG, also known as congenital disorder of glycosylation type Ic). This condition typically leads to developmental delay, vision problems, seizures, and other signs and symptoms.\n    *   **Mutations in the ALG6 Gene:** Mutations in the ALG6 gene result in the production of an abnormal enzyme with reduced or no activity. A common mutation replaces the protein building block (amino acid) alanine with the amino acid valine at position 333 in the enzyme. This mutation, written as Ala333Val or A333V, results in an enzyme with reduced activity.\n    *   **Impact of Impaired Glycosylation:** Without a properly functioning enzyme, glycosylation cannot proceed normally, and oligosaccharides are incomplete. As a result, glycosylation is reduced or absent. The wide variety of signs and symptoms in ALG6-CDG are likely due to impaired glycosylation of proteins and fats that are needed for normal function in many organs and tissues, including the brain, eyes, and hormone-producing (endocrine) system.\n\n**Other Names for This Gene**\n\n*   **ALG6 alpha-1,3-glucosyltransferase**\n\n**Additional Information & Resources**\n\n*   **References:** [Insert references here]\n\nNote: The cleaned output is a rewritten version of the original content, formatted to be more readable and concise. The structure and headings have been preserved to maintain clarity and organization.\n\n---\n\n**ALG6 Gene**\n\nThe ALG6 gene provides instructions for making the protein building block (amino acid) alanine with the amino acid valine at position 333 in the enzyme. This mutation, written as Ala333Val or A333V, results in an enzyme with reduced activity.\n\n**Other Names for This Gene**\n\n*   asparagine-linked glycosylation 6 homolog (S. cerevisiae, alpha-1,3-glucosyltransferase)\n*   asparagine-linked glycosylation 6 homolog (yeast, alpha-1,3-glucosyltransferase)\n*   asparagine-linked glycosylation 6, alpha-1,3-glucosyltransferase homolog\n*   asparagine-linked glycosylation protein 6 homolog\n*   dol-P-Glc:Man(9)GlcNAc(2)-PP-Dol\n*   alpha-1,3-glucosyltransferase\n*   dolichyl pyrophosphate Man9GlcNAc2\n*   alpha-1,3-glucosyltransferase\n*   dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichol\n*   alpha- 1->3-glucosyltransferase\n*   dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl\n*   glucosyltransferase\n*   dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylglucosyltransferase\n*   Man(9)GlcNAc(2)-PP-Dol\n*   alpha-1,3-glucosyltransferase\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n*   Tests of ALG6\n\nScientific Articles on PubMed:\n\n*   PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n*   ALG6 ALPHA-1,3-GLUCOSYLTRANSFERASE; ALG6\n\nGene and Variant Databases:\n\n*   NCBI Gene\n*   ClinVar",
    "category": "general"
  },
  {
    "title": "ALG6-congenital disorder of glycosylation: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/alg6-congenital-disorder-of-glycosylation/",
    "content": "**ALG6-congenital disorder of glycosylation**\n\nALG6-congenital disorder of glycosylation (ALG6-CDG, also known as congenital disorder of glycosylation type Ic) is an inherited condition that affects many parts of the body. The signs and symptoms of ALG6-CDG vary widely among people with the condition.\n\n**Description**\n\nIndividuals with ALG6-CDG typically develop signs and symptoms of the condition during infancy. They may have difficulty gaining weight and growing at the expected rate (failure to thrive). Affected infants often have weak muscle tone (hypotonia) and developmental delay.\n\nPeople with ALG6-CDG may have seizures, problems with coordination and balance (ataxia), or stroke-like episodes that involve an extreme lack of energy (lethargy) and temporary paralysis. They may also develop blood clotting disorders. Some individuals with ALG6-CDG have eye abnormalities including eyes that do not look in the same direction (strabismus) and an eye disorder called retinitis pigmentosa, which causes vision loss. Females with ALG6-CDG have hypergonadotropic hypogonadism, which affects the production of hormones that direct sexual development. As a result, most females with ALG6-CDG do not go through puberty.\n\n**Frequency**\n\nThe prevalence of ALG6-CDG is unknown, but it is thought to be the second most common type of congenital disorder of glycosylation. More than 30 cases of ALG6-CDG have been described in the scientific literature.\n\n**Causes**\n\nALG6-CDG is caused by mutations in the ALG6 gene. This gene provides instructions for making an enzyme that is involved in a process called glycosylation. Glycosylation is the process by which sugar molecules (monosaccharides) and complex chains of sugar molecules (oligosaccharides) are added to proteins and fats. The enzyme produced from the ALG6 gene transfers a simple sugar called glucose to the growing oligosaccharide. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or fat.\n\nALG6 gene mutations lead to the production of an abnormal enzyme with reduced or no activity. Without a properly functioning enzyme, glycosylation cannot proceed normally, and oligosaccharides are incomplete. As a result, glycosylation is reduced or absent.\n\n---\n\n**ALG6-congenital disorder of glycosylation**\n\nThe wide variety of signs and symptoms in ALG6-CDG are likely due to impaired glycosylation of proteins and fats that are needed for normal function in many organs and tissues, including the brain, eyes, liver, and hormone-producing (endocrine) system.\n\n**Causes of ALG6-CDG**\n\nALG6-CDG is caused by mutations in the ALG6 gene. This gene provides instructions for making an enzyme that is involved in a process called glycosylation. Glycosylation is the process by which sugar molecules (monosaccharides) and complex chains of sugar molecules (oligosaccharides) are added to proteins and fats. Glycosylation modifies proteins and fats so they can perform a wider variety of functions.\n\nThe enzyme produced from the ALG6 gene transfers a simple sugar called glucose to the growing oligosaccharide. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or fat. ALG6 gene mutations lead to the production of an abnormal enzyme with reduced or no activity. Without a properly functioning enzyme, glycosylation cannot proceed normally, and oligosaccharides are incomplete.\n\n**Inheritance**\n\nThis condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n**Other Names for This Condition**\n\nALG6-CDG is also known as:\n\n* Carbohydrate-deficient glycoprotein syndrome type Ic\n* Carbohydrate-deficient glycoprotein syndrome type V\n* CDG syndrome type Ic\n* CDG1C\n* CDGIc\n* Congenital disorder of glycosylation type Ic\n* Glucosyltransferase 1 deficiency\n\n**Additional Information & Resources**\n\nFor more information on ALG6-CDG, you can visit the following resources:\n\n* Genetic Testing Registry: ALG6-congenital disorder of glycosylation 1C\n* Genetic and Rare Diseases Information Center: ALG6-CDG\n* Patient Support and Advocacy Resources: National Organization for Rare Disorders (NORD)\n* Catalog of Genes and Diseases from OMIM: CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C\n* Scientific Articles on PubMed: Various studies on ALG6-CDG\n\n**References**\n\nFor further reading on ALG6-CDG, you can consult the following references:\n\n* Damen G, de Klerk H, Huijmans J, den Hollander J, Sinaasappel M. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):282-7.\n* Grunewald S, Imbach T, Huijben K, Rubio-Gozalbo ME, Verrips A, de Klerk JB, Stroink H, de Rijk-van Andel JF, Van Hove JL, Wendel U, Matthijs G, Hennet T, Jaeken J, Wevers RA. Clinical and biochemical characteristics of congenital disorder of glycosylation type Ic, the first recognized endoplasmic reticulum defect in N-glycan synthesis. Ann Neurol. 2000 Jun;47(6):776-81.\n* Imbach T, Burda P, Kuhnert P, Wevers RA, Aebi M, Berger EG, Hennet T. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6982-7.\n* Imbach T, Grunewald S, Schenk B, Burda P, Schollen E, Wevers RA, Jaeken J, de Klerk JB, Berger EG, Matthijs G, Aebi M, Hennet T. Multi-allelic origin of congenital disorder of glycosylation (CDG)-Ic. Hum Genet. 2000 May;106(5):538-45.\n* Sparks SE, Krasnewich DM. Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Westphal V, Xiao M, Kwok PY, Freeze HH. Identification of a frequent variant in ALG6, the cause of Congenital Disorder of Glycosylation-Ic. Hum Mutat. 2003 Nov;22(5):420-1.\n\n---\n\n**ALG6-congenital disorder of glycosylation**\n\n\\n\\n\n\n*other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic.* J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):282-7. doi: 10.1097/00005176-200403000-00010. Citation on PubMed\n\n\\n\\n\n\n*Grunewald S, Imbach T, Huijben K, Rubio-Gozalbo ME, Verrips A, de Klerk JB, Stroink H, de Rijk-van Andel JF, Van Hove JL, Wendel U, Matthijs G, Hennet T, Jaeken J, Wevers RA. Clinical and biochemical characteristics of congenital disorder of glycosylation type Ic, the first recognized endoplasmic reticulum defect in N-glycan synthesis.* Ann Neurol. 2000 Jun;47(6):776-81. Citation on PubMed\n\n\\n\\n\n\n*Imbach T, Burda P, Kuhnert P, Wevers RA, Aebi M, Berger EG, Hennet T. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic.* Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6982-7. doi: 10.1073/pnas.96.12.6982. Citation on PubMed or Free article on PubMed Central\n\n\\n\\n\n\n*Imbach T, Grunewald S, Schenk B, Burda P, Schollen E, Wevers RA, Jaeken J, de Klerk JB, Berger EG, Matthijs G, Aebi M, Hennet T. Multi-allelic origin of congenital disorder of glycosylation (CDG)-Ic.* Hum Genet. 2000 May;106(5):538-45. doi: 10.1007/s004390000293. Citation on PubMed\n\n\\n\\n\n\n*Sparks SE, Krasnewich DM. Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview.* 2005 Aug 15 [updated 2017 Jan 12]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1332/. Citation on PubMed\n\n\\n\\n\n\n*Westphal V, Xiao M, Kwok PY, Freeze HH. Identification of a frequent variant in ALG6, the cause of Congenital Disorder of Glycosylation-Ic.* Hum Mutat. 2003 Nov;22(5):420-1. doi: 10.1002/humu.9195. Citation on PubMed",
    "category": "general"
  },
  {
    "title": "ALK gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alk/",
    "content": "**ALK Gene**\n\nThe **ALK gene** provides instructions for making a protein called **ALK receptor tyrosine kinase**, which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction.\n\n**Normal Function**\n\nThe process begins when the kinase is stimulated at the cell surface and then attaches to a similar kinase (dimerizes). After dimerization, the kinase is tagged with a marker called a phosphate group in a process called phosphorylation. Phosphorylation turns on (activates) the kinase. The activated kinase is able to transfer a phosphate group to another protein inside the cell, which is activated as a result.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Neuroblastoma**: At least 16 mutations in the ALK gene have been identified in some people with neuroblastoma, a type of cancerous tumor composed of immature nerve cells (neuroblasts). Mutations in the ALK gene change single protein building blocks (amino acids) in ALK receptor tyrosine kinase. The most common mutation in neuroblastoma replaces the amino acid arginine with the amino acid glutamine at position 1275 (written as Arg1275Gln or R1275Q).\n\n---\n\n**ALK Gene**\n\nThis phenomenon, known as gene amplification, results in overexpression of ALK receptor tyrosine kinase.\n\n**Mutated or Overexpressed ALK Receptor Tyrosine Kinase**\n\nMutated or overexpressed ALK receptor tyrosine kinase no longer requires stimulation from outside the cell to be phosphorylated. As a result, the kinase and the downstream signaling pathway are constantly turned on (constitutively activated).\n\n**Constitutive Activation of ALK Receptor Tyrosine Kinase**\n\nConstitutive activation of ALK receptor tyrosine kinase may increase the proliferation of immature nerve cells, leading to neuroblastoma.\n\n**Neuroblastoma**\n\nAt least 16 mutations in the ALK gene have been identified in some people with neuroblastoma, a type of cancerous tumor composed of immature nerve cells (neuroblasts). Neuroblastoma and other cancers occur when a buildup of genetic mutations in critical genesâthose that control cell proliferation or differentiationâallows cells to grow and divide uncontrollably to form a tumor.\n\n**ALK Gene Mutations**\n\nMutations in the ALK gene change single protein building blocks (amino acids) in ALK receptor tyrosine kinase. The most common mutation in neuroblastoma replaces the amino acid arginine with the amino acid glutamine at position 1275 (written as Arg1275Gln or R1275Q).\n\n**Gene Amplification**\n\nOccasionally, extra copies of the ALK gene are found in people with neuroblastoma. This phenomenon, known as gene amplification, results in overexpression of ALK receptor tyrosine kinase.\n\n**ALK Gene and Cancer**\n\nThe presence of the partner protein allows phosphorylation of ALK receptor tyrosine kinase without dimerization. The fusion protein and signaling pathways activated by ALK receptor tyrosine kinase are constitutively activated, which may abnormally increase the proliferation of immature nerve cells, leading to cancer formation.\n\n**ALK Gene and Neuroblastoma**\n\nAt least 16 mutations in the ALK gene have been identified in some people with neuroblastoma. Somatic mutations in the ALK gene occur during the development of some cases of sporadic neuroblastoma, and inherited mutations in the ALK gene increase the risk of developing familial neuroblastoma.\n\n**ALK Gene and Lung Cancer**\n\nRearrangements of genetic material involving the ALK gene on chromosome 2 increase the risk of developing several other types of cancer. These rearrangements are somatic mutations, which means they occur during a person's lifetime and are present only in the cells that become cancerous.\n\n---\n\n**ALK Gene: MedlinePlus Genetics (Part 3/4)**\n\nThe ALK gene, located on chromosome 2, plays a crucial role in neuroblastoma and other cancers. Mutations in the ALK gene can lead to the development of cancer.\n\n**Mutations in Neuroblastoma**\n\nIn neuroblastoma, the most common mutation replaces the amino acid arginine with glutamine at position 1275 (Arg1275Gln or R1275Q). This mutation has been found in both familial and sporadic neuroblastoma. Extra copies of the ALK gene are also found in people with neuroblastoma, resulting in overexpression of the receptor tyrosine kinase.\n\n**Constitutive Activation**\n\nMutated or overexpressed ALK receptor tyrosine kinase no longer requires stimulation from outside the cell to be phosphorylated. As a result, the kinase and the downstream signaling pathway are constantly turned on (constitutively activated). This constitutive activation may increase the proliferation of immature nerve cells, leading to neuroblastoma.\n\n**Lung Cancer**\n\nRearrangements of genetic material involving the ALK gene on chromosome 2 increase the risk of developing several other types of cancer. These rearrangements are somatic mutations, which means they occur during a person's lifetime and are present only in the cells that become cancerous.\n\n**Translocations**\n\nOne type of rearrangement, called a translocation, exchanges genetic material between chromosome 2 and another chromosome. At least 15 translocations involving the ALK gene have been identified in people with anaplastic large cell lymphoma (ALCL), a rare form of cancer involving immune cells called T cells.\n\n**Inversions**\n\nAnother type of rearrangement, called an inversion, occurs when chromosome 2 is broken in two places and the resulting piece of DNA is reversed and re-inserted into the chromosome. A small group of people with non-small cell lung cancer have an inversion of chromosome 2, fusing the ALK gene with another gene called EML4.\n\n**Fusion Proteins**\n\nThe fusion proteins created by these rearranged genes have functions of both ALK receptor tyrosine kinase and the partner protein. The presence of the partner protein allows phosphorylation of ALK receptor tyrosine kinase without dimerization. The fusion protein and signaling pathways activated by ALK receptor tyrosine kinase are constitutively activated, which may abnormally increase the proliferation of immature nerve cells, leading to cancer formation.\n\n**Other Names for This Gene**\n\nALK tyrosine kinase receptor\nanaplastic lymphoma kinase\nanaplastic lymphoma receptor tyrosine kinase\nCD246\nCD246 antigen\nNBLST3\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry\n\n---\n\n**ALK Gene**\n\n**What is the ALK gene?**\n\nThe ALK gene provides instructions for making a protein called anaplastic lymphoma kinase, which plays a crucial role in cell signaling pathways.\n\n**Genomic Location**\n\nThe ALK gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**References**\n\n* Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 2010 Dec 28;299(2):81-94.\n* Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008 Oct 16;455(7215):967-70.\n* Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5.\n\n**Disclaimers**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALMS1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alms1/",
    "content": "**ALMS1 Gene**\n\nThe ALMS1 gene provides instructions for making a protein whose function is unknown. Researchers believe that the protein may play a role in hearing, vision, regulation of body weight, and functions of the heart, kidney, lungs, and liver. It may also affect how the pancreas regulates insulin, a hormone that helps control levels of blood glucose, also called blood sugar.\n\n**Normal Function**\n\nThe ALMS1 protein is present in most of the body's tissues, usually at low levels. Within cells, this protein is located in structures called centrosomes. Centrosomes play a role in cell division and the assembly of microtubules, which are proteins that transport materials in cells and help the cell maintain its shape. The ALMS1 protein is also found at the base of cilia, which are finger-like projections that stick out from the surface of cells. Almost all cells have cilia at some stage of their life cycle. Cilia are involved in cell movement and many different chemical signaling pathways.\n\n**Health Conditions Related to Genetic Changes**\n\n* AlstrÃ¶m syndrome: More than 80 mutations in the ALMS1 gene have been identified in people with AlstrÃ¶m syndrome. Most of these mutations lead to the production of an abnormally small version of the ALMS1 protein that does not function properly. Researchers propose that a lack of normally functioning ALMS1 protein in the brain could lead to overeating. A loss of this protein in the pancreas may cause insulin resistance, a condition in which the body cannot use insulin properly. The combined effects of overeating and insulin resistance impair the body's ability to handle excess glucose, leading to diabetes and obesity (two common features of AlstrÃ¶m syndrome).\n\n---\n\n**ALMS1 Gene**\n\nThe ALMS1 gene is associated with AlstrÃ¶m syndrome, a rare genetic disorder characterized by obesity, type 2 diabetes, and neurosensory degeneration.\n\n**Function of the ALMS1 Protein**\n\nNormally functioning ALMS1 protein in the brain could lead to overeating. A loss of this protein in the pancreas may cause insulin resistance, a condition in which the body cannot use insulin properly.\n\n**Impact on Body's Ability to Handle Excess Glucose**\n\nThe combined effects of overeating and insulin resistance impair the body's ability to handle excess glucose, leading to diabetes and obesity (two common features of AlstrÃ¶m syndrome).\n\n**Other Signs and Symptoms of AlstrÃ¶m Syndrome**\n\nIt is unclear how ALMS1 mutations cause the other signs and symptoms of AlstrÃ¶m syndrome. Researchers suspect that this condition is associated with malfunctioning cilia in many of the body's tissues and organs.\n\n**Mutations in the ALMS1 Gene**\n\nMore than 80 mutations in the ALMS1 gene have been identified in people with AlstrÃ¶m syndrome. Most of these mutations lead to the production of an abnormally small version of the ALMS1 protein that does not function properly.\n\n**References**\n\n* Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, Beck S, Boerkoel CF, Sicolo N, Martin M, Nishina PM, Naggert JK. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet. 2002 May;31(1):74-8.\n* Hearn T, Renforth GL, Spalluto C, Hanley NA, Piper K, Brickwood S, White C, Connolly V, Taylor JF, Russell-Eggitt I, Bonneau D, Walker M, Wilson DI. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alstrom syndrome. Nat Genet. 2002 May;31(1):79-83.\n* Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA, Wilson DI. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes. 2005 May;54(5):1581-7.\n* Joy T, Cao H, Black G, Malik R, Charlton-Menys V, Hegele RA, Durrington PN. Alstrom syndrome (OMIM 203800): a case report and literature review.\n\nNote: The cleaned output is formatted to be easy to read and understand, with bold headings and bullet points where necessary.\n\n---\n\n**ALMS1 Gene**\n\n**Genomic Location**\nThe ALMS1 gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALOX12B gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alox12b/",
    "content": "**ALOX12B Gene**\n\nThe ALOX12B gene provides instructions for making an enzyme called 12R-LOX. This enzyme is part of a family of enzymes called arachidonate lipoxygenases.\n\n**Normal Function**\n\n* The 12R-LOX enzyme helps add an oxygen molecule to arachidonic acid to make a substance called 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE).\n* 12R-HPETE is later converted to a signaling molecule that is involved in the formation of the layers of fats (lipids) within the outermost layer of the skin (the epidermis).\n* The lipid layers are necessary to prevent water loss (dehydration) through the skin.\n\n**Health Conditions Related to Genetic Changes**\n\n* Nonbullous congenital ichthyosiform erythroderma (NBCIE)\n\t+ More than 55 mutations in the ALOX12B gene have been found to cause NBCIE.\n\t+ This condition affects the skin and causes redness, fine white scales, an increased risk of infections, and excessive dehydration.\n\t+ Most of the mutations change single protein building blocks (amino acids) in the 12R-LOX enzyme.\n\t+ Many ALOX12B gene mutations lead to the production of a nonfunctional 12R-LOX enzyme, which disrupts the processing of the molecules involved in the formation of the lipid layer within the epidermis.\n\n---\n\n**ALOX12B Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Other Disorders**\n\n* ALOX12B gene mutations have been found to cause another form of ichthyosis called self-healing collodion baby.\n* Individuals with this condition are born with a tight, clear sheath covering their skin called a collodion membrane, which is usually shed during the first few weeks of life.\n* While babies with NBCIE (described above) may also be born with a collodion membrane, infants with self-healing collodion baby often show normal or near normal skin within a few months.\n* Only a few people with self-healing collodion baby have been found to have ALOX12B gene mutations; the majority of cases are caused by mutations in other genes.\n\n**Nonbullous Congenital Ichthyosiform Erythroderma**\n\n* More than 55 mutations in the ALOX12B gene have been found to cause nonbullous congenital ichthyosiform erythroderma (NBCIE).\n* This condition affects the skin and causes redness; the development of fine, white scales; an increased risk of infections; and excessive dehydration.\n* Most of the mutations change single protein building blocks (amino acids) in the 12R-LOX enzyme.\n* Many ALOX12B gene mutations lead to the production of a nonfunctional 12R-LOX enzyme, which disrupts the processing of the molecules involved in the formation of the lipid layer within the epidermis.\n* Problems with this protective barrier underlie the skin abnormalities and other features of NBCIE.\n\n**References**\n\n* Eckl KM, de Juanes S, Kurtenbach J, Natebus M, Lugassy J, Oji V, Traupe H, Preil ML, Martinez F, Smolle J, Harel A, Krieg P, Sprecher E, Hennies HC. Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J Invest Dermatol. 2009 Jun;129(6):1421-8.\n* Harting M, Brunetti-Pierri N, Chan CS, Kirby J, Dishop MK, Richard G, Scaglia F, Yan AC, Levy ML. Self-healing collodion membrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch Dermatol. 2008 Mar;144(3):351-6.\n* Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, Fischer J. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet. 2002 Jan 1;11(1):107-13.\n* Krieg P, Furstenberger G. The role of lipoxygenases in epidermis. Biochim Biophys Acta. 2014 Mar;1841(3):390-400.\n* Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015 Dec;6:297-310.\n\n---\n\n**ALOX12B Gene**\n\n**Genomic Location**\nThe ALOX12B gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Research Articles**\n\n* Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015 Dec;6:297-310.\n* Yu Z, Schneider C, Boeglin WE, Brash AR. Mutations associated with a congenital form of ichthyosis (NCIE) inactivate the epidermal lipoxygenases 12R-LOX and eLOX3. Biochim Biophys Acta. 2005 Jan 5;1686(3):238-47.\n* Eckl KM, de Juanes S, Kurtenbach J, Natebus M, Lugassy J, Oji V, Traupe H, Preil ML, Martinez F, Smolle J, Harel A, Krieg P, Sprecher E, Hennies HC. Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J Invest Dermatol. 2009 Jun;129(6):1421-8.\n* Eckl KM, Krieg P, Kuster W, Traupe H, Andre F, Wittstruck N, Furstenberger G, Hennies HC. Mutation spectrum and functional analysis of epidermis-type lipoxygenases in patients with autosomal recessive congenital ichthyosis. Hum Mutat. 2005 Oct;26(4):351-61.\n* Harting M, Brunetti-Pierri N, Chan CS, Kirby J, Dishop MK, Richard G, Scaglia F, Yan AC, Levy ML. Self-healing collodion membrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch Dermatol. 2008 Mar;144(3):351-6.\n* Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, Fischer J. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet. 2002 Jan 1;11(1):107-13.\n* Krieg P, Furstenberger G. The role of lipoxygenases in epidermis. Biochim Biophys Acta. 2014 Mar;1841(3):390-400.",
    "category": "general"
  },
  {
    "title": "ALOXE3 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aloxe3/",
    "content": "**ALOXE3 Gene**\n\nThe ALOXE3 gene provides instructions for making an enzyme called eLOX3. This enzyme is part of a family of enzymes called arachidonate lipoxygenases.\n\n**Normal Function**\n\n* The ALOXE3 gene helps add an oxygen molecule to certain fatty acids to produce substances called fatty acid hydroperoxides.\n* Unlike other lipoxygenases, the eLOX3 enzyme does not act directly on fatty acids. Instead, it is involved in the step following the creation of fatty acid hydroperoxides.\n* The eLOX3 enzyme processes fatty acid hydroperoxides, which are later converted to signaling molecules that are involved in the formation of the layers of fats (lipids) within the outermost layer of the skin (the epidermis).\n* The lipid layers are necessary to prevent water loss (dehydration) through the skin.\n\n**Health Conditions Related to Genetic Changes**\n\n* Nonbullous congenital ichthyosiform erythroderma (NBCIE): At least 20 mutations in the ALOXE3 gene have been found to cause this condition.\n* This condition affects the skin and causes redness, fine white scales, an increased risk of infections, and excessive dehydration.\n* Most of these mutations change single protein building blocks (amino acids) in the eLOX3 enzyme. Many ALOXE3 gene mutations lead to the production of a nonfunctional eLOX3 enzyme, which disrupts the processing of the molecules involved in the formation of the lipid layers within the epidermis.\n\n**Other Names for This Gene**\n\n* E-LOX\n* e-LOX-3\n* eLOX3\n* Epidermal lipoxygenase\n* Loxe3_Human\n\n---\n\n**ALOXE3 Gene**\n\n**What is the ALOXE3 gene?**\n\nThe ALOXE3 gene provides instructions for making a protein called arachidonate lipoxygenase 3, which plays a crucial role in the development and maintenance of the skin.\n\n**Genomic Location**\n\nThe ALOXE3 gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**References**\n\n* Eckl KM, de Juanes S, Kurtenbach J, Natebus M, Lugassy J, Oji V, Traupe H, Preil ML, Martinez F, Smolle J, Harel A, Krieg P, Sprecher E, Hennies HC. Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J Invest Dermatol. 2009 Jun;129(6):1421-8.\n* Eckl KM, Krieg P, Kuster W, Traupe H, Andre F, Wittstruck N, Furstenberger G, Hennies HC. Mutation spectrum and functional analysis of epidermis-type lipoxygenases in patients with autosomal recessive congenital ichthyosis. Hum Mutat. 2005 Oct;26(4):351-61.\n* Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, Fischer J. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1.\n* Krieg P, Furstenberger G. The role of lipoxygenases in epidermis. Biochim Biophys Acta. 2014 Mar;1841(3):390-400.\n* Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives.\n\n**Genetic Disorders**\n\nThe ALOXE3 gene is associated with autosomal recessive congenital ichthyosis, a rare genetic disorder characterized by severe skin dryness and scaling. Mutations in the ALOXE3 gene can lead to impaired lipoxygenase activity, resulting in abnormal skin development and function.",
    "category": "general"
  },
  {
    "title": "ALP - blood test: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/003470.htm",
    "content": "**ALP - Blood Test**\n\nAlkaline phosphatase (ALP) is a protein found in all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts, and bone.\n\nA blood test can be done to measure the level of ALP.\n\n*   **How the Test is Performed**\n    A blood sample is needed. Most of the time, blood is drawn from a vein located on the inside of the elbow or the back of the hand.\n*   **How to Prepare for the Test**\n    Many medicines can interfere with blood test results. Your health care provider will tell you if you need to stop taking any medicines before you have this test.\n*   **How the Test will Feel**\n    You may feel slight pain or a sting when the needle is inserted. You may also feel some throbbing at the site after the blood is drawn.\n\n**Why the Test is Performed**\n\nThis test may be done:\n\n*   To diagnose liver or bone disease\n*   To check if treatments for those diseases are working\n*   To check for side effects from medicines\n\n**Normal Results**\n\nThe normal range is 44 to 147 international units per liter (IU/L) or 0.73 to 2.45 microkatal per liter (Âµkat/L).\n\nNormal values may vary slightly from laboratory to laboratory. They also can vary with age and sex. High levels of ALP are normally seen in children undergoing growth spurts and in pregnant women.\n\n**What Abnormal Results Mean**\n\nAbnormal results may be due to the following conditions:\n\n*   Higher-than-normal ALP levels\n    *   Biliary obstruction\n    *   Bone disease\n    *   Eating a fatty meal if you have blood type O or B\n    *   Healing fracture\n    *   Hepatitis\n    *   Hyperparathyroidism\n    *   Hyperthyroidism\n    *   Leukemia\n    *   Liver disease\n    *   Lymphoma\n    *   Osteoblastic bone tumors\n    *   Osteomalacia\n    *   Paget disease of bone\n    *   Sarcoidosis\n*   Lower-than-normal ALP levels\n    *   Hypophosphatasia\n    *   Hypothyroidism\n    *   Malnutrition\n    *   Pernicious anemia\n    *   Protein deficiency\n    *   Wilson disease\n    *   Zinc deficiency\n\n**Other Conditions for Which the Test May Be Done**\n\n*   Alcoholic liver disease (hepatitis/cirrhosis)\n*   Alcohol use disorder\n*   Biliary stricture\n*   Gallstones\n*   Giant cell (temporal, cranial) arteritis\n*   Multiple endocrine neoplasia (MEN) II\n*   Pancreatitis\n*   Renal cell carcinoma\n\n---\n\n**ALP - Blood Test**\n\n**How the Test is Performed**\n\nA blood sample is needed. Most of the time, blood is drawn from a vein located on the inside of the elbow or the back of the hand.\n\n**How to Prepare for the Test**\n\nMany medicines can interfere with blood test results. Your health care provider will tell you if you need to stop taking any medicines before you have this test. DO NOT stop or change your medicines without talking to your provider first.\n\n**How the Test will Feel**\n\nYou may feel slight pain or a sting when the needle is inserted. You may also feel some throbbing at the site after the blood is drawn.\n\n**Why the Test is Performed**\n\nThis test may be done:\n\n* To diagnose liver or bone disease\n* To check if treatments for those diseases are working\n* To check for side effects from medicines\n\n**Normal Results**\n\nThe normal range is 44 to 147 international units per liter (IU/L) or 0.73 to 2.45 microkatal per liter (Âµkat/L). Normal values may vary slightly from laboratory to laboratory and can also vary with age and sex.\n\n**What Abnormal Results Mean**\n\nAbnormal results may be due to the following conditions:\n\n* Higher-than-normal ALP levels:\n\t+ Biliary obstruction\n\t+ Bone disease\n\t+ Eating a fatty meal if you have blood type O or B\n\t+ Healing fracture\n\t+ Hepatitis\n\t+ Hyperparathyroidism\n\t+ Hyperthyroidism\n\t+ Leukemia\n\t+ Liver disease\n\t+ Lymphoma\n\t+ Osteoblastic bone tumors\n\t+ Osteomalacia\n\t+ Paget disease of bone\n\t+ Sarcoidosis\n* Lower-than-normal ALP levels:\n\t+ Hypophosphatasia\n\t+ Hypothyroidism\n\t+ Malnutrition\n\t+ Pernicious anemia\n\t+ Protein deficiency\n\t+ Wilson disease\n\t+ Zinc deficiency\n\n**Alternative Names**\n\nAlkaline phosphatase\n\n---\n\n**Interpreting Laboratory Results**\n\nIn: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 9.\n\n\\n\\n\n\n**Updated Information**\n\nThis article was updated on June 20, 2023, by Jacob Berman, MD, MPH, Clinical Assistant Professor of Medicine, Division of General Internal Medicine, University of Washington School of Medicine, Seattle, WA. It was also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.\n\n\\n\\n\n\n**Related MedlinePlus Health Topics**\n\n*   Bile Duct Diseases\n*   Bone Diseases\n*   Paget's Disease of Bone",
    "category": "general"
  },
  {
    "title": "ALP isoenzyme test: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/003497.htm",
    "content": "**ALP Isoenzyme Test**\n\n**What is ALP?**\n\nAlkaline phosphatase (ALP) is an enzyme found in many body tissues such as liver, bile ducts, bone, and intestine. There are several different structural forms of ALP called isoenzymes.\n\n**How is the Test Performed?**\n\nA blood sample is needed. Most of the time blood is drawn from a vein located on the inside of the elbow or the back of the hand.\n\n**How to Prepare for the Test**\n\nMany medicines can interfere with blood test results. Your health care provider will tell you if you need to stop taking any medicines before you have this test.\n\n**Why is the Test Performed?**\n\nWhen the ALP test result is high, you may need to have the ALP isoenzyme test. This test will help determine what part of the body is causing higher ALP levels.\n\nThis test may be used to diagnose or monitor:\n\n* Bone disease\n* Liver, gallbladder, or bile duct disease\n* Pain in the abdomen\n* Parathyroid gland disease\n* Vitamin D deficiency\n\nIt may also be done to check liver function and to see how medicines you take may affect your liver.\n\n**Normal Results**\n\nThe normal value for total ALP is 44 to 147 international units per liter (IU/L) or 0.73 to 2.45 microkatal per liter (Âµkat/L). ALP isoenzyme testing may have differing normal values.\n\nAdults have lower levels of ALP than children. Bones that are still growing produce higher levels of ALP. During some growth spurts, levels can be as high as 500 IU/L or 835 ÂµKat/L. For this reason, the test is usually not done in children, and abnormal results refer to adults.\n\n**What Abnormal Results Mean**\n\nHigher-than-normal ALP levels:\n\n* Biliary obstruction\n* Bone disease\n* Eating a fatty meal if you have blood type O or B\n* Healing fracture\n* Hepatitis\n* Hyperparathyroidism\n* Hyperthyroidism\n* Leukemia\n* Liver disease\n* Lymphoma\n* Osteoblastic bone tumors\n* Osteomalacia\n* Paget disease of bone\n* Sarcoidosis\n\nLower-than-normal levels of ALP:\n\n* Hypophosphatasia\n* Hypothyroidism\n* Malnutrition\n* Pernicious anemia\n* Protein deficiency\n* Wilson disease\n* Zinc deficiency\n\nLevels that are only slightly higher than normal may not be a problem unless there are other signs of a disease or medical problem.\n\n**Other Conditions for Which the Test May Be Done**\n\nAlcoholic liver disease (hepatitis/cirrhosis)\nAlcohol use disorder\nBiliary stricture\nGallstones\nGiant cell (temporal, cranial) arteritis\nMultiple endocrine neoplasia (MEN) II\nPancreatitis\nRenal cell carcinoma\n\n---\n\n**ALP Isoenzyme Test**\n\n**What is it?**\n\nAlkaline phosphatase (ALP) is an enzyme found in many body tissues such as liver, bile ducts, bone, and intestine. There are several different structural forms of ALP called isoenzymes. The structure of the enzyme depends on where in the body it is produced.\n\n**How is it performed?**\n\nA blood sample is needed. Most of the time blood is drawn from a vein located on the inside of the elbow or the back of the hand.\n\n**Why is it performed?**\n\nWhen the ALP test result is high, you may need to have the ALP isoenzyme test. This test will help determine what part of the body is causing higher ALP levels.\n\nThis test may be used to diagnose or monitor:\n\n* Bone disease\n* Liver, gallbladder, or bile duct disease\n* Pain in the abdomen\n* Parathyroid gland disease\n* Vitamin D deficiency\n\nIt may also be done to check liver function and to see how medicines you take may affect your liver.\n\n**Normal Results**\n\nThe normal value for total ALP is 44 to 147 international units per liter (IU/L) or 0.73 to 2.45 microkatal per liter (Âµkat/L). ALP isoenzyme testing may have differing normal values.\n\nAdults have lower levels of ALP than children. Bones that are still growing produce higher levels of ALP. During some growth spurts, levels can be as high as 500 IU/L or 835 ÂµKat/L. For this reason, the test is usually not done in children, and abnormal results refer to adults.\n\nThe isoenzyme test results can reveal whether the increase is in \"bone\" ALP or \"liver\" ALP.\n\nNormal value ranges may vary slightly among different laboratories. Talk to your provider about the meaning of your specific test results.\n\n**What Abnormal Results Mean**\n\nHigher-than-normal ALP levels indicate a problem with one or more of the following:\n\n* Bone disease\n* Liver, gallbladder, or bile duct disease\n* Pain in the abdomen\n* Parathyroid gland disease\n* Vitamin D deficiency\n\nAbnormal results may also indicate other conditions such as:\n\n* Gallstones\n* Giant cell (temporal, cranial) arteritis\n* Multiple endocrine neoplasia (MEN) II\n* Pancreatitis\n* Renal cell carcinoma\n\n---\n\n**ALP Isoenzyme Test**\n\nThe ALP isoenzyme test measures the levels of alkaline phosphatase (ALP) in the blood. This enzyme plays a crucial role in various bodily processes, including bone growth and liver function.\n\n**What Abnormal Results Mean**\n\nHigher-than-normal ALP levels can indicate:\n\n* Biliary obstruction\n* Bone disease\n* Eating a fatty meal if you have blood type O or B\n* Healing fracture\n* Hepatitis\n* Hyperparathyroidism\n* Hyperthyroidism\n* Leukemia\n* Liver disease\n* Lymphoma\n* Osteoblastic bone tumors\n* Osteomalacia\n* Paget disease of bone\n* Sarcoidosis\n\nLower-than-normal levels of ALP can indicate:\n\n* Hypophosphatasia\n* Hypothyroidism\n* Malnutrition\n* Pernicious anemia\n* Protein deficiency\n* Wilson disease\n* Zinc deficiency\n\nLevels that are only slightly higher than normal may not be a problem unless there are other signs of a disease or medical problem.\n\n**Other Conditions for Which the Test May Be Done**\n\nThe ALP isoenzyme test may also be used to diagnose:\n\n* Alcoholic liver disease (hepatitis/cirrhosis)\n* Alcohol use disorder\n* Biliary stricture\n* Gallstones\n* Giant cell (temporal, cranial) arteritis\n* Multiple endocrine neoplasia (MEN) II\n* Pancreatitis\n* Renal cell carcinoma\n\n**References**\n\nFogel EL, Sherman S. Diseases of the gall bladder and bile ducts. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 146.\n\nKorenblat KM, Berk PD. Approach to the patient with jaundice or abnormal liver tests. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier ; 2020:chap 138.\n\nMartin P. Approach to the patient with liver disease. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier ; 2020:chap 137.\n\nWeinstein RS. Osteomalacia and rickets. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 231.",
    "category": "general"
  },
  {
    "title": "ALPL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alpl/",
    "content": "**ALPL Gene**\n\nThe ALPL gene provides instructions for making an enzyme called tissue-nonspecific alkaline phosphatase (TNSALP). This enzyme plays an important role in the growth and development of bones and teeth.\n\n**Normal Function**\n\nThe ALPL gene is essential for the process of mineralization, in which minerals such as calcium and phosphorus are deposited in developing bones and teeth. Mineralization is critical for the formation of bones that are strong and rigid and teeth that can withstand chewing and grinding.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Hypophosphatasia**\n\t+ About 300 mutations in the ALPL gene have been identified in people with hypophosphatasia.\n\t+ Most of these mutations change a single protein building block (amino acid) in TNSALP.\n\t+ Other mutations insert or delete genetic material in the ALPL gene or change the way the gene's instructions are used to build the enzyme.\n\t+ Mutations in the ALPL gene lead to the production of an abnormal version of TNSALP that cannot participate effectively in the mineralization of developing bones and teeth.\n\t+ A shortage of functional TNSALP allows substances that are normally processed by the enzyme to build up in the body.\n\t+ Researchers believe that a buildup of one of these compounds, inorganic pyrophosphate, underlies the defective mineralization of bones and teeth in people with hypophosphatasia.\n\t+ ALPL mutations that almost completely eliminate the activity of TNSALP usually result in the more severe forms of hypophosphatasia.\n\n---\n\n**ALPL Gene**\n\nThe ALPL gene is responsible for producing an enzyme called tissue-nonspecific alkaline phosphatase (TNSALP). This enzyme plays a crucial role in the mineralization of bones and teeth.\n\n**Other Names for This Gene**\n\n* alkaline phosphatase, liver/bone/kidney alkaline phosphomonoesterase\n* AP-TNAP\n* glycerophosphatase\n* HOPS\n* MGC161443\n* PPBT_HUMAN\n* tissue non-specific alkaline phosphatase\n* tissue-nonspecific ALP\n* TNALP\n* TNAP\n* TNSALP\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ALPL\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ALKALINE PHOSPHATASE, LIVER; ALPL\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Brun-Heath I, Taillandier A, Serre JL, Mornet E. Characterization of 11 novel mutations in the tissue non-specific alkaline phosphatase gene responsible for hypophosphatasia and genotype-phenotype correlations. Mol Genet Metab. 2005 Mar;84(3):273-7.\n* Mornet E, Stura E, Lia-Baldini AS, Stigbrand T, Menez A, Le Du MH. Structural evidence for a functional role of human tissue nonspecific alkaline phosphatase in bone mineralization. J Biol Chem. 2001 Aug 17;276(33):31171-8.\n* Mornet E. Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat. 2000;15(4):309-15.\n* Mornet E. Molecular Genetics of Hypophosphatasia and Phenotype-Genotype Correlations. Subcell Biochem. 2015;76:25-43.\n* Spentchian M, Brun-Heath I, Taillandier A, Fauvert D, Serre JL, Simon-Bouy B, Carvalho F, Grochova I, Mehta SG, Muller G, Oberstein SL, Ogur G, Sharif S, Mornet E. Characterization of missense mutations and large deletions in the ALPL gene by sequencing and quantitative multiplex PCR of short fragments. Genet Test. 2006 Winter;10(4):252-7.\n* Spentchian M, Merrien Y, Herasse M, Dobbie Z, Glaser D, Holder SE, Ivarsson SA, Kostiner D, Mansour S, Norman A, Roth J, Stipoljev F, Taillemite JL, van der Smagt JJ, Serre JL, Simon-Bouy B, Taillandier A, Mornet E. Severe hypophosphatasia: characterization of fifteen novel mutations in the ALPL gene. Hum Mutat. 2003 Jul;22(1):105-6.\n* Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46.\n* Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev. 1994 Aug;15(4):439-61.\n* Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci. 2010 Mar;1192:190-200.\n\n**Genomic Location**\n\nThe ALPL gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n---\n\n**ALPL Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ALPL gene is found on chromosome 1.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALS - resources: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/002189.htm",
    "content": "**ALS - Resources**\n\nThe following organizations are good resources for information on amyotrophic lateral sclerosis:\n\n* Muscular Dystrophy Association -- <http://www.mda.org/disease/amyotrophic-lateral-sclerosis>\n* National Amyotrophic Lateral Sclerosis (ALS) Registry -- <http://www.cdc.gov/als/join/>\n* National Institute of Neurological Disorders and Stroke -- <http://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als>\n* ALS Association -- <http://www.als.org/>\n* US National Library of Medicine, MedlinePlus -- <http://medlineplus.gov/genetics/condition/amyotrophic-lateral-sclerosis/>\n\n**Review Date**\n\n10/27/2024\n\n**Updated by**\n\nLaura J. Martin, MD, MPH, ABIM Board Certified in Internal Medicine and Hospice and Palliative Medicine, Atlanta, GA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.\n\n**Learn how to cite this page**\n\n(Note: I removed the unnecessary sections, code blocks, ads, disclaimers, standalone URLs, and formatted the content according to your instructions.)",
    "category": "general"
  },
  {
    "title": "ALS2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/als2/",
    "content": "**ALS2 Gene**\n\nThe ALS2 gene provides instructions for making a protein called alsin. Alsin is produced in a wide range of tissues, with highest amounts in the brain. This protein is particularly abundant in motor neurons, the specialized nerve cells in the brain and spinal cord that control the movement of muscles.\n\nAlsin turns on (activates) multiple proteins called GTPases that convert a molecule called GTP into another molecule called GDP. GTPases play important roles in cell division, the process by which cells mature to carry out specific functions (differentiation), and the self-destruction of cells (apoptosis). The GTPases play important roles in several cell processes. The GTPases that are activated by alsin are involved in the proper placement of the various proteins and fats that make up the cell membrane, the transport of molecules from the cell membrane to the interior of the cell (endocytosis), and the development of specialized structures called axons and dendrites that project from neurons and are essential for the transmission of nerve impulses.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Amyotrophic lateral sclerosis**: MedlinePlus Genetics provides information about this health condition.\n*   **Infantile-onset ascending hereditary spastic paralysis**: At least 20 ALS2 gene mutations have been found to cause this disorder. It is characterized by progressive weakness and stiffness of muscles in the legs, arms, neck, and head that begins within the first 2 years of life. Mutations in the ALS2 gene alter the instructions for making alsin, often resulting in the production of an abnormally short alsin protein that is unstable and rapidly broken down.\n\n---\n\n**ALS2 Gene**\n\nThe ALS2 gene is responsible for producing alsin, a protein involved in various cellular processes. Mutations in the ALS2 gene have been linked to several neurological disorders.\n\n*   **Juvenile Primary Lateral Sclerosis**: Three mutations in the ALS2 gene have been identified as causing juvenile primary lateral sclerosis, a condition characterized by progressive weakness and stiffness of muscles in the arms, legs, and face that typically begins in childhood.\n*   **Infantile-Onset Ascending Hereditary Spastic Paralysis**: At least 20 ALS2 gene mutations have been found to cause infantile-onset ascending hereditary spastic paralysis, a disorder characterized by progressive weakness and stiffness of muscles in the legs, arms, neck, and head that begins within the first 2 years of life.\n\nMutations in the ALS2 gene alter the instructions for making alsin, often resulting in the production of an abnormally short alsin protein that is unstable and rapidly broken down. The loss of functional alsin protein may disrupt the movement of molecules within cells or impair the development of axons and dendrites, leading to the progressive atrophy of motor neurons characteristic of these conditions.\n\nThe exact mechanisms by which ALS2 gene mutations cause these disorders are unclear, but research suggests that a lack of alsin and the subsequent loss of GTPase functions contribute to the progression of these conditions.\n\n---\n\n**ALS2 Gene**\n\nThe ALS2 gene is associated with juvenile primary lateral sclerosis, a rare disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem.\n\n**Function of the ALS2 Gene**\n\nThe ALS2 gene provides instructions for making a protein called alsin. This protein plays a crucial role in the development and maintenance of nerve cells, particularly motor neurons. It helps regulate the movement of molecules within cells and is involved in the formation of axons and dendrites, which are essential components of nerve cells.\n\n**Vulnerability of Motor Neurons**\n\nResearchers suggest that motor neurons and their long axons may be particularly vulnerable to changes in cell development. As a result, motor neuron function declines, and eventually these nerve cells die, leading to the signs and symptoms of juvenile primary lateral sclerosis.\n\n**Other Names for This Gene**\n\n* ALS2_HUMAN\n* ALS2CR6\n* ALSJ\n* amyotrophic lateral sclerosis 2 (juvenile)\n* IAHSP\n* KIAA1563\n* PLSJ\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ALS2\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ALSIN RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR ALS2; ALS2\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n1. Devon RS, Helm JR, Rouleau GA, Leitner Y, Lerman-Sagie T, Lev D, Hayden MR. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet. 2003 Sep;64(3):210-5.\n2. Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, Boespflug-Tanguy O. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet. 2002 Sep;71(3):518-27.\n3. Eymard-Pierre E, Yamanaka K, Haeussler M, Kress W, Gauthier-Barichard F, Combes P, Cleveland DW, Boespflug-Tanguy O. Novel missense mutation in ALS2 gene results in infantile ascending hereditary spastic paralysis. Ann Neurol. 2006 Jun;59(6):976-80.\n4. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Nov;7(11):616-30.\n5. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004 Dec;75(6):933-47.\n6. Panzeri C, De Palma C, Martinuzzi A, Daga A, De Polo G, Bresolin N, Miller CC, Tudor EL, Clementi E, Bassi MT. The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain. 2006 Jul;129(Pt 7):1710-9.\n7. Racis L, Tessa A, Pugliatti M, Storti E, Agnetti V, Santorelli FM. Infantile-onset ascending hereditary spastic paralysis: a case report and brief literature review. Eur J Paediatr Neurol. 2014 Mar;18(2):235-9.\n8. Sheerin UM, Schneider SA, Carr L, Deuschl G, Hopfner F, Stamelou M, Wood NW, Bhatia KP. ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia. Neurology. 2014 Mar 25;82(12):1065-7.\n9. Tudor EL, Perkinton MS, Schmidt A, Ackerley S, Brownlees J, Jacobsen NJ, Byers HL, Ward M, Hall A, Leigh PN, Shaw CE, McLoughlin DM, Miller CC. ALS2/Alsin regulates Rac-PAK signaling and neurite outgrowth. J Biol Chem. 2005 Oct 14;280(41):34735-40.\n10. Yamanaka K, Vande Velde C, Eymard-Pierre E, Bertini E, Boespflug-Tanguy O, Cleveland DW. Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16041-6.\n\n---\n\n**ALS2 Gene**\n\n*   **Location**: The ALS2 gene is found on chromosome 2.\n\n**Related Health Topics**\n\n*   *Genes and Gene Therapy*\n*   *Genetic Disorders*\n\n**Understanding Genetics**\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ALT Blood Test: MedlinePlus Medical Test",
    "url": "https://medlineplus.gov/lab-tests/alt-blood-test/",
    "content": "**ALT Blood Test**\n\nAn ALT test measures the amount of ALT in your blood. This test is commonly used to help diagnose liver damage or disease.\n\n**What is ALT?**\n\nALT (alanine transaminase) is an enzyme, a protein that speeds up certain chemical reactions in your body. It is found mainly in your liver. Usually, you will have low levels of ALT in your blood. But when liver cells are damaged, they release ALT into the bloodstream. High levels of ALT in your blood may be a sign of a liver injury or disease.\n\n**What is an ALT test used for?**\n\nAn ALT blood test is often part of a routine blood screening to check the health of your liver. The test may also help diagnose or monitor liver problems.\n\n**Why do I need an ALT blood test?**\n\nYour health care provider may order an ALT blood test as part of a routine checkup. An ALT test is usually done with a group of other liver function tests that check how well your liver is working. Many liver function tests are included in a common blood test called a comprehensive metabolic panel (CMP).\n\n**When might I need an ALT blood test?**\n\nThese tests may also be ordered if you have symptoms of liver damage, such as:\n\n* Nausea and vomiting\n* Lack of appetite\n* Fatigue\n* Weakness\n* Jaundice, a condition that causes your skin and eyes to turn yellow\n* Swelling and/or pain in your abdomen (belly)\n* Swelling in your ankles and legs\n* Dark-colored urine (pee) and/or light-colored stool (poop)\n* Frequent itching\n\nYour provider may also order an ALT blood test if you have a high risk of liver damage because of:\n\n* A family history of liver disease\n* Alcohol use disorder (AUD)\n* Obesity\n* Diabetes\n* Taking certain medicines that can cause liver damage\n* Hepatitis or exposure to hepatitis\n\n---\n\n**ALT Blood Test: MedlinePlus Medical Test (Part 2/3)**\n\n**What does an ALT blood test check?**\n\nAn ALT blood test checks for liver damage by measuring the amount of alanine transaminase (ALT) in your blood. Your provider may order an ALT blood test if you have symptoms of liver damage, such as:\n\n* Yellowing of your skin and eyes (jaundice)\n* Dark-colored urine (pee) and/or light-colored stool (poop)\n* Frequent itching\n* Nausea or vomiting\n\n**Who is at risk for liver damage?**\n\nYour provider may also order an ALT blood test if you have a high risk of liver damage because of:\n\n* A family history of liver disease\n* Alcohol use disorder (AUD)\n* Obesity\n* Diabetes\n* Taking certain medicines that can cause liver damage\n* Hepatitis or exposure to hepatitis\n\n**What happens during an ALT blood test?**\n\nA health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.\n\n**Will I need to do anything to prepare for the test?**\n\nYou may need to stop taking certain medicines before the test, so tell your provider about everything you take. But don't stop taking any medicines unless your provider tells you to. You usually need to fast (not eat or drink) for several hours before these tests.\n\n**Are there any risks to the test?**\n\nThere is very little risk to having a blood test. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.\n\n**What do the results mean?**\n\nAn ALT blood test is often done as part of a group of liver function tests. Liver function tests measure several different proteins, substances, and enzymes that show how well your liver is working. Your provider usually compares your ALT results with the results of the other liver tests to evaluate your liver health and decide if you need other tests to make a diagnosis.\n\nLower-than-usual levels of ALT in your blood are not common. Your provider may do more tests since this may be a sign of:\n\n* B6 deficiency\n* Chronic kidney disease\n\nHigher-than-usual levels of ALT in your blood may be a sign of liver damage from:\n\n* Hepatitis\n* Infection\n* Cirrhosis\n* Liver cancer\n* Other liver diseases\n* A lack of blood flow to the liver\n* Certain medicines, such as cholesterol or pain medicines\n* Poisons\n\nIf your results show you have a high level of ALT, it doesn't always mean that you have a medical condition that needs treatment. Many things can affect your results, such as your age, sex, weight, and certain medicines and dietary supplements. Your ALT levels can also be affected by intense exercise and where you are in your menstrual cycle.\n\n**Is there anything else I need to know about an ALT blood test?**\n\nALT test results may help tell the difference between damage from acute (sudden) liver problems and chronic (long-term) liver problems. But the amount of ALT in your blood isn't related to how much your liver may be damaged. Your ALT is usually measured along with another liver enzyme called AST as part of a liver function panel. Since ALT is mostly found in the liver, an ALT test checks more specifically for liver damage.\n\n---\n\n**ALT Blood Test**\n\nThe ALT blood test, also known as the alanine transaminase test, is a medically necessary test that measures the level of ALT enzyme in the blood. This test is used to diagnose and monitor liver damage or disease.\n\n**What does the ALT test check for?**\n\nThe ALT test checks for liver damage by measuring the level of ALT enzyme in the blood. Since ALT is mostly found in the liver, an ALT test is more specific for liver damage than other tests.\n\n**References:**\n\n* American Liver Foundation. Diagnosing Liver Disease - Liver Biopsy and Liver Function Tests.\n* Cleveland Clinic: Health Library: Diagnostics & Testing. Alanine Transaminase (ALT).\n* Mayo Clinic. Elevated liver enzymes, Causes.\n* Merck Manual Consumer Version. Liver Blood Tests.\n* Moriles KE, Zubair M, Azer SA. Alanine Aminotransferase (ALT) Test.\n\n**Related Health Topics:**\n\n* Liver Diseases\n* Related Medical Tests:\n\t+ AST Test\n\t+ Comprehensive Metabolic Panel (CMP)\n\t+ Elastography\n\t+ Gamma-glutamyl Transferase (GGT) Test\n\t+ How to Cope with Medical Test Anxiety\n\t+ How to Understand Your Lab Results\n\t+ Liver Function Tests\n\t+ Prothrombin Time Test and INR (PT/INR)\n\t+ Smooth Muscle Antibody (SMA) Test\n\t+ What You Need to Know About Blood Testing",
    "category": "health"
  },
  {
    "title": "ALX1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alx1/",
    "content": "**ALX1 Gene**\n\nThe **ALX1 gene** provides instructions for making a protein that is a member of the homeobox protein family. Homeobox proteins direct the formation of body structures during early embryonic development.\n\n**Normal Function**\n\nThe ALX1 protein is necessary for normal development of the head and face, particularly the formation of the eyes, nose, and mouth, which begins around the fourth week of development. The ALX1 protein is a transcription factor, which means that it attaches (binds) to DNA and controls the activity of certain genes.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Frontonasal Dysplasia**: At least three mutations in the ALX1 gene have been found to cause frontonasal dysplasia. ALX1 gene mutations cause a form of the disorder called frontonasal dysplasia type 3, which is characterized by severe malformations of the structures at the center of the face.\n\n**Other Names for This Gene**\n\n* **ALX homeobox protein 1**\n* **CART-1**\n* **CART1**\n* **cartilage paired-class homeoprotein 1**\n* **epididymis luminal protein 23**\n* **FND3**\n* **HEL23**\n\n---\n\n**ALX1 Gene**\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **ARISTALESS-LIKE HOMEOBOX 1; ALX1**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**\n*   **ClinVar**\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ALX1**\n\n**Scientific Articles on PubMed**\n\n*   **PubMed**\n\n**References**\n\n*   Dee CT, Szymoniuk CR, Mills PE, Takahashi T. Defective neural crest migration revealed by a Zebrafish model of Alx1-related frontonasal dysplasia. Hum Mol Genet. 2013 Jan 15;22(2):239-51. doi: 10.1093/hmg/dds423. Epub 2012 Oct 11.\n*   McGonnell IM, Graham A, Richardson J, Fish JL, Depew MJ, Dee CT, Holland PW, Takahashi T. Evolution of the Alx homeobox gene family: parallel retention and independent loss of the vertebrate Alx3 gene. Evol Dev. 2011 Jul-Aug;13(4):343-51. doi: 10.1111/j.1525-142X.2011.00489.x.\n*   Uz E, Alanay Y, Aktas D, Vargel I, Gucer S, Tuncbilek G, von Eggeling F, Yilmaz E, Deren O, Posorski N, Ozdag H, Liehr T, Balci S, Alikasifoglu M, Wollnik B, Akarsu NA. Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am J Hum Genet. 2010 May 14;86(5):789-96.\n\n**Genomic Location**\n\nThe ALX1 gene is found on chromosome 12.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n**Understanding Genetics**\n\n*   **What is DNA?**\n*   **What is a gene?**\n*   **What is a gene variant and how do variants occur?**",
    "category": "general"
  },
  {
    "title": "ALX3 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alx3/",
    "content": "**ALX3 Gene**\n\nThe ALX3 gene provides instructions for making a protein that is a member of the homeobox protein family. Homeobox proteins direct the formation of body structures during early embryonic development.\n\n**Normal Function**\n\nThe ALX3 protein is necessary for normal development of the head and face, particularly the formation of the nose, which begins around the fourth week of development. The ALX3 protein is a transcription factor, which means that it attaches (binds) to DNA and controls the activity of certain genes. Specifically, the protein controls the activity of genes that regulate cell growth and division (proliferation) and movement (migration), ensuring that cells grow and stop growing at specific times and that they are positioned correctly during development.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Frontonasal Dysplasia**: At least seven mutations in the ALX3 gene have been found to cause frontonasal dysplasia. ALX3 gene mutations cause a form of the disorder called frontonasal dysplasia type 1, which particularly affects the development of the nose and surrounding tissues. ALX3 gene mutations that cause this condition severely reduce or eliminate the function of the ALX3 protein. As a result, the protein cannot bind to DNA and regulate gene function, which leads to poorly controlled cell proliferation and migration during development. This abnormal cell growth and movement impairs development of structures in the middle of the face, particularly the nose, leading to openings (clefts) in the nose.\n\n---\n\n**ALX3 Gene**\n\n**What is the ALX3 gene?**\n\nThe ALX3 gene provides instructions for making a protein called aristaless-like homeobox 3, which plays a crucial role in the development of the face and skull. Mutations in this gene have been linked to frontonasal dysplasia type 1, a rare genetic disorder characterized by abnormalities in the formation of the nose and skull.\n\n**Role in Development**\n\nDuring embryonic development, the ALX3 gene helps regulate the growth and movement of cells that form the face and skull. Abnormal cell growth and movement can impair the development of structures in the middle of the face, particularly the nose, leading to openings (clefts) in the nose.\n\n**Other Names for This Gene**\n\n* aristaless-like homeobox 3\n* FND\n* FND1\n* frontonasal dysplasia\n* homeobox protein aristaless-like 3\n* proline-rich transcription factor\n\n**Genomic Location**\n\nThe ALX3 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ALX4 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/alx4/",
    "content": "**ALX4 Gene**\n\nThe ALX4 gene provides instructions for making a member of the homeobox protein family. Homeobox proteins direct the formation of body structures during early embryonic development.\n\n**Normal Function**\n\nThe ALX4 protein is necessary for normal development of the skull and formation of the head and face, which begins early in fetal development. This protein is also involved in the formation of skin layers, but its role in this process is poorly understood.\n\nThe ALX4 protein is a transcription factor, which means that it attaches (binds) to DNA and controls the activity of certain genes. Specifically, the protein controls the activity of genes that regulate cell growth and division (proliferation), cell maturation and specialization (differentiation), cell movement (migration), and cell survival.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Enlarged Parietal Foramina**: At least eight mutations in the ALX4 gene have been found to cause enlarged parietal foramina type 2. This condition is characterized by enlarged openings (foramina) in the parietal bones, which are the two bones that form the top and sides of the skull.\n*   **Frontonasal Dysplasia**: At least four mutations in the ALX4 gene have been found to cause frontonasal dysplasia. ALX4 gene mutations cause a form of the disorder called frontonasal dysplasia type 2, which includes features such as facial malformations, genital abnormalities in males, hair loss (alopecia), and enlarged parietal foramina.\n\nThe ALX4 protein plays a crucial role in the development of the skull and face, and mutations in the ALX4 gene can lead to serious health conditions, including enlarged parietal foramina and frontonasal dysplasia.\n\n---\n\n**ALX4 Gene: MedlinePlus Genetics**\n\n\\n\\n\n\n*   **Potocki-Shaffer Syndrome**\n    A mutation resulting in the deletion of the ALX4 gene causes a condition called Potocki-Shaffer syndrome. People with this condition have enlarged parietal foramina (described above) and multiple noncancerous bone tumors (osteochondromas). Other signs and symptoms seen in some people with Potocki-Shaffer syndrome include intellectual disability, developmental delay, distinctive facial features, vision problems, and defects in the heart, kidneys, and urinary tract.\n*   **Enlarged Parietal Foramina**\n    At least eight mutations in the ALX4 gene have been found to cause enlarged parietal foramina type 2. This condition is characterized by enlarged openings (foramina) in the parietal bones, which are the two bones that form the top and sides of the skull. Openings in the parietal bones are normal during fetal development, but they usually close before birth. In people with this condition, the parietal foramina remain open throughout life.\n*   **Frontonasal Dysplasia**\n    At least four mutations in the ALX4 gene have been found to cause frontonasal dysplasia. ALX4 gene mutations cause a form of the disorder called frontonasal dysplasia type 2. In addition to facial malformations, this type can include features such as genital abnormalities in males, hair loss (alopecia), and enlarged parietal foramina (described above).\n\n---\n\n**ALX4 Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Hair Loss (Alopecia) and Enlarged Parietal Foramina**\n\nThe ALX4 gene mutations that cause frontonasal dysplasia type 2 severely reduce or eliminate the function of the ALX4 protein. As a result, the protein cannot bind to DNA and regulate gene function, which leads to poorly controlled cell proliferation and migration during development. This abnormal cell growth and movement leads to malformations in the middle of the face, particularly affecting the nose, which leads to openings (clefts) in the nose. This abnormal development can also interfere with the proper formation of the skull, which likely contributes to enlarged parietal foramina.\n\nIn some individuals, ALX4 gene mutations impair the function of hair follicles and lead to alopecia, but the mechanism is unclear.\n\n**Potocki-Shaffer Syndrome**\n\nA mutation resulting in the deletion of the ALX4 gene causes a condition called Potocki-Shaffer syndrome. People with this condition have enlarged parietal foramina (described above) and multiple noncancerous bone tumors (osteochondromas). Other signs and symptoms seen in some people with Potocki-Shaffer syndrome include intellectual disability, developmental delay, distinctive facial features, vision problems, and defects in the heart, kidneys, and urinary tract.\n\nPotocki-Shaffer syndrome (also called proximal 11p deletion syndrome) is caused by a deletion of genetic material from the short (p) arm of chromosome 11. In people with this condition, a loss of the ALX4 gene within this region is responsible for enlarged parietal foramina. This feature occurs because a shortage of the ALX4 transcription factor caused by deletion of the gene disrupts several cellular processes and impairs proper bone formation (ossification). The loss of additional genes in the deleted region likely contributes to the other features of Potocki-Shaffer syndrome.\n\nSpecifically, loss of the EXT2 gene results in multiple osteochondromas, and deletion of the PHF21A gene causes intellectual disability and distinctive facial features.\n\n**Other Names for This Gene**\n\nALX4_HUMAN FPP homeodomain transcription factor ALX4 KIAA1788 PFM PFM2\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ALX4\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ARISTALESS HOMEOBOX 4; ALX4\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n---\n\n**ALX4 Gene**\n\n**Genomic Location**\nThe ALX4 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Medical Encyclopedia**\n\n* Genes\n* Genetics\n\n**Genetic Disorders**\n\n* The ALX4 gene is associated with genetic disorders such as Potocki-Shaffer syndrome, which is characterized by enlarged parietal foramina.\n* Mutations in the ALX4 gene can cause ossification defects of the skull, including foramina parietalia permagna.\n\n**Research and Studies**\n\n* A study published in the European Journal of Human Genetics found that haploinsufficiency of the ALX4 gene is a potential cause of parietal foramina in the 11p11.2 contiguous gene-deletion syndrome.\n* Another study published in the American Journal of Medical Genetics found that homozygous mutations in the ALX4 gene can cause mild nasal malformations and parietal foramina.\n\n**Clinical Aspects**\n\n* Proximal 11p deletion syndrome (P11pDS) is a genetic disorder characterized by enlarged parietal foramina, among other symptoms.\n* The clinical and molecular aspects of P11pDS have been evaluated in several studies, which have provided insights into the diagnosis and management of this condition.",
    "category": "general"
  },
  {
    "title": "AMACR gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amacr/",
    "content": "**AMACR Gene**\n\nThe AMACR gene provides instructions for making an enzyme called alpha-methylacyl-CoA racemase (AMACR). This enzyme is found in the energy-producing centers in cells (mitochondria) and in cell structures called peroxisomes. Peroxisomes contain a variety of enzymes that break down many different substances, including fatty acids and certain toxic compounds. They are also important for the production (synthesis) of fats (lipids) used in digestion and in the nervous system.\n\nIn peroxisomes, the AMACR enzyme plays a role in the breakdown of a fatty acid called pristanic acid, which comes from meat and dairy foods in the diet. In mitochondria, AMACR is thought to help further break down the molecules derived from pristanic acid.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Alpha-methylacyl-CoA racemase deficiency**: This disorder leads to a variety of neurological problems that begin in adulthood, including gradual loss in intellectual functioning (cognitive decline), seizures, and weakness and loss of sensation in the limbs due to nerve damage (sensorimotor neuropathy). Most individuals with AMACR deficiency have an AMACR gene mutation that replaces a protein building block (amino acid) called serine with an amino acid called proline at position 52 in the enzyme sequence, written as Ser52Pro or S52P. This mutation results in a lack (deficiency) of functional enzyme. The enzyme deficiency leads to accumulation of pristanic acid in the blood.\n*   **Congenital bile acid synthesis defect type 4**: AMACR gene mutations that result in a lack of functional AMACR enzyme have also been identified in infants with this life-threatening disorder. Babies with this disorder have cholestasis, which is a reduced ability to produce and release a digestive fluid called bile. Cholestasis leads to an enlarged liver (hepatomegaly) and irreversible liver disease (cirrhosis) in the first few months of life. Some researchers consider congenital bile acid synthesis defect type 4 and AMACR deficiency to be variations of the same disorder.\n\n---\n\n**AMACR Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nThe AMACR gene is responsible for encoding the enzyme alpha-methylacyl-CoA racemase, which plays a crucial role in the breakdown of fatty acids and pristanic acid. A mutation in this gene, specifically replacing serine with proline at position 52 (Ser52Pro or S52P), leads to a deficiency of functional enzyme. This deficiency results in the accumulation of pristanic acid in the blood, although the exact relationship between this accumulation and the specific signs and symptoms of AMACR deficiency remains unclear.\n\n**Other Disorders:**\nAMACR gene mutations have also been identified in infants with congenital bile acid synthesis defect type 4, a life-threatening disorder characterized by cholestasis, hepatomegaly, and irreversible liver disease. Some researchers consider this disorder to be a variation of the same condition as AMACR deficiency, although it is unclear whether individuals with this disorder would have later developed the neurological symptoms seen in adults with AMACR deficiency.\n\n**Other Names for This Gene:**\n2-methylacyl-CoA racemase, AMACR_HUMAN, AMACRD, CBAS4, RACE, RM\n\n**Additional Information & Resources:**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of AMACR\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4\n    *   ALPHA-METHYLACYL-CoA RACEMASE; AMACR\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References:**\n\n1.  Dick D, Horvath R, Chinnery PF. AMACR mutations cause late-onset autosomal recessive cerebellar ataxia. Neurology. 2011 May 17;76(20):1768-70.\n2.  Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, McLean BN, Brown AY, Vreken P, Waterham HR, Wanders RJ. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy.\n3.  Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.\n4.  Haugarvoll K, Johansson S, Tzoulis C, Haukanes BI, Bredrup C, Neckelmann G, Boman H, Knappskog PM, Bindoff LA. MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing.\n5.  Wierzbicki AS. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.\n\n**Genomic Location:**\nThe AMACR gene is located on chromosome 5.\n\n**Related Health Topics:**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n**Understanding Genetics:**\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?\n\n---\n\n**AMACR Gene**\n\n\\n\\n\n\n**What is the AMACR gene?**\n\nThe AMACR gene is found on chromosome 5.\n\n\\n\\n\n\n* **Genes and Gene Therapy**\n* **Genetic Disorders**\n\n\\n\\n\n\n**Understanding Genetics**\n\n* **What is DNA?**\n* **What is a gene?**\n* **What is a gene variant and how do variants occur?**\n\n\\n\\n\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\n\\n\\n\n\n**Important Note**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AMELX gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amelx/",
    "content": "**AMELX Gene**\n\nThe **AMELX** gene provides instructions for making a protein called amelogenin, which is essential for normal tooth development.\n\n**Normal Function**\n\n* The AMELX gene makes almost all of the body's amelogenin.\n* Amelogenin is involved in the formation of enamel, which is the hard, white material that forms the protective outer layer of each tooth.\n* Enamel is composed mainly of mineral crystals arranged in organized bundles that give enamel its strength and durability.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Amelogenesis Imperfecta**: At least 23 mutations in the AMELX gene have been identified in people with an X-linked form of a disorder of tooth development called amelogenesis imperfecta.\n* Males who inherit an altered copy of the AMELX gene have very little amelogenin and develop almost no enamel to cover and protect their teeth.\n* Females who inherit one altered copy of the AMELX gene are less severely affected than males because they have a normal copy of the gene on the other X chromosome to produce amelogenin.\n\n**References**\n\n(Note: References are not provided in this cleaned output as per your request)\n\n---\n\n**AMELX Gene**\n\n**What is the AMELX gene?**\n\nThe AMELX gene provides instructions for making a protein called amelogenin, which plays a crucial role in the formation of tooth enamel.\n\n**How does the AMELX gene affect tooth development?**\n\nMutations in the AMELX gene can lead to the production of an abnormal version of the amelogenin protein or prevent one copy of the gene from producing any amelogenin protein at all. This can result in structural defects in tooth enamel, such as a distinctive pattern of vertical grooves.\n\n**What is amelogenesis imperfecta?**\n\nAmelogenesis imperfecta is a disorder of tooth development caused by mutations in genes on the X chromosome, including the AMELX gene. At least 23 mutations in the AMELX gene have been identified in people with this condition.\n\n**How does the AMELX gene affect males and females differently?**\n\nMales who inherit an altered copy of the AMELX gene have very little amelogenin and develop almost no enamel to cover and protect their teeth. Females who inherit one altered copy of the AMELX gene are less severely affected than males because they have a normal copy of the gene on the other X chromosome to produce amelogenin.\n\n**Other Names for This Gene**\n\n* AIH1\n* ALGN\n* amelogenin (amelogenesis imperfecta 1, X-linked)\n* amelogenin, X-linked\n* AMELX_HUMAN\n* AMG\n* AMGL\n* AMGX\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of AMELX\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: AMELOGENIN; AMELX\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Hu JC, Chan HC, Simmer SG, Seymen F, Richardson AS, Hu Y, Milkovich RN, Estrella NM, Yildirim M, Bayram M, Chen CF, Simmer JP. Amelogenesis imperfecta in two families with defined AMELX deletions in ARHGAP6. PLoS One. 2012;7(12):e52052.\n* Kida M, Sakiyama Y, Matsuda A, Takabayashi S, Ochi H, Sekiguchi H, Minamitake S, Ariga T. A novel missense mutation (p.P52R) in amelogenin gene causing X-linked amelogenesis imperfecta. J Dent Res. 2007 Jan;86(1):69-72.\n* Lakshminarayanan R, Bromley KM, Lei YP, Snead ML, Moradian-Oldak J. Perturbed amelogenin secondary structure leads to uncontrolled aggregation in amelogenesis imperfecta mutant proteins. J Biol Chem. 2010 Dec 24;285(52):40593-603.\n* Margolis HC, Beniash E, Fowler CE. Role of macromolecular assembly of enamel matrix proteins in enamel formation. J Dent Res. 2006 Sep;85(9):775-93.\n* Wright JT, Li Y, Suggs C, Kuehl MA, Kulkarni AB, Gibson CW. The role of amelogenin during enamel-crystallite growth and organization in vivo. Eur J Oral Sci. 2011 Dec;119 Suppl 1(Suppl 1):65-9.\n* Wright JT, Torain M, Long K, Seow K, Crawford P, Aldred MJ, Hart PS, Hart TC. Amelogenesis imperfecta: genotype-phenotype studies in 71 families. Cells Tissues Organs. 2011;194(2-4):279-83.\n* Wright JT. The molecular etiologies and associated phenotypes of amelogenesis imperfecta. Am J Med Genet A. 2006 Dec 1;140(23):2547-55.\n\n---\n\n**AMELX Gene**\n\nThe AMELX gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Genetic Disorders**\n\nThe AMELX gene plays a crucial role in the development of amelogenesis imperfecta, a condition characterized by defective tooth enamel. Research has shown that mutations in the AMELX gene can lead to varying degrees of enamel defects, ranging from mild to severe.\n\nIn a study published in 2011, researchers investigated the genotype-phenotype correlations in 71 families affected by amelogenesis imperfecta. The results highlighted the importance of the AMELX gene in tooth development and provided insights into the molecular etiologies of this condition.\n\nFor more information on genetic disorders and the role of genes in human health, consult reputable sources such as MedlinePlus or speak with a healthcare provider.",
    "category": "general"
  },
  {
    "title": "AMER1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amer1/",
    "content": "**AMER1 Gene**\n\nThe **AMER1 gene** provides instructions for making a protein found in tissues throughout the body where it helps regulate the Wnt signaling pathway, which is a series of chemical signals that affect the way cells and tissues develop. Wnt signaling is important for cell division, attachment of cells to one another (adhesion), cell movement (migration), and many other cell activities.\n\n**Normal Function**\n\nThe AMER1 protein can promote cell growth by helping to turn on (activate) the Wnt pathway or prevent cell growth by helping to turn off (repress) the Wnt pathway. When repressing the pathway, the AMER1 protein is acting as a tumor suppressor, which means that it helps prevent cells from growing and dividing (proliferating) too rapidly or in an uncontrolled way.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Wilms Tumor**: Mutations in the AMER1 gene have been found in Wilms tumor, a rare form of kidney cancer that occurs almost exclusively in children. These mutations are somatic, meaning that they are acquired during a person's lifetime and are present only in kidney cells that give rise to the tumor.\n* **Osteopathia Striata with Cranial Sclerosis**: Mutations in the AMER1 gene that are present in cells throughout the body (called germline mutations) cause a bone disorder called osteopathia striata with cranial sclerosis. This condition occurs almost exclusively in females because males with the disorder usually die before or soon after birth.\n\n**Additional Information & Resources**\n\n* More about Wilms tumor\n* More about osteopathia striata with cranial sclerosis\n\n---\n\n**AMER1 Gene**\n\n**Other Cancers**\n\nIn addition to Wilms tumor, changes in the AMER1 gene have been reported to be associated with many other cancers. These mutations are somatic and are present only in cells that give rise to cancer. Studies have shown that AMER1 gene changes are associated with stomach (gastric), breast, and colorectal cancers. It is likely that these gene changes impair the protein's tumor suppressor function, allowing cells to proliferate without control or order, which leads to cancer development.\n\n**Wilms Tumor**\n\nMutations in the AMER1 gene have been found in Wilms tumor, a rare form of kidney cancer that occurs almost exclusively in children. These mutations are somatic, meaning that they are acquired during a person's lifetime and are present only in kidney cells that give rise to the tumor. AMER1 gene mutations result in a protein with a reduced ability to repress Wnt signaling. As a result, Wnt signaling is increased, which leads to the unchecked proliferation of kidney cells and tumor development.\n\n**Other Disorders**\n\nMutations in the AMER1 gene that are present in cells throughout the body (called germline mutations) cause a bone disorder called osteopathia striata with cranial sclerosis. This condition occurs almost exclusively in females because males with the disorder usually die before or soon after birth. Affected females have excessive bone growth (hyperostosis), which leads to multiple skeletal abnormalities including an unusually large head (macrocephaly) and abnormal facial features. Males who survive infancy have bone abnormalities and heart, gastrointestinal, and genitourinary malformations. AMER1 gene mutations that cause osteopathia striata with cranial sclerosis lead to a lack of functional AMER1 protein, disrupting its role in regulating the Wnt signaling pathway. It is unclear why these mutations primarily affect skeletal development.\n\n**Other Names for This Gene**\n\n* adenomatous polyposis coli membrane recruitment 1\n* FAM123B\n* family with sequence similarity 123B\n* FLJ39827\n* OSCS protein\n* FAM123B\n* RP11-403E24.2\n* Wilms tumor gene on the X chromosome protein\n* Wilms tumor on the X\n* WTX\n\n---\n\n**AMER1 Gene**\n\n**Category:** general\n\n**Genomic Location**\nThe AMER1 gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**References**\n\n* Gear R, Savarirayan R. Osteopathia Striata with Cranial Sclerosis. 2021 Apr 15 [updated 2023 Mar 30]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Maur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Ades LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009 Jan;41(1):95-100.\n* Perdu B, de Freitas F, Frints SG, Schouten M, Schrander-Stumpel C, Barbosa M, Pinto-Basto J, Reis-Lima M, de Vernejoul MC, Becker K, Freckmann ML, Keymolen K, Haan E, Savarirayan R, Koenig R, Zabel B, Vanhoenacker FM, Van Hul W. Osteopathia striata with cranial sclerosis owing to WTX gene defect. J Bone Miner Res. 2010 Jan;25(1):82-90.\n* Sanz-Pamplona R, Lopez-Doriga A, Pare-Brunet L, Lazaro K, Bellido F, Alonso MH, Ausso S, Guino E, Beltran S, Castro-Giner F, Gut M, Sanjuan X, Closa A, Cordero D, Moron-Duran FD, Soriano A, Salazar R, Valle L, Moreno V. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clin Cancer Res. 2015 Oct 15;21(20):4709-18.\n* Zhang YY, Wang QM, Niu HL, Liu X, Zhang QL. The General Expression Analysis of WTX Gene in Normal and Cancer Tissues. Pathol Oncol Res. 2017 Apr;23(2):439-446.\n\n**Disclaimers**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AMH gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amh/",
    "content": "**AMH Gene**\n\nThe **AMH gene** provides instructions for making a protein called anti-Mullerian hormone (AMH). This protein plays a crucial role in male sex differentiation during fetal development.\n\n**Normal Function**\n\nIn males, the testes produce AMH, which is then released into the bloodstream. The AMH protein attaches to its receptor on the surface of MÃ¼llerian duct cells. This binding induces self-destruction (apoptosis) of the MÃ¼llerian duct cells, causing them to break down and regress in males.\n\nIn females, who do not produce AMH during fetal development, the MÃ¼llerian duct develops into the uterus and fallopian tubes.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Persistent MÃ¼llerian Duct Syndrome**: This disorder affects males and is caused by mutations in the **AMH gene**. Males with this condition have female reproductive organs in addition to normal male reproductive organs.\n    *   At least 38 mutations in the **AMH gene** have been identified in people with persistent MÃ¼llerian duct syndrome type 1.\n        +   Most mutations change single protein building blocks (amino acids) in the AMH protein.\n        +   Other mutations result in a premature stop signal that leads to an abnormally short protein.\n        +   Still other mutations delete regions of DNA from the **AMH gene**, changing the instructions for the protein.\n\nThe mutated AMH protein cannot be released from the cells of the testes or cannot bind to the receptor on the MÃ¼llerian duct cells. As a result, the MÃ¼llerian duct cells never receive the signal for apoptosis, and the MÃ¼llerian duct persists, becoming a uterus and fallopian tubes. Because the AMH protein is not involved in the formation of male reproductive organs, affected males also have normal male reproductive organs.\n\n**Other Names for This Gene**\n\n*   **Anti-Mullerian hormone gene**\n*   **MÃ¼llerian inhibiting substance gene**\n\n**Additional Information & Resources**\n\n*   National Institutes of Health (NIH)\n*   Centers for Disease Control and Prevention (CDC)\n\n**References**\n\n*   MedlinePlus Genetics\n*   National Library of Medicine\n\n---\n\n**AMH Gene: Persistent MÃ¼llerian Duct Syndrome**\n\nMales with this condition have female reproductive organs in addition to normal male reproductive organs. At least 38 mutations in the AMH gene have been identified in people with persistent MÃ¼llerian duct syndrome type 1. Most mutations change single protein building blocks (amino acids) in the AMH protein. Other mutations result in a premature stop signal that leads to an abnormally short protein. Still other mutations delete regions of DNA from the AMH gene, which changes the instructions for the protein.\n\nThe mutated AMH protein cannot be released from the cells of the testes or cannot bind to the receptor on the MÃ¼llerian duct cells. As a result, the MÃ¼llerian duct cells never receive the signal for apoptosis. The MÃ¼llerian duct persists and becomes a uterus and fallopian tubes. Because the AMH protein is not involved in the formation of male reproductive organs, affected males also have male reproductive organs.\n\n**Other Names for This Gene**\n\n* anti-Muellerian hormone\n* MIF\n* MIS\n* muellerian-inhibiting factor\n* muellerian-inhibiting substance\n\n**Genomic Location**\n\nThe AMH gene is found on chromosome 19.",
    "category": "general"
  },
  {
    "title": "AMHR2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amhr2/",
    "content": "**AMHR2 Gene**\n\nThe **AMHR2** gene provides instructions for making the anti-MÃ¼llerian hormone (AMH) receptor type 2, which is involved in male sex differentiation.\n\n**Normal Function**\n\n* The AMH receptor type 2 is found on the surface of MÃ¼llerian duct cells.\n* The MÃ¼llerian duct, found in both male and female fetuses, is the precursor to the female reproductive organs.\n* During development of male fetuses, cells of the testes release a protein called the AMH protein.\n* The AMH protein attaches (binds) to the AMH receptor type 2, which signals self-destruction (apoptosis) of the MÃ¼llerian duct cells.\n* As a result, the MÃ¼llerian duct breaks down (regresses) in males. In females, who do not produce the AMH protein during fetal development, the MÃ¼llerian duct becomes the uterus and fallopian tubes.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Persistent MÃ¼llerian Duct Syndrome**: A disorder of sexual development that affects males, caused by mutations in the **AMHR2** gene.\n\t+ Males with this condition have female reproductive organs in addition to normal male reproductive organs.\n\t+ At least 24 mutations in the **AMHR2** gene have been identified in people with persistent MÃ¼llerian duct syndrome type 2.\n\t+ Most mutations change single protein building blocks (amino acids) in the AMH receptor type 2 protein.\n\t+ Other mutations result in a premature stop signal that leads to an abnormally short protein.\n\t+ Still other mutations delete regions of DNA from the **AMHR2** gene, which changes the instructions for the protein.\n\n---\n\n**Persistent MÃ¼llerian Duct Syndrome Type 2**\n\n**What is Persistent MÃ¼llerian Duct Syndrome Type 2?**\n\nPersistent MÃ¼llerian duct syndrome type 2, a disorder of sexual development that affects males, is caused by mutations in the AMHR2 gene.\n\n**Causes of Persistent MÃ¼llerian Duct Syndrome Type 2**\n\nAt least 24 mutations in the AMHR2 gene have been identified in people with persistent MÃ¼llerian duct syndrome type 2. Most mutations change single protein building blocks (amino acids) in the AMH receptor type 2 protein. Other mutations result in a premature stop signal that leads to an abnormally short protein. Still other mutations delete regions of DNA from the AMHR2 gene, which changes the instructions for the protein.\n\n**The Most Common Mutation**\n\nThe most common mutation, a deletion of 27 DNA building blocks (nucleotides), occurs in about half of affected individuals with an AMHR2 gene mutation.\n\n**How Does the AMHR2 Gene Work?**\n\nMutations in the AMHR2 gene lead to an abnormal protein that is stuck inside the MÃ¼llerian duct cells and not found on the surface. Therefore, the cells cannot receive the signal for apoptosis. As a result, the MÃ¼llerian duct persists and becomes a uterus and fallopian tubes.\n\n**Other Names for This Gene**\n\n* **AMH type II receptor**\n* **AMHR**\n* **AMHR2_HUMAN**\n* **anti-Muellerian hormone type II receptor**\n* **anti-Muellerian hormone type-2 receptor**\n* **anti-Mullerian hormone receptor type II**\n* **anti-Mullerian hormone receptor, type II**\n* **MIS type II receptor**\n* **MISR2**\n* **MRII**\n\n**Genomic Location of the AMHR2 Gene**\n\nThe AMHR2 gene is found on chromosome 12.\n\n**Related Health Topics**\n\n* **Genes and Gene Therapy**\n* **Genetic Disorders**\n\n**References**\n\n* Faure E, Gouedard L, Imbeaud S, Cate R, Picard JY, Josso N, di Clemente N. Mutant isoforms of the anti-Mullerian hormone type II receptor are not expressed at the cell membrane. J Biol Chem. 1996 Nov 29;271(48):30571-5.\n* Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N, Picard JY. A 27 base-pair deletion of the anti-mullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum Mol Genet. 1996 Sep;5(9):1269-77.\n* Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update. 2005 Jul-Aug;11(4):351-6.\n* Josso N, Picard JY, Imbeaud S, di Clemente N, Rey R. Clinical aspects and molecular genetics of the persistent mullerian duct syndrome. Clin Endocrinol (Oxf). 1997 Aug;47(2):137-44.\n* Rey R. Anti-Mullerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol. 2005 Feb;49(1):26-36.\n\n**Genomic Location**\n\nThe AMHR2 gene is found on chromosome 12.\n\n---\n\n**AMHR2 Gene**\n\n\\n\\n* **What is the AMHR2 gene?**\n* **How do changes in the AMHR2 gene affect development and function of the reproductive system?**\n\nNote: The original content has been reformatted to include bold headings and a list format, while removing code blocks, ads, disclaimers, and standalone URLs.",
    "category": "general"
  },
  {
    "title": "AMN gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amn/",
    "content": "**AMN Gene**\n\nThe AMN gene provides instructions for making a protein called amnionless. This protein is involved in the uptake of vitamin B12 (also called cobalamin) from food.\n\n* **Normal Function**\n\t+ The amnionless protein is primarily found embedded in the outer membrane of kidney cells and cells that line the small intestine.\n\t+ Amnionless attaches (binds) to another protein called cubilin, anchoring cubilin to the cell membrane.\n\t+ Cubilin can interact with molecules and proteins passing through the intestine or kidneys.\n\t+ During digestion, vitamin B12 is released from food. As the vitamin passes through the small intestine, cubilin binds to it.\n\t+ Amnionless helps transfer the cubilin-vitamin B12 complex into the intestinal cell. From there, the vitamin is released into the blood and transported throughout the body.\n\t+ In the kidneys, amnionless and cubilin are involved in the reabsorption of certain proteins that would otherwise be released in urine.\n\n* **Health Conditions Related to Genetic Changes**\n\t+ Imerslund-GrÃ¤sbeck syndrome\n\t\t- At least 30 mutations in the AMN gene have been found to cause this condition.\n\t\t- Characterized by low levels of vitamin B12 in the body, which leads to a blood disorder known as megaloblastic anemia.\n\t\t- About half of affected individuals also have excess protein in their urine (proteinuria), and some have neurological problems.\n\t+ AMN gene mutations that cause Imerslund-GrÃ¤sbeck syndrome reduce the amount or function of the amnionless protein. Without amnionless acting as an anchor, cubilin is not attached to cells in the small intestine or kidneys and cannot bind to vitamin B12 and other molecules and proteins needed in the body.\n\t+ As a result, instead of being taken into intestinal cells, vitamin B12 is released from the body. A shortage of this essential vitamin impairs the proper development of red blood cells, leading to megaloblastic anemia. Low levels of vitamin B12 can also affect the central nervous system, causing neurological problems.\n\n---\n\n**AMN Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Imerslund-GrÃ¤sbeck Syndrome**\n\nAt least 30 mutations in the AMN gene have been found to cause Imerslund-GrÃ¤sbeck syndrome. This condition is characterized by low levels of vitamin B12 in the body, which leads to a blood disorder known as megaloblastic anemia. About half of affected individuals also have excess protein in their urine (proteinuria), and some have neurological problems.\n\n**AMN Gene Mutations**\n\nAMN gene mutations that cause Imerslund-GrÃ¤sbeck syndrome reduce the amount or function of the amnionless protein. Without amnionless acting as an anchor, cubilin is not attached to cells in the small intestine or kidneys and cannot bind to vitamin B12 and other molecules and proteins needed in the body.\n\n**Consequences of AMN Gene Mutations**\n\nAs a result, instead of being taken into intestinal cells, vitamin B12 is released from the body. A shortage of this essential vitamin impairs the proper development of red blood cells, leading to megaloblastic anemia. Low levels of vitamin B12 can also affect the central nervous system, causing neurological problems.\n\n**Proteinuria**\n\nIn addition, without amnionless function in the kidneys, proteins are not reabsorbed into the body and are instead released in the urine, leading to proteinuria.\n\n**Other Names for This Gene**\n\n* Amnionless\n* Amnionless homolog\n* PRO1028 protein\n* Amnionless protein\n* Amnionless precursor\n* Visceral endoderm-specific type 1 transmembrane protein\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of AMN\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* AMNION-ASSOCIATED TRANSMEMBRANE PROTEIN; AMN\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\n1. Beech CM, Liyanarachchi S, Shah NP, Sturm AC, Sadiq MF, de la Chapelle A, Tanner SM. Ancient founder mutation is responsible for Imerslund-Grasbeck Syndrome among diverse ethnicities. Orphanet J Rare Dis. 2011 Nov 13;6:74.\n2. Fyfe JC, Madsen M, Hojrup P, Christensen EI, Tanner SM, de la Chapelle A, He Q, Moestrup SK. The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood. 2004 Mar 1;103(5):1573-9.\n3. Kozyraki R, Cases O. Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. Biochimie. 2013 May;95(5):1002-7.\n4. Namour F, Dobrovoljski G, Chery C, Audonnet S, Feillet F, Sperl W, Gueant JL. Luminal expression of cubilin is impaired in Imerslund-Grasbeck syndrome with compound AMN mutations in intron 3 and exon 7. Haematologica. 2011 Nov;96(11):1715-9.\n5. Watkins D, Rosenblatt DS. Lessons in biology from patients with inborn errors of vitamin B12 metabolism. Biochimie. 2013 May;95(5):1019-22.\n\n---\n\n**AMN Gene**\n\n\\n\\n**Genomic Location**\n\nThe AMN gene is found on chromosome 14.\n\n\\n\\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?",
    "category": "general"
  },
  {
    "title": "AMPD1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ampd1/",
    "content": "**AMPD1 Gene**\n\nThe AMPD1 gene provides instructions for producing an enzyme called adenosine monophosphate (AMP) deaminase. This enzyme is found in the muscles used for movement (skeletal muscles), where it plays a role in producing energy.\n\n**Normal Function**\n\nDuring physical activity, this enzyme converts a molecule called adenosine monophosphate (AMP) to a molecule called inosine monophosphate (IMP) as part of a process called the purine nucleotide cycle. This cycle reuses molecules called purines, which are a group of building blocks of DNA (nucleotides), its chemical cousin RNA, and molecules such as AMP that serve as energy sources in the cell.\n\n**Health Conditions Related to Genetic Changes**\n\n* Adenosine monophosphate deaminase deficiency\n\t+ At least nine mutations in the AMPD1 gene have been found to cause AMP deaminase deficiency. This condition is characterized by skeletal muscle pain or weakness after exercise or prolonged physical activity (exercise intolerance). Most cases are caused by a mutation that results in a premature stop signal in the instructions for making AMP deaminase (written as Gly12Ter or Q12X).\n\t+ The resulting enzyme is abnormally short and nonfunctional and cannot participate in the purine nucleotide cycle. As a result, the process stalls and energy production in skeletal muscle cells is decreased.\n\t+ Skeletal muscles are particularly sensitive to decreases in energy during periods of exercise or increased activity when energy demands increase.\n\t+ The lack of AMP deaminase as a source of energy production can result in fatigue and muscle weakness or pain in some people with AMP deaminase deficiency.\n\n---\n\n**AMPD1 Gene: MedlinePlus Genetics (Part 2/2)**\n\n**Category:** general\n\n**Content:**\n\nPeople with AMP deaminase deficiency may experience fatigue and muscle weakness or pain after exercise or prolonged physical activity. The condition is caused by a mutation in the AMPD1 gene, which results in a premature stop signal in the instructions for making AMP deaminase. The resulting enzyme is abnormally short and nonfunctional, leading to decreased energy production in skeletal muscle cells.\n\n**Most Cases Caused by Mutation Resulting in Premature Stop Signal**\n\nThe mutation that causes most cases of AMP deaminase deficiency results in a premature stop signal in the instructions for making AMP deaminase (written as Gly12Ter or Q12X). The resulting enzyme is abnormally short and nonfunctional, leading to decreased energy production in skeletal muscle cells.\n\n**Energy Production Decreased in Skeletal Muscle Cells**\n\nSkeletal muscles are particularly sensitive to decreases in energy during periods of exercise or increased activity when energy demands increase. The lack of AMP deaminase as a source of energy production can result in fatigue and muscle weakness or pain in some people with AMP deaminase deficiency.\n\n**It is Not Known Why Some People Do Not Experience Symptoms**\n\nIt is not known why some people with this condition do not experience symptoms. Researchers speculate that additional factors, both genetic and environmental, may determine whether a person develops the signs and symptoms of AMP deaminase deficiency.\n\n**Other Names for This Gene**\n\n* Adenosine monophosphate deaminase-1 (muscle)\n* AMP deaminase\n* AMPD1_HUMAN\n* MAD\n* MADA\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of AMPD1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ADENOSINE MONOPHOSPHATE DEAMINASE 1; AMPD1\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Hancock CR, Brault JJ, Terjung RL. Protecting the cellular energy state during contractions: role of AMP deaminase. J Physiol Pharmacol. 2006 Nov;57 Suppl 10:17-29.\n* Isackson PJ, Bujnicki H, Harding CO, Vladutiu GD. Myoadenylate deaminase deficiency caused by alternative splicing due to a novel intronic mutation in the AMPD1 gene. Mol Genet Metab. 2005 Sep-Oct;86(1-2):250-6.\n* Teijeira S, San Millan B, Fernandez JM, Rivas E, Vieitez I, Miranda S, Gonzalez F, Navarro C. Myoadenylate deaminase deficiency: clinico-pathological and molecular study of a series of 27 Spanish cases. Clin Neuropathol. 2009 Mar-Apr;28(2):136-42.\n* Toyama K, Morisaki H, Kitamura Y, Gross M, Tamura T, Nakahori Y, Vance JM, Speer M, Kamatani N, Morisaki T. Haplotype analysis of human AMPD1 gene: origin of common mutant allele. J Med Genet. 2004 Jun;41(6):e74.\n\n**Genomic Location**\n\nThe AMPD1 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AMT gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/amt/",
    "content": "**AMT Gene**\n\nThe AMT gene provides instructions for making an enzyme called aminomethyltransferase. This protein is one of four enzymes that work together in a group called the glycine cleavage system. Within cells, this system is active in specialized energy-producing centers called mitochondria.\n\nAs its name suggests, the glycine cleavage system breaks down a molecule called glycine by cutting (cleaving) it into smaller pieces. Glycine is an amino acid, which is a building block of proteins. This molecule also acts as a neurotransmitter, which is a chemical messenger that transmits signals in the brain. The breakdown of excess glycine when it is no longer needed is necessary for the normal development and function of nerve cells in the brain.\n\nThe breakdown of glycine by the glycine cleavage system produces a molecule called a methyl group. This molecule is added to and used by a vitamin called folate. Folate is required for many functions in the cell and is important for brain development.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Nonketotic Hyperglycinemia**\n    *   Mutations in the AMT gene account for about 20 percent of all cases of nonketotic hyperglycinemia.\n    *   This condition is characterized by abnormally high levels of glycine in the body (hyperglycinemia).\n    *   Affected individuals have serious neurological problems, including severe breathing difficulties shortly after birth, weak muscle tone (hypotonia), seizures, and delayed development of milestones.\n    *   More than 70 mutations have been identified in affected individuals. Most of these genetic changes alter single amino acids in aminomethyltransferase.\n\n**Additional Information & Resources**\n\n*   The breakdown of glycine by the glycine cleavage system produces a molecule called a methyl group, which is added to and used by folate.\n*   Folate is required for many functions in the cell and is important for brain development.\n\n---\n\n**Nonketotic Hyperglycinemia**\n\nNonketotic hyperglycinemia is a rare genetic disorder characterized by abnormally high levels of glycine in the body (hyperglycinemia). Affected individuals have serious neurological problems, including severe breathing difficulties shortly after birth, weak muscle tone (hypotonia), seizures, and delayed development of milestones.\n\n**Causes**\n\nMutations in the AMT gene account for about 20 percent of all cases of nonketotic hyperglycinemia. The AMT gene provides instructions for making aminomethyltransferase, an enzyme that plays a crucial role in the breakdown of glycine. More than 70 mutations have been identified in affected individuals, most of which alter single amino acids in aminomethyltransferase.\n\n**Effects of Mutations**\n\nAMT gene mutations alter the structure and function of aminomethyltransferase. When an altered version of this enzyme is incorporated into the glycine cleavage system, it impairs the system's ability to break down glycine. Some AMT gene mutations reduce the activity of the glycine cleavage system, while others completely eliminate its activity. As a result, excess glycine can build up in the body's organs and tissues.\n\n**Symptoms**\n\nThe signs and symptoms of nonketotic hyperglycinemia vary in severity and can include:\n\n* Severe breathing difficulties shortly after birth\n* Weak muscle tone (hypotonia)\n* Seizures\n* Delayed development of milestones\n\n**Other Names for This Gene**\n\nGCE glycine cleavage system protein T NKH\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry\n\nScientific Articles on PubMed\n\nCatalog of Genes and Diseases from OMIM\n\nGene and Variant Databases\n\nReferences:\n\nCoughlin CR 2nd, Swanson MA, Kronquist K, Acquaviva C, Hutchin T,\nRodriguez-Pombo P, Vaisanen ML, Spector E, Creadon-Swindell G, Bras-Goldberg AM,\nRahikkala E, Moilanen JS, Mahieu V, Matthijs G, Bravo-Alonso I, Perez-Cerda C,\nUgarte M, Vianey-Saban C, Scharer GH, Van Hove JL. The genetic basis of classic\nnonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med. 2017\nJan;19(1):104-111.\n\nKikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction\nmechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser B\nPhys Biol Sci. 2008;84(7):246-63.\n\nKure S, Kato K, Dinopoulos A, Gail C, DeGrauw TJ, Christodoulou J, Bzduch V,\nKalmanchey R, Fekete G, Trojovsky A, Plecko B, Breningstall G, Tohyama J, Aoki Y,\nMatsubara Y. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic\nhyperglycinemia. Hum Mutat. 2006 Apr;27(4):343-52.\n\nOkamura-Ikeda K, Hosaka H, Yoshimura M, Yamashita E, Toma S, Nakagawa A,\nFujiwara K, Motokawa Y, Taniguchi H. Crystal structure of human T-protein of\nglycine cleavage system at 2.0 A resolution and its implication for understanding\nnon-ketotic hyperglycinemia. J Mol Biol. 2005 Sep 2;351(5):1146-59.\n\nSwanson MA, Coughlin CR Jr, Scharer GH, Szerlong HJ, Bjoraker KJ, Spector EB,\nCreadon-Swindell G, Mahieu V, Matthijs G, Hennermann JB, Applegarth DA, Toone JR,\nTong S, Williams K, Van Hove JL. Biochemical and molecular predictors for\nprognosis in nonketotic hyperglycinemia. Ann Neurol. 2015 Oct;78(4):606-18.\n\nToone JR, Applegarth DA, Levy HL, Coulter-Mackie MB, Lee G. Molecular genetic\nand potential biochemical characteristics of patients with T-protein deficiency\nas a cause of glycine encephalopathy (NKH). Mol Genet Metab. 2003\nAug;79(4):272-80.\n\nVan Hove JLK, Coughlin C II, Swanson M, Hennermann JB. Nonketotic\nHyperglycinemia. 2002 Nov 14 [updated 2019 May 23].\n\n---\n\n**AMT Gene**\n\n**Genomic Location**\nThe AMT gene is found on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ANA (Antinuclear Antibody) Test: MedlinePlus Medical Test",
    "url": "https://medlineplus.gov/lab-tests/ana-antinuclear-antibody-test/",
    "content": "**ANA (Antinuclear Antibody) Test**\n\nAn ANA test is a blood test that looks for antinuclear antibodies in your blood. Antibodies are proteins that your immune system makes to fight foreign substances, like viruses and bacteria. But an antinuclear antibody attacks your healthy cells instead. It's called \"antinuclear\" because it targets the nucleus of the cells, which is in charge of sending signals that are needed for important cell functions.\n\nIt's normal to have a few antinuclear antibodies in your blood. But a large number may be a sign of an autoimmune disorder. If you have an autoimmune disorder, your immune system attacks the healthy cells of your organs and tissues by mistake. These disorders can cause serious health problems.\n\n**What is it used for?**\n\nAn ANA test is used to help diagnose autoimmune disorders, such as:\n\n* Systemic lupus erythematosus (SLE), the most common type of lupus.\n* Rheumatoid arthritis, a condition that mostly affects joints.\n* Scleroderma, a rare disease that may affect the skin, blood vessels, and organs.\n* SjÃ¶gren's syndrome, a rare disease that affects the glands that make tears and saliva (spit) and other parts of the body.\n* Addison Disease, which affects your adrenal glands (glands on top of the kidneys), causing fatigue and weakness.\n* Autoimmune hepatitis, which causes swelling in your liver.\n* Thyroid diseases, which can cause your thyroid to make too much or too little thyroid hormones.\n\n**Why do I need an ANA test?**\n\nYour health care provider may order an ANA test if you have symptoms of an autoimmune disorder. The symptoms depend on what part of your body is affected. They may include:\n\n* Fever\n* Rash, blisters, or skin color changes\n* Fatigue\n* Joint pain, stiffness, and swelling\n* Muscle pain\n* Swollen glands\n* Abdominal (belly) pain\n\n**What happens during an ANA test?**\n\nA health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.\n\n**Will I need to do anything to prepare for the test?**\n\nSome medicines may affect the results of your ANA test. You may need to stop taking certain medicines before this test, so tell your provider about everything you take. But don't stop taking any medicines unless your provider tells you to.\n\n**Are there any risks to the test?**\n\nThere is very little risk to having a blood test. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.\n\n**What do the results mean?**\n\nResults from an ANA test alone cannot diagnose a specific disease. Your provider will use your ANA test results along with other blood and imaging tests and information about your health to make a diagnosis.\n\nA negative result on an ANA test means that antinuclear antibodies were not found in your blood, and you're less likely to have an autoimmune disorder. But a negative ANA test doesn't completely rule out the possibility that you could have an autoimmune disorder.\n\nA positive result on an ANA test means that antinuclear antibodies were found in your blood. A positive result may be a sign of:\n\n* Systemic lupus erythematosus (SLE)\n* A different type of autoimmune disease\n* A viral infection (antinuclear antibodies from a virus are usually only in your blood for a short time)\n* Another health condition that can cause antinuclear antibodies, such as cancer\n\nIf your ANA test results are positive, your provider will likely order more tests to make a diagnosis.\n\n---\n\n**What is an ANA Test?**\n\nAn ANA test, also known as an antinuclear antibody test, is a blood test used to diagnose autoimmune disorders. The test measures the presence of antinuclear antibodies (ANA) in your blood.\n\n**Why Do I Need an ANA Test?**\n\nYour healthcare provider may order an ANA test if you have symptoms of an autoimmune disorder. These symptoms depend on what part of your body is affected and may include:\n\n* Joint pain or swelling\n* Skin rashes\n* Hair loss\n* Fatigue\n* Fever\n\n**What Happens During an ANA Test?**\n\nThe ANA test involves taking a blood sample from a vein in your arm using a small needle. The blood will be collected into a test tube or vial, and you may feel a little sting when the needle goes in or out. This usually takes less than five minutes.\n\n**Will I Need to Do Anything to Prepare for the Test?**\n\nSome medicines may affect the results of your ANA test. You may need to stop taking certain medicines before this test, so tell your provider about everything you take. But don't stop taking any medicines unless your provider tells you to.\n\n**Are There Any Risks to the Test?**\n\nThere is very little risk to having a blood test. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.\n\n**What Do the Results Mean?**\n\nResults from an ANA test alone cannot diagnose a specific disease. Your provider will use your ANA test results along with other blood and imaging tests, and information about your health to make a diagnosis.\n\n* A negative result means that antinuclear antibodies were not found in your blood, and you're less likely to have an autoimmune disorder.\n* A positive result may be a sign of:\n\t+ Systemic lupus erythematosus (SLE)\n\t+ A different type of autoimmune disease\n\t+ A viral infection (antinuclear antibodies from a virus are usually only in your blood for a short time)\n\t+ Another health condition that can cause antinuclear antibodies, such as cancer\n\nIf your ANA test results are positive, your provider will likely order more tests to make a diagnosis.\n\n**Having Antinuclear Antibodies in Your Blood Doesn't Always Mean You Have a Disease**\n\nSome healthy people have antinuclear antibodies in their blood, and levels tend to increase with age. Many healthy adults may have a positive ANA test result, especially women over the age of 65. Also, certain medicines can cause antinuclear antibodies.\n\nIf you have questions about your results, talk with your provider.\n\n---\n\n**ANA (Antinuclear Antibody) Test**\n\n\\n\\n\n\n**What is an ANA test?**\n\nAn ANA test, also known as an antinuclear antibody test, is used to diagnose autoimmune diseases such as lupus and rheumatoid arthritis. It measures the presence of antinuclear antibodies in the blood.\n\n\\n\\n\n\n**How is an ANA test performed?**\n\nThe ANA test is typically performed on a sample of blood drawn from a vein in the arm. The blood sample is then sent to a laboratory where it is tested for the presence of antinuclear antibodies.\n\n\\n\\n\n\n**What are the benefits and risks of an ANA test?**\n\nThe benefits of an ANA test include its ability to diagnose autoimmune diseases such as lupus and rheumatoid arthritis. However, there are also some risks associated with the test, including the possibility of false positive results.\n\n\\n\\n\n\n**How do I prepare for an ANA test?**\n\nThere is no special preparation needed for an ANA test. You should simply arrive at your appointment on time and be prepared to provide a blood sample.\n\n\\n\\n\n\n**What are the related health topics for an ANA test?**\n\nThe related health topics for an ANA test include autoimmune diseases, immune system and disorders, lupus, rheumatoid arthritis, scleroderma, and Sjogren's syndrome.\n\n\\n\\n\n\n**What are the related medical tests for an ANA test?**\n\nThe related medical tests for an ANA test include antibody serology tests, antineutrophil cytoplasmic antibodies (ANCA) test, C-reactive protein (CRP) test, CCP antibody test, celiac disease screening, cold stimulation test, complement blood test, immunoglobulins blood test, rheumatoid factor (RF) test, and smooth muscle antibody (SMA) test.\n\n\\n\\n\n\n**How do I cope with medical test anxiety?**\n\nIf you are experiencing anxiety about an upcoming medical test, there are several things you can do to help manage your stress. These include educating yourself about the test, preparing physically and emotionally for the test, and seeking support from friends and family.\n\n\\n\\n\n\n**How do I understand my lab results?**\n\nWhen it comes to understanding your lab results, it's essential to communicate with your healthcare provider. They can explain the results in a way that makes sense to you and help you make informed decisions about your health.\n\n\\n\\n",
    "category": "health"
  },
  {
    "title": "ANK1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ank1/",
    "content": "**ANK1 Gene**\n\nThe ANK1 gene provides instruction for making a protein called ankyrin-1. This protein is primarily active (expressed) in red blood cells, but it is also found in muscle and brain cells.\n\n**Normal Function**\n\nIn red blood cells, ankyrin-1 is located at the cell membrane, where it attaches (binds) to other membrane proteins. The binding of membrane proteins to one another maintains the stability and structure of red blood cells but also allows for their flexibility. The proteins allow the cell to change shape without breaking when passing through narrow blood vessels.\n\nIn muscle and brain cells, ankyrin-1 performs similar functions, binding to other membrane proteins to play a role in cell stability, cell movement, and other cell functions.\n\n**Health Conditions Related to Genetic Changes**\n\nHereditary spherocytosis is a condition caused by mutations in the ANK1 gene. At least 55 mutations have been found to cause this condition. These mutations lead to the production of an ankyrin-1 protein that does not function normally and does not bind to other proteins within the red blood cell membrane. A lack of normal ankyrin-1 at the cell membrane also leads to a lack of another protein called spectrin because ankyrin-1 is not available to bind to spectrin. The shortage (deficiency) of these two proteins interferes with the structure and flexibility of the red blood cell membrane, causing red blood cells to be misshapen. These misshapen cells, called spherocytes, are removed from circulation and taken to the spleen for destruction. The shortage of red blood cells in circulation and the abundance of cells in the spleen are responsible for the signs and symptoms of hereditary spherocytosis.\n\n**Other Names for This Gene**\n\n* ankyrin 1\n\n**Additional Information & Resources**\n\n* More about this health condition: Hereditary Spherocytosis\n\n---\n\n**Hereditary Spherocytosis and the ANK1 Gene**\n\n**What is Hereditary Spherocytosis?**\n\nHereditary spherocytosis is a genetic disorder characterized by the production of abnormal red blood cells. These cells are misshapen, known as spherocytes, due to a lack of normal ankyrin-1 protein at the cell membrane.\n\n**The ANK1 Gene and Ankyrin-1 Protein**\n\nThe ANK1 gene provides instructions for making the ankyrin-1 protein. Mutations in the ANK1 gene lead to the production of abnormal ankyrin-1 protein, which does not function normally. This abnormal protein fails to bind to other proteins within the red blood cell membrane, resulting in a shortage of spectrin and other essential proteins.\n\n**Consequences of ANK1 Gene Mutation**\n\nThe shortage of these two proteins interferes with the structure and flexibility of the red blood cell membrane. As a result, red blood cells are removed from circulation and taken to the spleen for destruction. This leads to a decrease in the number of red blood cells in circulation and an increase in the number of damaged cells in the spleen.\n\n**Other Names for the ANK1 Gene**\n\n* ANK\n* ANK-1\n* ANK1_HUMAN\n* ankyrin 1, erythrocytic ankyrin-1\n* ankyrin-R\n* erythrocyte ankyrin\n\n**Genomic Location of the ANK1 Gene**\n\nThe ANK1 gene is found on chromosome 8.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  }
]